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Late-onset retinal macular degeneration (L-ORMD) is a fully penetrant autosomal dominant 
macular degeneration resulting from a Ser163Arg substitution in the gene encoding the protein 
C1QTNF5. Clinically L-ORMD results in dark adaptation delay in the fifth decade, central visual 
loss in the sixth decade and further progressive visual field loss in successive decades of life. 
Pathologically the disease results in thick sub-retinal deposits, which have a similar composition to 
drusen seen in AMD, retinal pigment epithelial (RPE) loss, and neuro-retinal atrophy.  The 
function of C1QTNF5 is incompletely understood however within the eye it is expressed most 
strongly by the RPE cells.  
An in vitro model for L-ORMD was developed using human induced pluripotent stem cells 
(hiPSCs) derived from patients and with stem cells from patient’s unaffected siblings used as 
controls.  The hiPSCs were differentiated to RPE (hiPSC-RPE).  L-ORMD hiPSC-RPE shared 
baseline characteristics with sibling control hiPSC-RPE.  In order to model in vivo conditions 
hiPSC-RPE were grown on permeable supports in human serum enriched media.  Case hiPSC-RPE 
cell lines were found to activate the complement pathway resulting in increased deposition of the 
terminal complement complex (TCC) C5b-9 when compared to control hiPSC-RPE.  Using 
depleted serum, deposition was not affected by depletion of classical and lectin pathway 
components but was reduced by depletion of alternative complement pathway components.  
Depletion of complement components C3 and C5 abolished TCC deposition. The addition of a 
monoclonal antibody against C5 also reduced TCC deposition.   
The role of complement dysregulation in L-ORMD pathogenesis was confirmed by 
immunostaining of L-ORMD and age-matched control human donor retinal sections.  L-ORMD 
retinal sections displayed increased C3d and C5b-9 deposition.  Using mutant and wild type-
protein generated from a bacterial expression system it was found that the mutant protein was less 
stable than the wild-type.  In addition the wild type protein formed multimers whilst the mutant 
was mainly monomeric. A surface plasmon resonance  (SPR) study showed an increased affinity of 
wild-type C1QTNF5, especially in multimeric form for complement factor H  (CFH), a key 
regulator of the alternative complement pathway when compared to mutant protein.  
Taken together these studies implicate dysfunction of the alternative complement pathway in L-
ORMD disease mechanism and have suggested a role for C1Q TNF5 in the extracellular matrix.  





Age-related macular degeneration (AMD) is the commonest cause of blindness in the developed 
world.  The number of people suffering with AMD continues to increase placing burdens on health 
and social care systems worldwide. There are two main forms of AMD.  The first is wet AMD in 
which leakage from blood vessels at the back of the eye results in visual loss.  The second and 
commonest form of AMD is dry AMD, which results from deposits forming under the retina.  In 
dry AMD there is a slow loss of retinal cells eventually leading to visual loss. Currently there are 
no treatments to modify the progression of dry AMD.  Understanding AMD disease mechanism 
and the development of new treatments has been hampered by the lack of clinically relevant 
models This highlights the need to develop new platforms that adequately model human disease in 
order to develop new treatments for AMD.  However, AMD is a highly variable disease which 
makes it difficult to study. 
Late-onset retinal macular degeneration (L-ORMD) is a severe inherited form of macular 
degeneration resulting from the mutation in the gene that codes the protein C1QTNF5. Unlike 
AMD all patients who carry the gene mutation associated with L-ORMD undergo retinal 
degeneration in a step-wise manner.  The disease recapitulates key clinical and pathological 
characteristics of AMD, which make it a good model disorder for AMD.   
In this dissertation, I describe how I developed a model for macular degeneration using stem cells 
derived from patients with L-ORMD.  The model implicated dysfunction in regulation of an innate 
immune pathway known as the complement system in L-ORMD disease mechanism.  This 
suggests that AMD and L-ORMD share a common disease mechanism. The finding was verified in 
both a mouse model of L-ORMD and in human L-ORMD retinal donor samples. An interaction 
was found between C1QTNF5, the protein mutated in L-ORMD and one of the key regulators of 
the complement pathway an innate immune system, suggesting a role for L-ORMD in the eye.  
Complement was found tot be abnormally activated in L-ORMD eyes. By targeting components of 
the complement pathway, it was possible to abolish the abnormal complement system activity and 
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1.  Introduction 
      
1.1   Age-related macular degeneration  
 
1.1.1 AMD background 
 
Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in 
those aged over 50 in the developed world (Evans and Wormald, 1996, Friedman et al., 2004). It is 
the third most common cause of all blindness worldwide (Pascolini et al., 2004).  Clinically, there 
are two main forms of AMD, an exudative “wet” form or neovascular AMD (nvAMD) and a non-
exudative “dry” form.  NvAMD results in acute onset of leakage of fluid, resulting in acute 
blindness, whilst dry AMD results in slow onset of visual loss (Davis et al., 2005).  Ninety percent 
of acute registerable blindness results from nvAMD although only 20% of total cases of AMD are 
attributable to nvAMD (Evans and Wormald, 1996).  Although the morphology of the diseases is 
different, the disease processes are not distinct and 10-15% of dry AMD patients eventually 
develop the nvAMD form.   
 
AMD does not usually present clinically prior to 55 years of age (Klein et al., 2004). As the 
average age of populations continues to increase and life expectancy increases the prevalence of 
AMD is expected to increase further with an ageing population (Minassian et al., 2011). The 
prevalence of AMD in Europe is around 1.5% in those aged over 40 but increases to between 7 to 
10% in those aged over 75 (Augood et al., 2006). Similar trends are likely in other developed 
countries and consequently, the worldwide burden of blindness of AMD is projected to increase 
from 196 million in 2020 to 288 million in 2040 (Wong et al., 2014). 
 
Visual loss in AMD has been linked to a number of other sequelae that reduce quality of life  
Late-stage AMD has been linked with a loss of independence and depression and in the older age 
group with multiple sensory impairment (Lin et al., 2004, Rovner et al., 2002, Berman and 
Brodaty, 2006). Patients are also likely to be placed under an increasing financial burden due to 
lack of income. AMD also places a heavy financial burden on health and social care systems.  In 
the United Kingdom in 2000 it was estimated that costs from visual aid provision, tax allowances, 
residential care, community care and social security benefits was £6455 per person during the first 
year and £6295 per person during each subsequent year {Meads, 2003 #203}. Meanwhile the cost 
of treating nvAMD was estimated to be £300 million per year for new patients alone (Smith, 2010, 






1.1.2 AMD clinical features 
 
AMD presents with different features at different stages of disease.  The disease mainly effects the 
macula which is responsible for central vision (figure 1.1).  In the early stages, it is difficult to 
differentiate AMD from normal ageing (Sarks et al., 1999). In early disease, AMD is characterised 
by a number of deposits.  Sub-retinal drusenoid deposits  (SDD) also known as reticular 
pseudodrusen are found in between the photoreceptors and RPE layer (Zweifel et al., 2010) (figure 
1.2).   They are small and faint (125-250um) and therefore difficult to view on clinical examination 
and with fundus colour photography.  SDD are thought to develop early in the disease process as 
they have been linked with early drusen (De Bats et al., 2013). In addition, SDD have been linked 
with choroidal thinning and the reduction in size of photoreceptor outer segments.  Since the SDD 
are located in the peri-fovea it is thought that SDD are likely to initially affect rods, which have 
their highest concentration in this region (Curcio et al., 2013). Rods appear to be affected more 
than cones in early AMD.   This supported by both histopathological and dark adaptation studies.   
 
  
Figure 1.1 Fundus photograph labelled with foveal (f), para-foveal (Pa) and peri-foveal (Pe) 




Figure 1.2 Diagram illustrating different forms of drusen with location in the outer retina.  
Pseudodrusen (SDD) is found adjacent to the photoreceptors (PR) and above the RPE.  Basal 
Laminar deposit (BLamD) is found above Bruch’s membrane (BrM) whilst basal linear deposit 
(BLinD) is found outside the basement membrane of the RPE.  (Nivison-Smith, L., Milston, R., 
Madigan, M. and Kalloniatis, M., 2014. Age-related macular degeneration: linking clinical 




Deposits basal to the RPE include drusen.  Drusen are focal nodules found between the RPE and 
Bruch’s membrane (BM).  They are described by their outline and size.  They present as discrete 
nodules in hard drusen or yellowy plaques with less distinct boundaries in the form of soft drusen.  
Fundus photography is still the gold standard for imaging drusen. Drusen are perhaps the best 
clinical indicator of progression to AMD.  The age-related eye disease study (AREDS) initially 
classified drusen into 9 types (Davis et al., 2005).  This was later simplified to a 5 stage severity 
scale which in combination with pigmentation provided a prognostic indicator of progression of 
AMD (Ferris et al., 2005) (Table 1.1).  Small drusen were classed as smaller than 63 um, 
intermediate drusen 63 to 125um and large drusen as greater than 125um but less than 250um and 
very large drusen are greater than 250um.  Intermediate, large and very large drusen were 
characteristic of early AMD and conferred greater risk of progression whilst small drusen could 
normally also be seen in ageing.  Soft drusen indicate a later stage of disease as they lift the RPE 
and consequently the edges are less distinct as they are not bounded by RPE adhesion to BM.  On 
ocular coherence tomography (OCT) they appear as flatter lesions occasionally with a space in the 
sub-RPE on either side whilst hard drusen are usually more raised. Fundus autofluorescence  
(FAF) shows increased fluorescence to the edges of drusen suggesting that RPE on the edge are 
under stress perhaps from direct pressure (Bindewald et al., 2005). Drusen stain early during 
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fundus fluorescein angiogram (FFA) and increase in fluorescence with time.  This can be 
differentiated from leaking vessels as the size of hyperfluorescence due to drusen does not change.  
AMD classification Definition 
No ageing changes No drusen or pigmentary changes 
Normal ageing changes No pigmentary changes. Only small drusen 
(<63um) 
Early AMD Medium drusen (>63um), no pigmentary 
changes 
Intermediate AMD Large drusen (>125um) and/or any 
pigmentary changes 
Late AMD Neovascular AMD and/or geographic 
atrophy 
Table 1.1 Classification of AMD from the AREDS study based on drusen and 
pigmentary changes (adapted from Ferris et al., 2005) 
 
Cuticular drusen are a particular form of drusen appearing in large numbers from the peri-fovea to 
the mid peripheral macula.  They are very small in size (25-75um) and hence difficult to see clearly 
on fundus examination especially in their early stages.  Cuticular drusen are also found sub-RPE 
and above BM and have similar composition to soft drusen (Leng et al., 2009, Spaide and Curcio, 
2010). They show early fluorescence with fluorescein angiography.  ICG shows cuticular lesions 
as raised lesions. Using FAF, Cuticular drusen show reduced fluorescence at their centres 
surrounded by a ring of increased autofluorescence. Early AMD is also clinically associated with 
pigmentary changes at the macula.  These are mainly associated with clumping and migration of 
RPE which are more easily seen with OCT (Okubo et al., 1999).  
 
In late-stage AMD, patients lose visual acuity as the foveal photoreceptors are lost (Sunness, 1999, 
Kim et al., 2002).  Approximately 15% of advanced and late stage AMD patients can suffer from 
geographic atrophy (GA). In GA, large areas of RPE are lost with associated loss of overlying 
photoreceptors and underlying atrophy of the choriocapillaris.  Although geographic atrophy can 
be clearly seen with fundus photography, the edges are often poorly defined. Recently, FAF and 
infra-red (IR) have enabled better delineation of areas of GA which has allowed for better 
monitoring of progression. FAF has no autofluorescence in areas of GA and often increased FAF 
in areas at the edge of GA lesions providing high contrast. OCT shows thinning in areas of atrophy 
and loss of the RPE, photoreceptor or in later stages all the neuro-retina (Curcio et al., 1996). IR 
reflectivity shows increased reflectivity from the atrophic lesion as the RPE no longer mask the IR 




10-15% of patients who suffer with late-stage dry AMD develop nvAMD (Chew et al., 2014). In 
nvAMD, new blood vessels develop in the choroid under the BM known as choroidal new vessels 
(CNV). Type I CNV remain below the RPE whilst type II CNV penetrate the RPE. The new blood 
vessels are fragile and may leak a lipid-rich fluid and hence the term exudative AMD is often used 
interchangeably.  The new vessels can also bleed and result in haemorrhagic macular degeneration.   
However, the neuro-retinal RPE interface is usually maintained until late in disease and therefore 
vision is stable until late in the disease in type I CNV.  In type II CNV any leakage disrupts 
photoreceptor function and results in a more acute loss of vision (Grossniklaus and Green, 2004).  
Bleeds and lipid exudation are easily identifiable by fundus photography, however early CNV are 
more subtle and may appear as greyish membranes in the macula.  Angiography is the best way to 
visualise CNV.  Angiographically, type I membranes are described as occult.  As vessels grow sub-
RPE they are flat, leakage is protected by overlying RPE, and therefore there is a slow spreading 
hyperfluorescence Type II CNV leak early and produce a lacy network following the new vascular 
network.  Type II CNV result in a classic pattern of hyperfluorescence.  Type II lesions are more 
clearly seen with indocyanine green angiography  (ICG) which highlights the choroidal to retinal 
circulatory link (Grossniklaus and Green, 2004).  
.  
1.1.3 AMD pathology 
 
AMD is a complex polygenic and multifactorial disease with marked clinical variability.  The 
variability makes AMD difficult to study. The variation results from an interplay between multiple 
genes, environmental risk factors and alterations in the local microenvironment in the neuro-
retinal, RPE, BM and choroid complex. Although many factors have now been identified as risks 
for AMD a clear understanding of initial injury in early disease and an understanding of how these 
pathways lead to disease is still unclear. This section will briefly summarise the current 
understanding of pathogenesis and demonstrate the difficulty in studying the disease. 
 
Whilst managing AMD clinicians  noted that AMD had familial clustering  (Gass, 1972).  
However many of the identified traits did not show clear Mendelian inheritance. As many of the 
associations with AMD result from single nucleotide polymorphisms (SNPs), identifying genes has 
been difficult with traditional linkage analysis.  However, recent genome wide association studies 
(GWAS) have been able to identify common allelic variants in the DNA of large patient cohorts 
with AMD.  The most common and important SNPs that have been found and replicated in a wide 
variety of populations relate to components of the complement pathway, an innate immune system. 
The complement pathway is discussed in more detail in section 1.4. However, other SNPs have 
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also been found related to the immune system, extracellular matrix (ECM), oxidative stress, 
cellular function and neovascular cytokines which are discussed below. 
 
Defects in extracellular matrix turnover are implicated in macular degeneration.  HTRA1 (10q26) 
gene is associated with AMD. It is involved in the breakdown of ECM proteins including 
complement terminal component regulators clusterin, vitronectin and fibromudulin (Kanda et al., 
2007, Fritsche et al., 2008). HTRA is also found in drusen (Yang et al., 2006). A meta-analysis 
showed that HTRA1 was strongly associated with AMD giving a 7.46 times increased risk (Tang 
et al., 2009). The HTRA gene is located close to the ARMS2 gene, which is also implicated in 
AMD.  Fibulin 5 (14q31.1) is also associated with AMD and is involved in ECM turnover. It 
assists in the polymerisation of elastin fibres.  In normal eyes fibulin 5 expression is localised to 
the BM and the choroid. In AMD it is also localised to sub-RPE deposits including drusen (Tang et 
al., 2009).  Fibulin 5 may be downstream of HTRA1 in helping modulate elastin in Bruch’s 
membrane (Clausen et al., 2011). COL8A1 (3q12.3) and COL10A1 (6q21-q22) code for collagen 
XIII and X respectively. Neither of these collagens is thought to play a major role in the sub-RPE 
or BM.  Consequently, their roles in pathogenesis have not been clearly defined.  The collagens 
have been proposed to play a part in ECM integrity and neovascularisation (Yu et al., 2011, 
Rooney et al., 1993). 
 
In addition to extracellular matrix turnover, genes associated with lipid metabolism have also been 
associated with AMD.  APOE (19q13.2) codes for Apoliprotein E (ApoE).  ApoE is involved in 
lipid metabolism and transport.  Mice deficient in ApoE were found to show signs of cellular 
stress.  Cells from these mice expressed proteins associated with ageing and cells had reduced 
reserves of antioxidants (Bonomini et al., 2010). ApoE has three isoforms: Epsilon 2 (Ɛ2), Epsilon 
3 (Ɛ3) and Epsilon 4 (Ɛ4). Patients carrying Ɛ2 alleles were found to have increased risk of AMD 
whilst those carrying Ɛ4 were found to have a reduced risk (Baird et al., 2004, Souied et al., 1998). 
A meta-analysis of studies on ApoE and risk in AMD found that there was a 20% risk of AMD 
attributable to the Ɛ2 isoform and a 40% protective effect associated with the Ɛ4 isoform 
(Thakkinstian et al., 2006).  This suggests that lipid metabolism may play a part in AMD 
pathogenesis. Lipids are also found in the basal deposits in early AMD and may be due to early 
cellular dysfunction.  Another associated gene involved in lipid transport is the VLDLR (9p24) 
gene that codes for a receptor for the very low density lipoprotein.  Case-control and familial 
studies have implicated the VLDLR gene in risk for AMD (Haines et al., 2006).  VLDL not only 
transports lipids but is also thought to have a direct response in reducing angiogenesis (Chen et al., 
2007).  VLDL receptor knockout mice were found to have marked sub-retinal neovascularisation 




ARMS2 (10q26) is closely located to the HTRA1 gene. The exact function of ARMS2 is not 
known however, it is thought to play a part in mitochondrial function (Kanda et al., 2007). ARMS2 
protein has been localised to mitochondrial membranes implicating the protein in mitochondrial 
metabolism. This relationship was further strengthened when cigarette smoking was found to 
further increase susceptibility to AMD in patients with ARMS2 polymorphisms (Schmidt et al., 
2006). ARMS2 greatly increases the risk of AMD and patients homozygous for SNPs in ARMS2 
were found to be eight times more likely to develop AMD (Rivera et al., 2005). 
 
Looking at specific risk factors for nvAMD, VEGFA (6p12) has been associated with nvAMD. 
This gene codes for vascular endothelial growth factor (VEGF).  VEGF is a growth factor that is 
important in generation of new blood vessels. Polymorphisms in VEGFA have been shown to 
increase AMD risk particularly in late-stage neovascular disease (Haines et al., 2006, Churchill et 
al., 2006).  SERPINF1 (17p13.3) codes for pigment epithelial derived factor (PEDF). PEDF has 
several functional roles. It is anti-angiogenic, neurotrophic and inhibits tumour growth. An allelic 
variant of PEDF is associated with nvAMD (Lin et al., 2008).  Previously vitreous PEDF levels 
have been found to be lower in AMD patients suggesting that PEDF has a protective role in 
nvAMD (Holekamp et al., 2002). 
 
Looking at the immune system TLR3 (4q35) and TLR4 (9q33.1) code for toll like receptors. These 
are part of the innate immune system and activate a range of pathways in the immune system. 
TLR3 is linked to apoptosis in cellular stress response. TLR3 SNPs have been shown to reduce the 
risk of AMD (Yang et al., 2008). TLR4 recognises lipopolysaccharides and it is a mediator of the 
stress response.  TLR4 SNPs have been shown to increase the risk of AMD in one non-replicated 
study (Zareparsi et al., 2005). 
 
 
In addition to genetic risk factors for AMD environmental factors are also thought to contribute to 
AMD pathogenesis.  Large population based studies have highlighted environmental and lifestyle 
associations with AMD. Chakravarthy et al. recently performed a meta-analysis of these studies 
and number of other similar studies from across the globe.  The 26 studies included 94, 058 
patients.  16 factors were identified. 3,178 patients suffered from end-stage AMD. In all studies, 
there was a strong association with age. Changes during ageing have already been described in the 




Oxidative stress is implicated in AMD.  Amongst lifestyle factors associated with AMD, cigarette 
smoking has the strongest association. Cigarette smoke is made up of a number of constituents and 
it is not known which of the components of smoke is important in pathogenesis.  However, it is 
thought that smoking alters the inflammatory balance within the retina. As a result patients with 
AMD risk alleles in the complement factor H  (CFH) gene are placed at additional risk of 
developing AMD above that of the normal population (DeAngelis et al., 2007).   In addition, 
smoking is thought to induce oxidative stress.  Oxidative stress is already implicated in disease 
pathogenesis. Diet also suggests a role for oxidative stress in the progression to late-stage AMD. 
Studies have found a beneficial effect from using beta-carotene, vitamin C and vitamin E and zinc 
supplements, which reduced the risk of losing visual acuity. Meanwhile ultraviolet light, a 
suggested source of photo-oxidative stress in the retina, has been associated with AMD.  A meta-
analysis of fourteen studies identified an increasing risk of AMD with greater sunlight exposure. 
Even the non-population based studies identified a significant risk when the data was pooled 
(p=0.004) (Sui et al., 2013). 
 
At a cellular and molecular level a number of processes have been found to result in AMD 
progression.  Firstly, a number of cellular pathways, which play a part in normal retinal 
physiology, have been found to dysfunction. One of the primary roles of RPE cells is 
photoreceptor homeostasis. RPE phagocytose photoreceptor outer segments (OSs). Lipofuscin 
accumulates within RPE with age and is thought to be a by-product of incomplete lysosymal 
digestion of photoreceptor OS (Sui et al., 2013).  One of the components of lipofuscin is N-
retinylidene-N-retinyl-ethanolamine (A2E).  A2E has been shown to affect RPE function by 
reducing degradation and processing of lipids (Holz et al., 1999, Finnemann et al., 2002, Lakkaraju 
et al., 2007).  It also sensitizes RPE to light induced damage and induces innate immune system 
activation. As a result, A2E is likely to be a mediator of RPE cell death and is associated with 
AMD (Sparrow and Cai, 2001). Apolipoprotein E (Apo-E) has been noted in drusen and variant Ɛ2 
is a risk for AMD (McKay et al., 2011).   
 
Inflammation has been implicated as one of the initial causes of injury in AMD.  The first studies 
that identified inflammatory mediators were histopathology studies from AMD patients. In early 
AMD, immunoglobulins have been identified in drusen (Newsome et al., 1987, Johnson et al., 
2000, Mullins et al., 2000a).  Various inflammatory mediators have also been found including c-
reactive protein. A cell-mediated response is also triggered with dendritic cells found to be in direct 




Cell-mediated inflammation was thought to be the primary mechanism of cell injury as 
mononuclear cells, multinucleated giant cells, active microglia and dendritic cells all identified in 
AMD (Hageman et al., 2001, Anderson et al., 2002, Penfold et al., 1986, Penfold et al., 1985).    In 
addition, a humoral response with retinal autoantibodies have been detected in the sera of patients 
(Gurne et al., 1991). The retina, which is normally relatively immune privileged, loses some of this 
privilege during inflammation partly due to breakdown of the blood-retinal barrier (Ohta et al., 
1999, Ohta et al., 2000).  It is unclear what may trigger this but several infectious agents have been 
implicated in causing the initial inflammatory response (Ishida et al., 2003, Kalayoglu et al., 2005). 
The most compelling evidence that chronic inflammation plays a central role in AMD comes from 
the finding of activated complement pathway components in drusen.  There is also an increased 
risk of AMD in allelic variants of genes involved in the complement pathway.  The complement 
pathway will be discussed in more detail in the complement pathway chapter. 
 
Taken together the information in this section illustrates that there are a multitude of factors which 
may contribute to the development of AMD.  This provides not only marked inter-individual 
differences but also differences in phenotype and pathology in the eyes of individuals.  
Consequently studies of AMD require large numbers to confirm phenotype correlations.  
 
1.1.4 Animal models of macular degeneration 
 
A number of animal models have been developed in order to recapitulate AMD in the laboratory 
setting.  The majority of animal models of AMD are murine.  Animal models allow the study of the 
interaction between neuro-retina, RPE, BM and choroid complex with systemic modulators of 
disease. Murine models have shown phenotypes in mutations of human genes related to AMD and 
have therefore been proposed (Mishima and Kondo, 1981) as a good way of modelling AMD 
(Elizabeth Rakoczy et al., 2006).  There are however several limitations with the use of rodent 
models.  Firstly, rodents do not have a macula (Zeiss, 2010).  There is no cone rich region in 
rodents unlike porcine or primate models.  A further point is that rodent physiology appears to be 
different from human retinal physiology .  For example, the models do not appear to have any 
drusen like sub-RPE deposit with some evidence that lysosomes are exocytosed apically rather 
than basally as in human RPE (Mishima and Kondo, 1981). As a result, findings from animal 
studies have to be interpreted within this context of several limitations for modelling of human 
AMD. This section looks at animal models of different stages of AMD. 
 
One of the earliest changes in AMD is the development of deposits in BM.  The deposits found 
between the RPE basement membrane and inner collagenous layer are known as BLinD.  The 
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deposits developing between the RPE and the RPE basement membrane and are known as BLamD. 
BLinD formation is associated with AMD. BM is also known to thicken with age. Ageing in 
different mice strains is thought to result in similar changes (Ramkumar et al., 2010, Dithmar et al., 
2001).  Mice fed with a high glucose or fat diet also have BM thickening.  APOE has three main 
allelic variants that confer differing risk of AMD.  These are Ɛ4, Ɛ3 and Ɛ2 respectively in 
decreasing risk of AMD. ApoE null mice develop thickened BM with both sub-RPE lipid and 
intra-BM lipid deposits. Knock-in mice have also been developed with the various risk alleles. 
These mice all develop BM thickening and sub-RPE deposits when provided a high fat diet (Malek 
et al., 2005).  Whilst the Ɛ4 allele is protective in humans, it appears to cause the most severe 
disease in these murine models (Malek et al., 2005). Low density lipoprotein (LDL) receptor 
knockout mouse also have thickened BM. In a similar manner to the APOE knockout mice they 
have raised triglyceride levels. CD36 knockout mice also develop BM thickening.  CD36 binds 
oxidised phospholipids on RPE (Picard et al., 2010).  Both mice require feeding on a high fat diet 
to develop their phenotypes. These studies highlight the potential role of aberrant lipid metabolism 
in early AMD. 
 
Drusen is a feature of early AMD. A number of mouse models develop white drusenoid deposits.  
Studies demonstrate that drusenoid deposits are unlikely to be composed of constituents of drusen 
and are likely to be due to microglia or macrophages (Luhmann et al., 2009).   Additionally, the 
RD8 mutation has been found to cause white lesions in the retina in several models of retinal 
disease (Chang et al., 2013).  The RD8 mutation does not conform to any human gene mutation 
associated with AMD.  Modelling drusen using rodent models has proven difficult.  However, 
primates have a macula region with a fovea and a retina that appears to have RPE with basal 
exocytosis of lysosomal material (Ishibashi et al., 1986, Gouras et al., 2008). Both Rhesus 
monkeys and Macaques have been reported to develop drusen (Gouras et al., 2008, Umeda et al., 
2005).  Thirty-two percent developed drusen, which contained ApoE, amyloid P, C5 and C5b-9 
however this required 16.9 years on average making experimental design difficult (Umeda et al., 
2005). However, primate models have failed to recapitulate later disease features such as 
geographic atrophy or CNV. 
 
Oxidative stress has been implicated in AMD as a potential source of initial RPE injury with 
incomplete digestion of photoreceptor OS.  One of the products of OS digestion is 
docosahexaenoic acid (DHA).  An oxidised product from DHA is carboxy-ethylpyrole (CEP).  
When mice were innoculated with CEP they developed AMD related phenotypes including 
deposition of complement components in sub-RPE deposits followed by loss of overlying RPE.  
The model highlighted interactions between the complement pathway and oxidative stress 
12 
 
(Hollyfield et al., 2008). Superoxide dismutase (SOD) is one of the main regulators of reactive 
oxygen species (ROS) in the RPE. In mice however, the knockout of SOD1 has resulted in BM 
thickening and drusen-like deposit, RPE loss and CNV in mice aged greater than 10 months 
(Imamura et al., 2006). Similarly, knockdown of SOD2 resulted in RPE degeneration, BM 
thickening and photoreceptor loss (Justilien et al., 2007).   
 
A number of allelic variants for genes encoding the components of the complement system and the 
alternative complement pathway in particular have been associated with AMD. The complement 
system is discussed in more detail below. Perhaps the most studied gene in AMD is CFH, a 
negative regulator of the alternative complement pathway. A CFH null mouse has been generated 
which developed a mild neuro-retinal degeneration.  However, the mouse did not develop BM 
thickening or sub-RPE deposits.  It also developed autofluorescent lesions in the retina.  Thus far, 
this model has not been checked for the RD8 mutation, which can also result in similar changes 
(Coffey et al., 2007). 
 
Chemokines direct immune cells to sites of inflammation. Ccl2, also known as monocyte 
chemoattractant protein, is raised in AMD patients (Sennlaub et al., 2013).  In Ccl2 knockout mice 
there was an increase in BM thickness, drusen like deposits and complement component deposition 
by 9 months (Ambati et al., 2003). Older mice also developed CNV.  However, there is some 
debate over the phenotype of this mouse with a further study noting no progression of deposit 
(Luhmann et al., 2009).  This suggests that in mice the clearance of deposits may be performed by 
macrophages as these deposits also contained the OS fragments A2E (Ambati et al., 2003). 
Meanwhile Cx3cr-1 null mice have an accumulation of microglia in the sub-retina.  Fundoscopy 
reveals drusen like lesions at corresponding sites. However, further detailed study following 
removal of any RD8 mutations failed to replicate the phenotype (Luhmann et al., 2009). 
 
Geographic atrophy and CNV are the hallmarks of late-stage AMD.  A GA pattern is found in 
Dicer1 knockout mice with downstream signalling similar to that found in humans (Tarallo et al., 
2012). There have been a number of animal species used for modelling CNV using lasers (Ryan, 
1979, Criswell et al., 2004).  Neovascularisation peaks at approximately 4-6 weeks with regression 
of vessels starting as early as 3 weeks (Ohkuma and Ryan, 1983, Ryan, 1982).  
 
In summary, there are a variety of potential animal models for AMD.  The majority of 
these are murine and require some manipulation in order to show features of AMD.  
However, the lack of phenotypes in murine mutants of key macular degeneration 
associated genes suggests that murine pathophysiology is different to that in man.  This 
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points to the need to develop a humanized model of macular degeneration. 
 
 
1.1.5 Studying complex disorders using monogenic disease 
 
Our knowledge of many common complex diseases has been generated from the initial study of 
rare inherited forms of these common conditions that have highlighted critical pathways in disease 
pathogenesis. This section will briefly review some diseases in which this approach has benefitted 
understanding of more common disease.   
 
Perhaps the best example of mechanistic determination from rare familial forms comes from the 
study of Alzheimer’s disease (AD). Approximately only 1-6% of AD is early onset (Rocca et al., 
1991).  Autosomal dominant inheritance is rare making up only 13% of inherited types of early 
onset AD (Campion et al., 1999). The inherited forms have altered the processing of amyloid 
precursor protein (APP). The identification of the role of presenilins and APP in the formation of 
deposits in AD helped in the understanding of plaque formation in AD. 
 
In diabetes mellitus (DM), maturity onset diabetes young (MODY) is a form of diabetes has certain 
traits of type 2 diabetes but occurs in the young (<25).  MODY is a cause of less than five percent 
of DM (Ledermann, 1995).  Currently six genes are known to cause MODY.  All have an 
autosomal dominant inheritance pattern.  Some of the MODY mutations are linked to 
abnormalities in glucokinase function and have provided insights into beta islet cell dysfunction 
and in understanding the pathophysiology in DM (McCarthy, 2004). 
 
As in AD, the final critical pathways for hypertension have also been made clear by investigation 
of Mendelian inherited forms of hypertension.  Although population studies have highlighted how 
ageing, body mass index, diet, lack of exercise and salt intake are risk factors for the disease the 
molecular mediators of hypertension were not clear.  Studies of gene defects in the epithelial 
sodium channels in the cortical collecting tubule can cause severe hypertension as in Liddle’s 
syndrome (Knight et al., 2006). Further studies from autosomal dominant inherited hypertension 
have highlighted the importance of the renin-aldosterone and angiotensin system and provided 
targets for treatment of essential hypertension (Snyder, 2002).  
 
Rare Mendelian inherited diseases, which share traits with more common complex diseases, 
provide a platform to study disease mechanisms and can highlight common pathogenic pathways. 
Using rarer inherited monogenic forms of macular degeneration may also provide a suitable 






1.2 Late-onset retinal macular degeneration  
 
 
AMD is a common complex and highly variable disease, which can result in severe visual 
disability.  Although there are treatments for certain forms of late-stage AMD there is a need to 
develop early preventative treatments for all AMD.  Understanding early disease pathogenesis has 
been hampered by the dearth of models replicating human pathophysiology and this in turn has 
limited the developments of new treatments.  This points towards the need to develop a reliable 
humanised model of macular degeneration.  The use of monogenic diseases with key 
characteristics of AMD may provide a pathway for the better understanding AMD. 
 
L-ORMD is a rare monogenic disorder of the retina resulting from a mutation in the gene 
C1QTNF5. It is dominantly inherited and fully penetrant. Patients carrying the gene progress 
through a series of signs and symptoms in various stages of the disease.    It shares key clinical and 
pathological characteristics with age-related macular degeneration and has consequently been 
proposed as a good model for macular degeneration (table 1.2).  This section summarises clinical 







 L-ORMD AMD 
 
Age of onset 50-60 years old 70-80 years old 
 
Central phenotype Early peri-foveal yellow 
dots and pigmentation, later 
atrophy and choroidal 
neovascularisation 
Varied forms of drusen 
including soft, hard, 
reticular pseudodrusen and 
cuticular drusen 
Peripheral phenotype Marked scalloped atrophy in 
later disease extending to far 
periphery 
Normal 
Dark adaptation Delay most sensitive 15 
degrees temporal to the 
fovea 
Delay most sensitive at the 
fovea 
Full field ERG Reduction in amplitude and 
increased latency in late-
stage disease 
Usually normal 
Visual field Field field loss starting 
centrally extending to the 
far periphery in late disease. 
Automated usually normal 
with mild changes in 
extensive AMD 
Anterior segment Long anterior zonules, and 
peripupillary atrophy 
Normal 
Table 1.2: A comparison of phenotypic features in L-ORMD and AMD. 
 
 
1.2.1 L-ORMD clinical characteristics 
 
Patients are asymptomatic during the first four decades of their life. However, they do exhibit 
phenotypic signs of L-ORMD.  On dilatation, patients are noted to have long anterior zonules on 
their lenses (Ayyagari et al., 2005). The youngest patient reported was aged 24 years.  Patients may 
also display iris atrophy particularly in the peripupillary ruff and mid periphery and some may 
develop pigmentary secondary glaucoma (Ayyagari et al., 2000, Ayyagari et al., 2005, Subrayan et 
al., 2005).   
 
L-ORMD has been classified to three main stages (table 1.3). The first symptoms described by 
patients usually occur in their fifth decade of life.  Patients describe dark adaptation difficulties.  
Examination shows early drusenoid changes with yellow dots in their peripheral macula (Milam et 
al., 2000).  Dark adaptation investigations show early latency although there is some variability 
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(Ayyagari et al., 2005). Other investigations including kinetic perimetry and electroretinography 
(ERG) are normal in the early stage of the disease. As the disease progresses areas of neuro-retinal 
atrophy develop in the peripheral macula and gradually increasing in size initially sparing the fovea 
(Milam et al., 2000). Consequently best-corrected visual acuity (BCVA) may be relatively well 
preserved till late in the disease. Visual field testing may show abnormalities from 10 to 40 degrees 
from the central vision (Milam et al., 2000).  
 
Stage Age Phenotypic features 
 
1 0-40  Normal fundus 
 Long anterior zonules 
2 40-60  Normal best corrected visual 
acuity 
 Dark adaptation delay 
 Peri-foveal yellow dots 
 Pigmentation in the macula 
 Early atrophy sparing the fovea 
3 >60  Reduced best corrected visual 
acuity 
 Atrophy involving the fovea 
 Neovascularisation 
 Scalloped atrophy of the 
peripheral retina 
 Scotomas on perimetry 
 Reduced full field ERG 
 
Table 1.3: Summary of clinical findings at each stage of L-ORMD  
 
 
In late-stage disease, the fovea also becomes affected resulting in a marked loss of central vision 
(Kuntz et al., 1996). Additionally, CNV may develop which rapidly involute to form gliotic scars 
(Ayyagari et al., 2005). Areas of atrophy are well demarcated and mid-peripheral bone spicule 
changes occur (Kuntz et al., 1996, Duvall et al., 1986). Interestingly, these cases reported sharply 
demarcated lines between healthy and atrophic retina as the prominent feature of affected eyes as 
well as mid-peripheral bone spicule pigmentation. More recent clinical studies using spectral 
domain ocular coherence tomography  (SD-OCT) have revealed a loss of photoreceptors and 
thinning of the neuro-retina in atrophic and peri-atrophic areas (Vincent et al., 2012, Soumplis et 
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al., 2013).  At this stage full field ERG is reduced showing prominent rod-cone dystrophy (Vincent 
et al., 2012). 
The disease continues to progress beyond the macula and in the ninth and tenth decades 
patients have almost full field visual loss with an atrophic retina resembling retinitis 
pigmentosa. 
 
1.2.2 L-ORMD pathology 
  
Light microscopy of donor L-ORMD eyes revealed thick sub-RPE deposits extending from the 
ora serrata to the macula and were approximately 50um thick (figure 1.3).  The deposits 
extended from the basal lamina of the RPE to the inner collagenous layer of Bruch’s membrane. 
At the macula there was disruption of photoreceptors, RPE and Bruch’s membrane, although the 
anterior retina was not affected (Milam et al., 2000, Kuntz et al., 1996).  Rod outer segments 
were shortened with disorganised disc membranes especially at the macula  (Duvall et al., 1986). 
New blood vessels were formed extending from the choriocapillaris through Bruch’s membrane, 




Figure 1.3 Electron micrograph image of a L-ORMD post-mortem donor retina.  The image shows 
a thick heterogeneous deposit below the RPE.  The outer layer of the deposit has lipid globules 
which have been extracted during the preparation of the sample (Arrowheads).  Below the 
deposit above the elastic lamina of Bruch’s membrane is a new fibrovascular layer with a CNV. 
Apically photoreceptor outer segments are visible (curved arrowheads). This image is modified 
from (Milam et al. 2000 ) 
Immunohistochemistry of the deposits revealed collagen, lipids, amyloid P, lysozyme, elastin, 
apolipoprotein B-100, calcium, esterified and unesterified cholesterol and rhodopsin, with Muller 
cell processes also observed in some regions (Kuntz et al., 1996, Milam et al., 2000). 
Autofluorescence studies have also found marked lipofuscin autofluorescence in L-ORMD RPE 
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(Duvall et al., 1986).  
 
Electron microscopy demonstrated fibrous growth, with deposits anteriorly showing amorphous 
material with electron dense material inclusions and posteriorly showing more granular material 
and possible macrophages. There was apical displacement of RPE by spherical deposits, which 
consisted of basal lamina-like surface shells and cores containing wide-spaced collagen. 
 
 
1.2.3 Hypotheses of C1QTNF5-mediated pathogenesis 
 
 
The C1Q and tumour necrosis factor 5 (C1QTNF5) gene is located on chromosomal region 11q23.  
C1QTNF5 is translated from 3 exons. The whole gene is found within a 3’ untranslated region of 
the mouse frizzled-related protein (MFRP) gene. The gene is conserved across vertebrate species 
(Hayward et al., 2003). The mutation responsible for L-ORMD occurs from a C to G substitution 
in the third exon. C1QTNF5 protein is composed of a globular C1Q domain, a collagen like 
domain and signal peptide at the nitrile end.  The protein has a molecular weight of 25kDa 
(Kishore et al., 2004, Tu and Palczewski, 2012).   The mutation codes for an amino acids within 
the globular C1Q domain (gC1Q).   
 
The exact function of C1QTNF5 has yet to be established.  In the eye, C1QTNF5 is most highly 
expressed in the baso-lateral RPE and the ciliary body epithelium (Ayyagari et al., 2005). A 
systemic expression analysis revealed that C1QTNF5 was most highly expressed in the stromal 
cells of adipose tissue as well as having lower expression in brain and testes (Wong et al., 2008).    
It has been hypothesised that C1QTNF5 plays a role in lipid metabolism because of a similarity in 
structure to adiponectin.  C1QTNF5 was suggested to act as a circulating adipokine particularly in 
the absence of other members of the C1QTNF family and in insulin resistance (Schmid et al., 
2013). Meanwhile a role in glucose metabolism was proposed because serum levels of C1QTNF5 
were raised in insulin resistant rodents (Park et al., 2009). Additionally, in human studies, levels of 
C1QTNF5 reduced as insulin resistance decreased following exercise (Lim et al., 2012). 
C1QTNF5 was shown to phosphorylate 5’ adenosine monophosphate-activated protein kinase 
(AMPK) leading to increased cell surface recruitment of glucose transporter type 4 (GLUT4) 
receptors to increase glucose uptake (Park et al., 2009).  MFRP and C1QTNF5 also interact, 
suggesting a functional relationship between the two proteins. MFRP is a transmembrane protein 
containing N-terminal cytoplasmic region, a transmembrane domain, and an extracellular region 
with tandem repeats of two cubulin domains, low-density lipoprotein receptor related sequence, 





It is also unclear how mutant C1QTNF5 causes pathology in L-ORMD.  Mutant C1QTNF5-
expressing transfected cells showed significantly reduced adhesion when compared with the wild-
type C1QTNF5 expressing transfected cells. There was a differential adhesion with reduced 
binding to laminin but no difference with fibronectin (Shu et al., 2006b). One proposed mechanism 
of deposit formation was through reduced adhesion of RPE to Bruch’s membrane resulting in an 
increased ECM deposition in the sub-RPE space.  
 
Mutation in C1QTNF5 results in an alteration of transport and processing of the protein.  In studies 
using stably transfected cell lines wild-type C1QTNF5 was found to be secreted whilst mutant 
protein was not (Shu et al., 2006b). A western blot of the conditioned media showed good 
migration of wild type protein but not the mutant suggesting that aggregation of the mutant play a 
role in dysfunction.  C1QTNF5 was found in cell lysates as well as the secretome of transfected 
cells.  However, mutant protein was only found in the cell lysates (Mandal et al., 2006a) Staining 
of C1QTNF5 suggested a co-localisation with ER markers (Shu et al., 2006b). Taken together the 
evidence points to mutant C1QTNF5 not being secreted and retained as aggregates in the 
endoplasmic reticulum potentially causing a disorder of protein degradation.  It is not clear whether 
L-ORMD results in a gain of function from cellular stress or whether this causes a loss of function 
from reduced secretion of wild type protein. 
 
1.2.4 Mouse models of L-ORMD 
 
Thus far, only one heterozygous knock in mouse model of L-ORMD has been published (Chavali 
et al., 2011).  These mice replicate many of the changes found in humans.  They demonstrate early 
slow rod-B wave recovery on ERG which is similar to the dark adaptation delay seen in patients. In 
addition, they have retinal white spots, RPE abnormalities, sub-RPE deposit vascular leakage and 
photoreceptor loss.  From 10 months onwards mice developed hyperfluorescent white spots which 
increased with age. However, histopathology revealed only pynknotic photoreceptor nuclei at 12 
months with swollen inner segments by 15 months with cells loss only being identified at 21 
months.  Expression of C1QTNF5 and rhodopsin was significantly reduced by twelve months.  
These findings were consistent even after removal of RD8 mutations from the mice (Sahu et al., 
2015). 
 
Dinculescu et al. also attempted to produce a murine model of L-ORMD by delivering mutant 
C1QTNF5 using an AAV vector with expression driven by a BEST1 promoter (Dinculescu et al., 
2015). One eye of the C57BL/6 mice received 1ul 1 x 1012 genome copies/ml.  The other eye was 
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left as an untreated control. Two months post procedure expression of AAV C1QTNF5 was found 
throughout the RPE.  Mutant C1QTNF5 was found to be retained within RPE forming large 
spherical aggregates. The mutant also secreted towards the basal side forming a sub-RPE layer 
whilst wild type C1QTNF5 was also found on the apical RPE.  Nine months post procedure mice 
showed RPE loss and photoreceptor and neuro-retinal layer thinning. The deposits were found to 
contain high levels of mutant C1QTNF5. 
 
In summary, L-ORMD is a fully penetrant disease in which all patients carrying the mutation 
develop pathology. The pathology occurs earlier and is more severe than AMD.  Additionally, L-
ORMD displays many of the traits of AMD.  There is a good animal model of disease for 
potentially translation and to date transfected non-retinal cell models have suggested pathological 
mechanisms.  Taken together these suggest that L-ORMD is a good disease to model macular 
degeneration. 
 
1.3    The Complement System 
 
The complement system is part of the innate immune system.  The complement system plays 
several roles including defence against pathogens, removal of apoptotic cells and debris, clearance 
of immune complexes and stimulation of adaptive immune responses (Walport, 2001).  The 
pathway is an amplification cascade.  It is composed of over 40 proteins with three main triggering 
arms which culminate in a final common pathway leading to the formation of a membrane attack 
complex (C5b-9).    The main aim of this section is to provide background information regarding 
the normal role of the pathway including a more detailed look at the principle components and 
regulators and in particular complement factor H.  Although there is a large amount of evidence for 
the role of the complement pathway in AMD pathogenesis it is still unclear whether complement 
dysfunction is the initiating mechanism for disease or whether the complement propagates AMD.  
In addition, it is still unclear why a system whose primary role is to protect the body from attack 
does itself appear to cause localised activation and injury.  
 
1.3.1 The activation and regulation of complement activity 
 
The complement cascade is initiated by three main pathways; the classical, the lectin and the 
alternative pathway (Walport, 2001)(figure 1.4). Each pathway has its own particular set of triggers 
to initiate the cascade. The classical pathway is activated when C1q binds to the Fc portion of IgM 
or IgG complexes or to CRP, beta-amyloid and low density lipoprotein.  In addition, C1Q can be 
activated by binding to apoptotic cells (Gaboriaud et al., 2004). C1q activates the enzyme C1r 
which then cleaves C1s. C1s activates C2 to C2a and C2b and activates C4 to release C4a and C4b 
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(Nauta et al., 2002).  C2b and C4b form a complex, which acts as a C3 convertase.  The lectin 
pathway is initiated when the molecules mannose-binding lectin (MBL) and ficolins  (L, H and M) 
bind to bacterial surfaces (Thiel, 2007).  This complex activates serine proteases which in turn 
cleaves thioester bonds on C2 and C4 resulting in the formation of C2a and C2b in addition to C4a 
and C4b.  C4b and C2b then form a complex, which acts as a C3 convertase. 
The alternative complement pathway has a continuous tickover (Pangburn et al., 1981). It is 
activated by the hydrolysis of C3 to form C3 (H2O). When this molecule binds with Bb from the 
CFD mediated cleavage of CFB it forms a C3 convertase C3 (H2O)Bb (Pangburn et al., 1981). All 
three C3 convertases convert C3 to C3a an anaphylatoxin and C3b an opsonin. This activates the 
major amplification loop of the complement system. C3b binds to CFB, which is cleaved by CFD 
to Bb and Ba (Montes et al., 2009).  The Bb fragment remains bound to C3b, which forms a C3 
convertase to produce further C3b, thereby, increasing the number of C3b molecules in the 
amplification loop.  Generated C3b binds to the C3 convertase C3bBb to form C3bBb3b in the 
alternative pathway.  C3b also binds to C4b2b generated from the classical and lectin pathways. 
The addition of an extra C3b to these complexes forms a C5 convertase, which cleaves C5 to C5a 
an anaphylatoxin and C5b.  C5b binds to C6, C7, C8 and C9 to form the terminal complement 
complex (TCC).  Multiple C9s bind to the complex and form a ring on the cell membrane to create 
a perforation in the membrane. 
 
Figure 1.4 Schematic of the complement pathway.  The diagram shows that three main 
pathways exist which converge on C3.   C3b cleavage from C3 leads to the formation of C5 
convertases which cleaves C5b.  This complexes with factors C6, C7, C8 and C9 to form a terminal 
complement complex C5b-9 also known as the membrane attack complex. Rutemark, C., Alicot, 
E., Bergman, A., Ma, M., Getahun, A., Ellmerich, S., Carroll, M.C. and Heyman, B., 2011. 
Requirement for complement in antibody responses is not explained by the classic pathway 





The complement cascade has several regulators in order to prevent widespread destruction from 
deposition of MAC complexes. The classical and lectin pathways are inhibited by C1 esterase 
inhibitor. A C2 receptor inhibitor also prevents the activation of C2 by C1s (Inal et al., 2005). The 
main regulator of the tickover loop of the alternative complement pathway is complement factor H 
(CFH).  The role of CFH is regulation is discussed in more detail below.  However, it is thought 
that in the fluid phase CFH-related proteins (CFHR) may also help inhibit the alternative 
complement pathway CFHR-1 has been shown to both assist the decay of C3 convertases and help 
inactivate C3b to iC3b in a similar manner to CFH.  The CFHR is thought to act mainly in the fluid 
phase as it lacks many of the cell surface binding components of CFH (Jozsi et al., 2007).  The 
further breakdown of iC3b leads to the cleavage of C3d the surface bound thioester domain of C3. 
The equivalent inhibitor of the lectin and classical pathways is C4b-binding protein.  Together 
CFH, CFHR and C4b-binding proteins also help recognise self-glycosaminosglycans  (GAGs) and 
self-sialic acids and prevent attack on self-cell surfaces.CFHR-1 protein also binds to C5 
convertases to inhibit their function (Heinen et al., 2009).  Cells also express decay accelerators 
which help the breakdown of convertases including CD55 a decay accelerating factor  (DAF) and 
membrane co-factor protein also known as CD46 (Persson et al., 2010). The TCC formation is also 
regulated by a cell surface regulator CD59 that prevents the formation on cell surfaces.  CD59 
prevents C9 polymerising on cell membranes and in so doing prevents MAC formation.  Soluble 
regulators such as vitronectin and clusterin are able to bind to formed complexes in the 
extracellular matrix to prevent the formation of the TCC complex. There is also some evidence that 
these compounds decay MAC itself (Johnson et al., 2011). 
 
1.3.5 Complement dysregulation in AMD pathogenesis 
 
Drusen is one of the first clinical hallmarks of early AMD. Various studies have identified 
complement components in drusen suggesting that complement may be involved early in AMD 
pathogenesis. Early components of the complement pathway CFB and anaphlyatoxins C3a andC5a 
have been found in drusen (Gold et al., 2006).  Meanwhile terminal pathway component C5 and 
C5b-9 were found to be at the core of drusen (Mullins et al., 2000a). Additionally regulators of the 
complement pathway including CFH, vitronectin, clusterin and MCP have also been shown to be 
present (Johnson et al., 2001, Hageman et al., 2006).  
 
Cadaveric samples from AMD patients showed raised levels of complement pathway proteins in 
the BM and choroid when compared with control eyes (Yuan et al., 2010). The expression levels 
were greatest at the macula. The vitreous of patients also showed raised levels of complement 
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pathway C3, CFB and CFD in the vitreous of advanced disease when comparing levels to patients 
with early disease (Loyet et al., 2012).  Additionally, MAC complex deposition was greatest in the 
RPE/choroid of AMD patients (Hageman et al., 2005).  Regulators of complement pathway 
activation have also been shown to be abnormal in human cadaveric studies. MCP was reduced in 
early AMD and CD59 expression was reduced in the RPE of AMD patients (Vogt et al., 2011, 
Ebrahimi et al., 2013).  In late stage disease, CNV removed at the time of surgery showed C3a, 
C5a and C5b-9 immunostaining of these vessels suggesting activation of complement pathways 
(Lommatzsch et al., 2008).  Examples of damage caused by complement dysregulation in other 
systems include systemic lupus erythematosus  (SLE), atypical haemolytic uraemic syndrome  
(aHUS) and dense deposit disease  (DDD) (Manderson et al., 2004, Kavanagh et al., 2012, 
Martinez-Barricarte et al., 2010). Similarly, complement dysregulation may lead to pathogenesis in 
AMD.  
 
It is still not completely clear whether the increase in complement component deposition seen in 
AMD is due to localised or systemic factors. Bb, C3, C3d, iC3b, and CFD were all raised in 
patients with AMD (Reynolds et al., 2009, Scholl et al., 2008).  C3d, CFB, Ba and CFD were also 
raised at greater levels in advanced AMD.  In addition, these complement components could be 
combined with genotypic information to accurately predict AMD in up to 79% of cases (Hecker et 
al., 2010).  A single standard deviation increase in levels of these products increased the risk of 
AMD 5 fold. The link between CFH serum levels and AMD has been more mixed (Hakobyan et 
al., 2008, Hecker et al., 2010). However, CFH autoantibodies are reduced in AMD patients 
(Dhillon et al., 2010). 
 
Genetic studies have also exposed an association between allelic variants of complement pathway 
components and AMD. The first single nucleotide polymorphism (SNP) found to be associated 
with AMD was discovered in CFH (1q32) gene (Haines et al., 2005, Hageman et al., 2005, Klein 
et al., 2005, Edwards et al., 2005).  CFH is a negative regulator of the alternative complement 
pathway. The discovery of the Y402H polymorphism has been replicated in different populations 
(Haines et al., 2005, Hageman et al., 2005, Klein et al., 2005, Edwards et al., 2005).  The 
polymorphism is thought to have a 25% to 50% attributable risk. Additionally it was found to 
result in patients showing signs of AMD 7 years earlier than AMD patients without the 
polymorphism and it also increased the rate of disease progression (Mori et al., 2007, Baird et al., 
2006). A mouse model for human Y402H was developed which developed some changes similar 
to AMD including sub-retinal deposit. The SNP codes for a region of component compound 
module (CCP) 7 on CFH. This region binds heparin, CRP and necrotic cells (Clark et al., 2006, 
Laine et al., 2007, Ormsby et al., 2008). Further studies on CFH have revealed many more allelic 
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variants with strong associations with AMD (Li et al., 2006). The C2/CFB (6p21.3) gene codes for 
complement component C2.  SNPs in C2 and CFB had a protective effect on AMD (Sun et al., 
2012). The protective variant of CFB was shown to have four times less affinity with C3b.  
Therefore the C2 allelic variant was less likely to form the C3 convertase in the amplification loop 
(Montes et al., 2009). Another protective variant in the CFB gene was found in the cleaved signal 
peptide region and has been proposed to alter the secretion of CFB (Gold et al., 2006).  C3 is 
encoded by the C3/CFD (19p13.3-p13.2) gene. C3 polymorphisms are associated with an 
increased attributable risk of AMD. A substitution of arginine to glycine at position 102 in the C3 
protein results in a 2.6 fold increase in AMD risk for those homozygous for the variant. The 
population attributable risk for CFD in AMD is low but a meta-analysis of studies does show an 
association for AMD in CFD SNPs (Stanton et al., 2011). Patients with AMD also have higher 
levels of CFD.   
 
CFI is encoded by the CFI (4q25) gene. CFI has an association with AMD (Yu et al., 2011).  The 
allelic variant associated with AMD is found in an intronic region of the gene and is therefore 
thought to affect the promoter region of CFI.  SERPING1 (11q12-q13.1) codes for a naturally 
occurring inhibitor of C1, which prevents its activation in the classical complement pathway.  
Polymorphisms were found to be associated with AMD and later confirmed with a case control 
study (Ennis et al., 2008).  The finding is relatively surprising in the light of all the previous 
associations with the alternative complement pathway.   
 
In summary, there is strong evidence for a role for the complement pathway in AMD pathogenesis. 
This suggests value of investigating the complement pathway in a model of macular degeneration. 
 
 




1.4.1 Retinal pigment epithelium, Bruch’s membrane and choroid 
 
The RPE is the primary cell type expressing C1QTNF5 within the eye.  The RPE is also known to  
 
show disorganisation and is lost in L-ORMD.  There is evidence from transfected cell studies that 
RPE dysfunction also plays a role in L-ORMD disease mechanism.  As a result, the RPE is likely 





The RPE layer is a pigmented, polarised, polygonal monolayer of cells. It is a cuboidal epithelium 
found between the photoreceptor outer segments and the Bruch’s membrane below it.  RPE cells 
are relatively flat with height of approximately 10-12um and a width of approximately 14um at the 
macula.  In the periphery, the width of cells increases to approximately 60um. The RPE are 
polarized cells with an apical-basal polarity (Marshall, 1987, Streeten, 1969).  At its apical surface 
the RPE is in contact with an extracellular matrix known as the interphotoreceptor matrix. In order 
to make contact with photoreceptors the RPE project microvilli.  These small microvilli are 
important for phagocytosis and form sheaths around the photoreceptors (Bairati and Orzalesi, 
1963, Spitznas and Hogan, 1970). The basal surface develops multiple infoldings that increase the 
absorptive and secretive surface area. The apical portion of the lateral walls are important for cell 
to cell adhesion and contain tight junctions and occasional gap junctions (Rahner et al., 2004, 
Konari et al., 1995).  These junctions are important in maintaining the integrity of the monolayer 
and controlling the passage of molecules.  Thus the majority of apical basal flow is controlled by 
the RPE cell itself and therefore enables the cell to modify the composition of the 
interphotoreceptor matrix to maintain the photoreceptor microenvironment.  Although the 
junctions between RPE cells are tight, they are not in the same order of function as other tight 
junctions for instance the blood brain barrier.  There have been various reports of transepithelial 
resistance (TER) from approximately 850 Ω/cm2 to 200 Ω/cm2 (Hu and Bok, 2001).  Cells located 
in the blood brain barrier are reported to have a TER between 1000-2000 Ω/cm2  (Rizzolo, 2007). 
 
The RPE cell is itself packed full of organelles.  The organelles have a polarised organisation.  The 
apical surface is dense with melanosomes.  The nucleus, Golgi body and mitochondria are found 
towards the basal surface.  In keeping with its phagocytic role and anti-oxidative role the RPE has 
many phagosomes which are mobilised using a microtubular intermediate filament architecture.  
The RPE has a high number of mitochondria suggesting high metabolic function. 
 
The RPE is known to have a number of functional roles in the healthy retina including light 
absorption, photoreceptor outer segment phagocytosis, control of oxidative stress, recycling of 
photoreceptor pigment, control of extra cellular composition and growth factor secretion. These 
roles are discussed below as dysfunction in these properties has been linked to various diseases. 
 
The RPE is placed under large amounts of oxidative stress. Within the eye, light is focused on to 
the macula and the fovea in particular.  Ultraviolet is filtered by the cornea and lens and 
consequently blue light cause the greatest damage to the retina and result in photo-oxidative stress. 
RPE also contain large numbers of mitochondria involved in normal generation of adenosyl 
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triphosphate (ATP) to provide the cell with energy.  The nicotinamide adenine dinucleotide 
phosphate (NADPH) dependent oxidases found in organelles also produce large quantities of 
(reactive oxygen species) ROS (Brown and Griendling, 2009). Other enzymatic pathways that lead 
to ROS formation include the cyclo-oxygenase, lipoxygenase and cytochrome p450 pathways.  
Organelles also produce ROS during normal cellular housekeeping including peroxisomes, which 
manage large chain fatty acids from the membranes and endoplasmic reticulum which degrade 
misfolded protein (Dixon and Stockwell, 2014).  The burden of oxidative stress is increased further 
by the phagocytosis of photoreceptor outer segments (discussed below). The enzymatic cascade 
that results from the breakdown products of phagocytosis results in the formation of lipofuscin.  
Following phagocytosis the outer segments are transported to the Golgi body in phagosomes. In 
the phagosomes NADPH-oxidase dependent oxidation results in the generation of hydrogen 
peroxide (H2O2) (Tate et al., 1995).   
In order to combat oxidative stress the RPE has a number of adaptations. Melanosomes are 
organelles that make and store melanin (Raposo and Marks, 2007). Melanosomes also contain a 
range of anti-oxidant enzymes whilst their membranes contain ion channels.  These functional 
elements within melanosomes play a part in scavenging reactive oxygen species (Simon et al., 
2008, Hu et al., 2008).  To catalyse the breakdown of H2O2  the RPE upregulates the generation of 
catalase (Tate et al., 1995).  The RPE also contains a number of other non-enzymatic antioxidants.  
These include carotenoids, zeaxanthin, lutein, α tocopherol and carotene (Liles et al., 1991).   
In order for photoreceptors to function properly they have to regenerate new outer segment (OS) 
discs and remove used discs.  Rods regenerate their outer segments within a fortnight (Young and 
Droz, 1968).  Each RPE is in contact with approximately 300 OSs and phagocytoses between 20-
30,000 discs daily (Young and Bok, 1969). The physiological regulation of phagocytosis is 
regulated by the light/dark cycle and temperature.  RPE perform two main types of phagocytosis; 
specific and non-specific.  Specific phagocytosis requires several steps. αVβ5 integrin on apical 
microvilli recognises photoreceptor OS packets and activates downstream players in phagocytosis 
including MerTK (Finnemann et al., 1997).  The MerTK activated complex interacts with myosin 
IIa.  Together this results in the formation of a phagocytic cup, which enables the microvilli to 
engulf OS. Invagination is thought to be (cAMP) mediated (Edwards and Flaherty, 1986). Non-
specific phagocytosis is similar to pathways found elsewhere in the body and exhibited by 
phagocytic cells such as macrophages.  
The RPE also recycles photoreceptor visual pigments, which are essential for phototransduction.  
Light causes the change in 11 cis retinal to all-trans retinal via several intermediates including 
meta-rhodopsin II (Hargrave, 2001). This activates transducin and induces a hyperpolarisation of 
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the photoreceptor and an alteration of neurotransmitter release to bipolar cells, which effectively 
transduces light energy to produce a neural response.    In rods, all-trans retinal is released from the 
membrane of photoreceptor discs into the lumen. It then binds with N-retinlidene-
phosphatidylethanolamine (N-ret-PE) (Liu et al., 2000).  The complex then joins ABCA4, a large 
transmembrane transporter that transfers the complex into the cytoplasm of the outer segment 
(Allikmets et al., 1998).  Retinol dehydrogenase (RDH) converts all-trans retinal to all-trans 
retinol that subsequently binds to interphotoreceptor binding protein (IRBP) and transfers all-trans 
retinol to the retinal pigment epithelium (Rattner et al., 2000).  Once in the RPE, all-trans retinol is 
released and binds to cellular retinol binding protein (CRBP) which moves into the endoplasmic 
reticulum (ER) where it is esterified by lecithin:retinol acyl transferase  (LRAT) (Fong et al., 
1984).  RPE-65 hydrolyses retinyl esters to 11-cis retinol, which is bound to cellular retinaldehyde 
binding protein (CRALBP) (Hamel et al., 1993, Moiseyev et al., 2006).  LRAT esterifies the 11-cis 
retinol to 11-cis retinyl ester for storage if required (Ruiz et al., 1999).  11-cis retinol is then 
converted to 11-cis retinal by RDH 5 and 11.  CRALBP binds 11-cis retinal before transferring it 
to IRBP, which transfers 11-cis retinal to replenish photoreceptors (Bunt-Milam and Saari, 1983). 
 
The RPE maintains the ECM for photoreceptor homeostasis by enabling transport through cellular 
transporters or by paracellular transport.  Water flows from apical to basal through the cell via a 
number of transport mechanisms (Hughes et al., 1984, Chihara and Nao-i, 1985).  Glucose and 
substances required by the photoreceptor such as DHA are transported from basal to apical (Kita 
and Marmor, 1992, Bazan et al., 1992, Hsu and Molday, 1994). Conversely, waste products from 
the photoreceptors such as lactic acid are transported in the opposite direction (Hamann et al., 
2000).  The RPE also controls extracellular pH by modulating bicarbonate levels.  In order to 
support photoreceptors the RPE secretes fibroblast growth factor (FGF ) (Khaliq et al., 1995).  The 
RPE also secretes a number of other factors including transforming growth factor beta (TGF-β), 
ciliary neurotrophic factor (CNTF), insulin like growth factor and platelet derived growth factor 
(PDGF) (Khaliq et al., 1995, Cao et al., 1997, Campochiaro et al., 1994). Pigment epithelium 
derived factor (PEDF) maintains the stability of the choroidal blood vessel cells and prevents 
proliferation of these cells and hence neo-vascularisation (Dawson et al., 1999).  It also protects the 
neuro-retina from stress-induced damage (Cao et al., 2001).  VEGF is secreted at low levels by the 
RPE mainly basally (Adamis et al., 1993).  Its role in normal function is to maintain 
choriocapillaris vascular endothelial cell viability (Burns and Hartz, 1992).  Thus the RPE plays a 
role in maintaining the local homeostasis of the outer retina. 
 
The RPE layer is attached on its basal surface to the BM.  This acellular pentalaminar structure lies 
between the retinal pigment epithelium and choroid. Histologically the BM can be divided into five 
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layers with a total thickness of only approximately 3.2um that varies according to location within 
the retina.  The outer most layer is the basement membrane of the choriocapillaris. The middle 
layer is an elastin layer that is sandwiched in between two collagenous layers known as the outer 
and inner collagenous layer. The inner most layer of BM is the RPE basement membrane. 
 
Looking at each of these layers starting with the outermost layer the choriocapillaris basement 
membrane is mainly composed of type IV, V and VI collagen in addition to laminin and heparan 
sulphate and is 0.14um thick (Aisenbrey et al., 2006).  Collagen type VI forms the majority of this 
layer and forms microfibrils onto which other structures adhere. The outer collagenous layer of 
BM is composed of collagen type I, II and V which arrange themselves into a grid covered with a 
range of active molecules including glycosaminosglycans  (GAGs), molecules involved in the 
coagulation cascade and complement cascade components (Marmor, 1998). It is approximately 
0.7um thick. The elastin layer is approximately the same thickness as the outer collagenous layer at 
0.8 um and is several times thinner at the macula than the periphery (Chong et al., 2005).  It 
contains elastin fibres, collagen type IV and fibronectin.  The elastin fibres contain small spaces 
sized at approximately 1um to enable the passage of substances through the layer (Marmor, 1998). 
The inner collagenous layer is double the thickness of the outer collagenous layer at 1.4 um but 
otherwise the structures and composition are almost identical (Marmor, 1998). Finally, the inner 
most layer is the RPE basement membrane.  This layer is approximately 0.15 um thick. The 
structure of BM is thought to help cell adhesion, migration, differentiation, control of substances 
transported across the BM and the prevention of choroidal vascularisation of the neuro-retina.  
 
Blood supply to the RPE is provided by the choroid.  This is a vascular layer found outside of the 
Bruch’s membrane-RPE complex.  In humans, the choroid is thickest at birth. It decreases in 
thickness with age from approximately 200um at birth to 80 um by the ninth decade (Ramrattan et 
al., 1994).  The choroid is thickest at the fovea reducing in thickness at the periphery. The Choroid 
is made up of several layers. The choriocapillaris, which lies just outside the Bruch’s membrane, is 
a thin network of fenestrated capillaries.  The choriocapillaris is only 10um thick at the fovea and 
thins more peripherally to approximately 7 um.  The diameter of the capillaries varies between 20-
40um which is larger than normal capillary diameter (Bill et al., 1983). Sattler’s layer sits outside 
the choriocapillaris and contains small to medium sized vessels (Hayreh, 1975).  The vessels 
supply and drain the choriocapillaris. Haller’s layer contains larger medium to large vessels that in 
turn supply and drain the Sattler’s layer (Hayreh, 1975).  In between the vessels lies elastin and 





1.4.2 Human induced pluripotent stem cells (hiPSCs) 
 
After conception, the developing zygote divides to form the morula and blastocyst. These cells 
continue to divide into an inner cell mass and an outer layer of cells known as the epiblast.  Cells 
from the inner cell mass were first isolated and grown in 1998 and were called human embryonic 
stem cells (hESCs) (Thomson et al., 1998).  HESCs were said to be pluripotent stem cells. Stem 
cells have the ability to self-renew and differentiate to other cell types. Cell potency describes the 
ability of a cell to differentiate into other cells.  Pluripotent cells are able to differentiate to cells of 
the three germ layers, which include the endoderm, ectoderm and mesoderm.  With each 
successive differentiation, cells lose their ability to differentiate to other cell types.  However, an 
increasing body of evidence pointed to the fact that under the correct conditions even terminally 
differentiated somatic cells could be reprogrammed back to a pluripotent state  (Gurdon, 1962, 
Wilmut et al., 1997).  Takahashi et al. further interrogated the factors responsible for somatic 
cellular reprogramming and were able to distil these down to four transcription factors.  Using 
these factors, they were able to reprogram first mouse fibroblast cells to a pluripotent state 
(Takahashi and Yamanaka, 2006) and later human fibroblasts to a pluripotent state (Takahashi et 
al., 2007). The resultant cells were called human induced pluripotent stem cells (hiPSCs) as they 
shared properties with other pluripotent cells such as hESCs. 
 
1.4.3   Retinal differentiation of hiPSCs 
 
Retinal differentiation of hiPSCs can be divided generally in to either default differentiation or 
directed differentiation protocols.  Default methods generate RPE without the addition of 
exogenous transcription factors.  The protocols utilise the tendency of pluripotent cells to 
differentiate to neural lineages in the absence of other factors (Munoz-Sanjuan and Brivanlou, 
2002). However, the technique is not efficient and produces mixed populations of cells. 
Additionally, some lines may not have an intrinsic capacity for retinal differentiation, which may 
be dependent on endogenous expression of retinal differentiation genes (Mellough et al., 2012). 
 
In contrast, directed differentiation uses exogenous transcription factors, proteins or small 
molecules to help to recapitulate early embryological development.  For retinal differentiation cells 
are directed through a step wise differentiation through pluripotent cells to primitive anterior neural 
phenotype, retinal progenitor before terminal differentiation in to either RPE or neuro-retinal 
lineages. Directed differentiation protocols had initially been optimised using hESCs (Klimanskaya 
et al., 2004, Lamba et al., 2006, Meyer et al., 2009, Osakada et al., 2008). Fibroblast growth factor 
was shown to be a key regulator of pluripotency in human pluripotent cells (Vallier et al., 2005). 
Removing basic FGF from pluripotent cell maintenance media initiated differentiation (Reubinoff 
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et al., 2001). Neuroectodermal induction requires suppression of other differentiation pathways 
including mesodermal and endodermal cell fates. Suppression of bone morphogenetic protein can 
induce a neuroectodermal like stage (Tropepe et al., 2001). Inhibition of SMAD signalling 
increased neural enrichment to over 90% from 10% (Chambers et al., 2009).  A subset of neurally 
differentiated cells were shown to develop an eye field specification and form retinal cells via a 
retinal progenitor stage (Vugler et al., 2008). Neural progenitors can be directed to a retinal cell 
fate by substances that increase MITF expression such as Activin A (Meyer et al., 2011).  Neuro-
retinal progenitors can in turn be patterned to either RPE or neuro-retinal fate by a number of 
different mediators  (Hirami et al., 2009, Jin et al., 2011, Lamba et al., 2010, Mellough et al., 2012, 
Osakada et al., 2009b).  
   
1.4.4   Disease modelling using hiPSCs 
 
With increasing evidence that hiPSC derived cells recapitulate key physiological and functional in 
vivo characteristics there has been a shift in focus from optimising differentiation protocols to 
modelling retinal disease. The study of retinal disease has been hampered by the limited 
availability of disease causing cell types, which is difficult to obtain from patients. HiPSCs provide 
a valuable alternative. With the correct differentiation protocols hiPSCs can provide an almost 
limitless supply of disease specific cell lines to model human disease.  This approach has been 
used successfully to model diseases from a variety of conditions affecting a number of different 
organ systems. Examples of diseases successfully modelled which have provided insights into 
disease mechanism include amyotrophic lateral sclerosis, long QT syndrome, Alzheimer’s disease, 
sickle cell disease and Friedrich’s ataxia (Bellin et al., 2012, Malan et al., 2011, Yahata et al., 
2011, Zou et al., 2011, Liu et al., 2011). 
 
Looking specifically at modelling diseases of the RPE using hiPSC-RPE several diseases have 
already been studied using this approach.   HiPSC-RPE derived from a patient with gyrate atrophy 
revealed potentially translatable patient specific findings. Gyrate atrophy results from reduced 
activity of the enzyme ornithine aminotransferase (OAT).  Rare variants are able to be corrected 
using vitamin B6 (Meyer et al., 2011).  The study identified that vitamin B6 was able to increase 
OAT activity in the cell lines derived from the patient. The findings could be directly applicable to 
the care of the donor patient. HiPSC-RPE derived from patients with Best vitelliform macular 
dystrophy discovered that mutant RPE developed several types of metabolic dysfunction when 
compared with control RPE including build-up of lipofuscin on feeding of cells, abnormal fluid 
flux, delayed degradation of photoreceptor outer segments and increased oxidative stress after 
feeding (Singh et al., 2013b). Subcellular localisation studies identified an endoplasmic reticulum 
31 
 
localisation of BEST1 protein suggesting that abnormal BEST1 has a role in regulating 
intracellular calcium flux. HiPSC have also been generated from patients with AMD. HiPSC-RPE 
derived from patients with ARMS2/HTRA1 associated with AMD were found on unbiased 
proteomic screening to have increased levels of SOD2 and markers of oxidative stress when 
compared to cells derived from controls with protective risk alleles suggesting a role for inherent 
vulnerability to oxidative stress in RPE cells in disease pathogenesis (Yang et al., 2014a).  
 
There are however several limitations to modelling disease using hiPSCs. When comparing hiPSCs 
to hESCs transcriptional differences have been noted (Liao et al., 2010). HiPSCs have been shown 
to retain some of the epigenetic background of the original cell of the parent cell despite complete 
reprogramming (Bar-Nur et al., 2011, Kim et al., 2010). HiPSCs contained differentially 
methylated DNA regions that were related to the cell of origin (Kim et al., 2010).  Additionally, X-
reactivation does not readily occur when generating hiPSCs (Pomp et al., 2011, Tchieu et al., 
2010).  Failure of transcriptional activation of epigenetically silenced regions can limit the impact 
of using hiPSCs particularly when genes of interest are in transcriptionally silenced regions 
(Urbach et al., 2010). 
 
During hiPSC generation and maintenance, a number of genetic changes may occur in hiPSCs 
when compared to the donor cell of origin.  These changes may limit interpretation of the effect of 
the disease causing mutations.  First generation reprogramming methods generated hiPSCs by 
insertion of transgenes in to the genome.  These insertions could not only silence host cell genes 
but also lead to non-silenced transgene expression (Soldner et al., 2009).  Prolonged culture and 
passaging of hiPSCs has been shown to result in an accumulation of genetic mutations and 
karyotypic abnormalities which may lead to significant differences in gene expression which are 
not related to the disease phenotype  (Ben-David et al., 2011, Laurent et al., 2011). These factors 
can be mitigated by thorough validation. 
 
Additionally not all diseases are suitable for modelling using hiPSCs.  Firstly, the terminally 
differentiated cells generated in culture from hiPSCs are matured for only a short time and may 
reflect functionally immature cells (Kuzmenkin et al., 2009, Peng et al., 2010). This may be 
beneficial when studying developmental diseases or when cell maturity is not relevant to the study 
of a disease mechanism (Itzhaki et al., 2011), but may hamper the study of chronic disease. 
However, hiPSC derived RPE also show phenotypes of functionally mature cells including high 
TER, photoreceptor OS phagocytosis, functional release of growth factors, fluid flux and ATP 
induced calcium release (Kokkinaki et al., 2011). This suggests that hiPSC-RPE can be used to 
study adult disease. A further limitation in modelling certain diseases is the inherent variation in 
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generation of hiPSCs and differentiation of disease specific cell lines.  Disease phenotypes need to 
be robust to enable the identification of in vitro phenotypes.  Finally, the study of complex diseases 
which are not confined to cell autonomous disease mechanisms, may be challenging but may be 
overcome with the use of experimental design such as co-culture to recapitulate in vivo conditions  
(Di Giorgio et al., 2007). 
In summary, increasing evidence points to the utility of hiPSC disease modelling within the 
context of limitations of the platform.  Many of the limitations can now be mitigated against by 
using newer hiPSC protocols and by using good experimental design.  This points to the use of 




1.5      Rationale, Aims and Hypotheses 
 
 
There has been a rapid development in therapy for both AMD and inherited retinal disease.   Some 
of the treatments used for AMD are potentially applicable to L-ORMD (Aye et al., 2010). In order 
to monitor disease progression there needs to be an understanding of natural history and phenotype 
of disease to provide clinical biomarkers. This first aim of this part of the study is to refine the 
phenotype of L-ORMD using multimodal imaging and to investigate tools to monitor progression 
in L-ORMD using an observational study to investigate a cohort of L-ORMD patients. 
Although studies have established causal factors in AMD pathogenesis, understanding of the 
stepwise sequence of events that leads to AMD is still unclear.  Currently, it is difficult to identify 
patients who will develop AMD and consequently the study of early AMD has been limited. 
Additionally, it is still unclear what causes the initial injury in macular degeneration.    L-ORMD is 
a good model of AMD as it replicates key clinical and pathological features of AMD. Unlike 
AMD, L-ORMD has Mendelian inheritance and therefore it is possible to identify patients by 
genetic testing early or prior to clinical disease onset.  This provides an opportunity to study 
disease processes in early macular degeneration.  
 Pathology studies have shown that drusen, an early marker of AMD, contains activated 
complement components. Additionally, genetic studies have demonstrated that mutations in 
complement pathway components lead to an increased risk for the development of AMD.  Taken 
together this provides evidence that complement dysfunction plays a role in early macular 
degeneration.  The second aim of the study is to see whether complement dysfunction also plays a 
role in L-ORMD. The hypothesis is that localised complement dysregulation also plays a role in L-
ORMD pathogenesis. In order to demonstrate complement pathway involvement in L-ORMD 
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disease mechanism I firstly use in vivo retinal samples from a L-ORMD mouse model and later 
human L-ORMD donors to study complement activation.   
Developments in cell biology now enable the generation of stem cells from patients with inherited 
diseases.  The step-wise differentiation of these stem cells with defined protocols provides a 
virtually unlimited source of cells carrying disease-causing mutations. RPE cells have been 
proposed to play a central role in L-ORMD disease pathogenesis. I aimed to generate RPE from L-
ORMD patients and their unaffected siblings in order to develop an in vitro model for L-ORMD.  
The initial hypothesis of this part of the studies was that RPE generated from cases would show 
cell autonomous differences from that generated from sibling controls.    I next aimed to study 
whether any differences in complement activation identified during the in vivo studies could be 
recapitulated using the cell model.  The hypothesis was that localised complement dysregulation 
could be identified in case RPE when compared to control RPE. 
CFH is a regulator of the alternative complement pathway. Allelic variants of CFH are associated 
with AMD.  In previous work performed by Dr Xinhua Shu (unpublished) an interaction between 
C1QTNF5, the protein affected in L-ORMD, and CFH has been identified.  The aim is to generate 
wild-type and mutant protein and to test the affinity of the mutant and wild-type with purified 
CFH.  The hypothesis is that the mutation alters the affinity of C1QTNF5 for CFH.   
Taken together the overall aim is to provide a greater understanding of L-ORMD clinical 
characteristics and to better understand the disease mechanisms that cause the clinical phenotypes.  
It is hoped that findings from this series of studies will provide insights not only for L-ORMD 
























2.      L-ORMD in vivo studies 
 
2.1       Introduction and rationale 
 
L-ORMD exhibits many clinical similarities with AMD in early disease and has been proposed as 
a good model for AMD.  Clinical similarities include dark adaptation delay, drusen like deposits, 
pigmentation, choroidal neovascularisation and neuro-retinal atrophy (Jacobson et al., 2001, Milam 
et al., 2000, Ayyagari et al., 2005) (Table 2.1).  Recently, the rapid development of newer devices 
have enabled more detailed investigation of both the retinal structure and function. Although L-
ORMD is a rare condition, one of the largest cohorts of L-ORMD patients resides in South East 
Scotland and North East England. These patients have not been phenotyped previously.  
Consequently, the initial aim is to compare the phenotype of our cohort with previous reports in the 
literature (table 2.1). Although genetic testing is now available to identify L-ORMD, it is often 
difficult to differentiate L-ORMD clinically from other conditions in the early stages. This study 
provides an opportunity to update the L-ORMD phenotype using a multimodal approach. The 
study aims to look at structural changes in early L-ORMD and to see how this correlates with 
clinical presentation. The hypothesis is that using newer multimodal imaging techniques L-ORMD 














to be affected 
Studies 
Kuntz et el. 1996 5 3 Automated 
perimetry 
Milam et al. 2000 7 6 Goldman 
perimetry, 
ERG, DA 






Jacobsen et al. 2001 23 12 Goldman 
perimetry, 
ERG, DA 
Moroi et al. 2003 15 7 Anterior 
segment 
exam 
Ayyagari et al. 2005 55 38 
 
ERG, DA 




2013   4 4 SD-OCT,  
ERG 





2015 9 9 Dark 
adapted 
ERG 
Table 2.1 Summary of previous clinical studies and investigations. 






The earliest histological changes in AMD include basal deposits in Bruch’s membrane. Depending 
on the layer of the deposit the terms basal linear deposit (BLinD) and basal laminar deposit 
(BLamD) have been used (Sarks et al., 1980).  BLinD are found below the basement membrane 
layer of the RPE in Bruch’s memebrane and above the inner collagenous layer whilst BLamD are 
found in between the RPE membrane and RPE basement membrane. BLinD are composed of 
vitronectin, apolipoprotein B and E and neutral lipids such as cholesterol (Curcio and Millican, 
1999). BLamD contain wide spaced collagen and amorphous material (Curcio and Millican, 1999, 
Spraul et al., 1999). BLamD can occur with normal ageing whilst BLindD is more specific for 
AMD (Green and Enger, 1993, Loffler and Lee, 1986). Drusen are also a hallmark of early AMD 
but are also seen in senescence. BLamD have been found to contain activated complement 
pathway components in a similar manner to drusen (Anderson et al., 2002). Drusen consist of 
vitronectin, apolipoprotein B and E, neutral lipids and alpha-crystallins (Crabb et al., 2002, Malek 
et al., 2003). They have been particularly linked with the complement cascade.  They contain 
compounds such as c-reactive protein, cholesterol and amyloid which can activate the complement 
cascade (Farkas et al., 1971). Additionally they also contain activated complement components 
including the final common pathway of the complement system the membrane attack complex 
(Mullins et al., 2001). Histopathological investigation of L-ORMD retina has previously revealed 
that the sub-RPE deposit in L-ORMD results forms a bilayer (Duvall, J. et el., 1986). The outer 
layer is mainly composed of lipids whilst the inner layer consists of wide-spaced collagen. The 
deposit also contains amyloid P, lysozyme, elastin, apolipoprotein B-100, calcium, cholesterol and 
rhodopsin in a similar manner to drusen.   
 
Although localised complement dysregulation has been implicated in macular degenerations the 
role of the complement pathway has not been investigated in L-ORMD. The aim of the 
histopathological section of the study was to see if there was a difference in complement activation 
between L-ORMD retina and controls. Recently, a mouse model for L-ORMD was characterised.  
As human donor retinal samples for L-ORMD were rare, I first used the retina of a recently 
generated mouse model.  Next  investigated complement deposition using human L-ORMD retinal 
samples.  The hypothesis was that complement dysregulation contributes to L-ORMD disease 
pathogenesis.  
 
2.2   Methods  
 
Shyamanga Borooah (University of Edinburgh) or Vasileois Papastavrou (Newcastle University) 
designed, recruited all patients and performed all visual acuity and microperimetry studies.  The 
medical photography department of the Princess Alexandra eye pavilion and the Royal Victoria 
38 
 
infirmary Newcastle performed fundus photography, SLO, FFA and ICG. James Cameron 
(University of Edinburgh) performed OCT on AMD patients and on a subset of L-ORMD patients.  
For recording of details images were reviewed by at least two ophthalmologists including Dr 
Ashraf Khan, Dr James Cameron and Professor Baljean Dhillon (University of Edinburgh). The 
electrodiagnostics department of Greater Glasgow and Clyde NHS performed multifocal ERG.  
Shyamanga Borooah (University of Edinburgh) performed all statistical analyses. 
 
For the immunohistochemistry experiments, all studies were performed by Dr Shyamanga Borooah 
with guidance from staff of the shared university research facility (University of Edinburgh).  
Human donor samples from Edinburgh were fixed and paraffin embedded blocks by Professor 
James Ironside. Human donor samples from San Diego were fixed and paraffin embedded blocks 
by Professor Christine Curcio (university of Alabama). Mice retinal samples were obtained from 
mice generated by Professor Radha Ayyagari (University of San Diego).  The mice were 
generated, bred, grown and culled with samples fixed and embedded by Professor Ayyagari’s 
team.   
 
The data analysis for this dissertation was generated using the Real Statistics Resource Pack 
software (Release 4.3). This was used to provide summary data including arithmetic mean and 
standard deviation (SD).  Standard error (SE) was calculated and used for graphs where three or 
more samples were used. For comparative statistics, two groups were first individually checked for 
normality in distribution using the Shapiro-Wilk test of normality.  If deemed normal, a t-test was 
used.  If the data was not normally distributed then a non-parametric test such as the Mann 
Whitney U-test was used for comparison. 
 
2.2.1 Patients 
Patients were included if they had been confirmed to carry the Ser163Arg mutation and were at 
least in stage 2 L-ORMD i.e. having some changes at the macula visible on ophthalmoscopy. 
Patients were excluded if they had had previous retinal surgery, diabetic retinopathy or retinal laser 
surgery. Additionally, patients were excluded if they did not have a clear optical view of the fundus 
due to media opacities.  We examined 20 eyes of 10 patients from a large cohort of L-ORMD 
patients.  
Patients were at various stages of L-ORMD disease process after stage 2.  The patients were 
stratified according to severity of disease 
The study was reviewed by the institutional ethics board of Newcastle University Hospitals NHS 




2.2.2 Clinical vision studies 
 
Distance visual acuity testing was performed at 4m using a standardised backlit 4m ETDRS 
LogMAR chart (Precision vision, La Salle, Illinois) with a diffuser.  This method has been used 
previously been shown to be repeatable with good intra class correlation in macular degeneration 
patients (Aslam et al., 2014). Standardised charts were changed for each eye being tested in order 
to prevent patients memorising letters. Patients wore their latest optometric prescription in trial 
frames.  Each line had five letters. Patients were asked to read each letter starting with letters on 
the top row.  Patients were asked to continue until they were unable to read a complete line.  If 
patients were unsure of letters, they were asked to best guess.  The LogMAR score was calculated 
by assigning each letter correctly identified a score of 0.02 (Ferris et al., 1982). Patient’s left eye 
and right eye visual acuity were tested and responses noted on a scoring sheet. 
Near visual acuity was measured using a Bailey-Lovie reading chart (Bailey and Lovie, 1980).  
The test uses lines of 5 unrelated words of equal standard letter size starting with the largest letters 
on the top line.  There is a logarithmic reduction in size of letters with each line (N80-N2). Testing 
was performed under standard lighting conditions at 25 cm with the patients wearing a +4.00 
reading correction over the most recent prescription.   The chart has previously been shown to be 
repeatable in AMD patients and appears to correlate well with measures of visual acuity related to 
normal activities of daily living (Aslam et al., 2014, McClure et al., 2000). 
2.2.3 Clinical imaging 
 
For colour fundus photography a TRC-501X (Topcon medical systems, New Jersey, U.S.A) was 
used.  This device has a 50 degree lens.  Patients were dilated with 1 drop of tropicamide 1% 
(Bausch and Lomb ltd, U.K.) to each eye at least thirty minutes prior to examination. Following 
which each eye was photographed.  Focus, contrast and white balance were adjusted manually by a 
trained medical photographer. Images were captured on a Nikon D90 (Nikon, Japan) digital 
camera.  This modality of digital imaging is not a new imaging format however, was used to 
provide true colour images representations in a close format to that provided by newer imaging 
formats described below. 
Fluorescein sodium is a water soluble molecule (354 Daltons). It is 20 percent in solution and 80% 
protein bound.  Fluorescein fluoresces at approximately 520nm. It diffuses into tissues staining 
them and if there is any break of the blood retinal barrier fluorescein readily leaks.  The dye is 
masked by the retinal pigment epithelium except in early choroidal filling.  A bolus of 4ml of 20% 
fluorescein sodium (Martindale pharmaceuticals, Essex) was injected through an intravenous line.  




ICG is a molecule of size 775 Daltons and, unlike fluorescein (354 Daltons) the molecule is almost 
completely protein bound and does not normally escape from retinal vasculature with its blood-
retinal barrier. However, the choroidal vasculature with its fenestrated capillaries does permit a 
slow leak of ICG (Bouchenaki et al., 2002).  The staining of the choroidal structures can be masked 
providing areas of hypofluorescence or absent fluorescence. ICG fluoresces at 830nm, which 
enables it to be easily imaged using infra-red imaging devices at a different spectrum to fluorescein 
and therefore allows simultaneous imaging. 25 mg of ICG-Pulsion powder (Pulsion medical 
systems, Germany) was reconstituted to5mg/ml in 5ml of water for injection. A bolus of the ICG 
was injected through an intravenous line. 
 
Studies have now shown the utility of using SLO images to study AMD and in particular GA.  A 
SLO is able to measure in vivo fluorescence generated from fluorophores in the retinal pigment 
epithelium (Feeney-Burns et al., 1980, Katz, 2002) thought to be produced from photoreceptor 
outer segment metabolism in the RPE which could only previously be studied in vitro (von 
Ruckmann et al., 1995, Delori et al., 1995, Bellmann et al., 1997).  Reduced autofluorescence may 
signify reduced functioning photoreceptor-RPE activity reducing retinal sensitivity.  Increased 
fluorescence may signify a prognostic indicator of future photoreceptor-RPE death and has been 
used for prognosis in GA (Scholl et al., 2004, Holz et al., 2007).   
 
Confocal SLO images were obtained for fundus autofluorescence (wavelength=480 nm) using the 
Spectralis SLO machine  (Heidelberg Engineering, Heidelberg, Germany). Central fixation was 
attempted and images of the central 30 degrees field of view were taken at a resolution of 768 x768 
pixels. This was similar to settings previously used in geographic atrophy (Schmitz-Valckenberg et 
al., 2008). As some of the L-ORMD patients had poor central fixation the automatic eye tracking 
software (Automatic real-time (ART)) packaged with the Spectralis was used with a score of 20. 
This showed the average of 20 B-scan confocal SLO images. To measure the size of areas of 
atrophy semi-automated software was used (Heidelberg eye explorer v6.0c, Heidelberg 
Engineering).  An initial pilot study was performed with two masked ophthalmologists given 10 
images from L-ORMD patients. The ophthalmologists were asked to measure the area of atrophy. 
A Cronbach’s statistic of agreement was calculated to measure the amount of agreement.  In order 
to measure the rate of increase at least two images were chosen greater than one year apart for each 
patient. 
Spectral domain OCT imaging was carried out using a Heidelberg Spectralis SD OCT (Heidelberg 
Engineering, Heidelberg, Germany) with 870 nm wavelength (Helb et al., 2010). The Spectralis 
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has an acquisition speed of 40,000 A-scans per second and scans to a depth of 2.8 mm. The 
resolution of images is approximately 4µm per pixel. To obtain images of the posterior pole 61 
scans were taken covering an area of 9 x 7.5mm.  Each scan was averaged with an ART of at least 
9. To assess the foveal morphology the number of B scans averaged was increased to 100 using 
ART settings in concordance with recent papers on structure functional assessments of GA (Pilotto 
et al., 2015). Images were also taken of the choroid using the enhanced depth imaging (EDI) 
function on the Spectralis. Analysis was made using Heidelberg eye explorer software (version 
6.0c) which automatically segmented retinal layers providing thickness measurements.  
Measurements were taken at the fovea to use a landmark as in recent publications.  In addition, 8 
participants who were age-matched were selected and used as age-matched controls for measures 
of retinal volume, neuro-retinal thickness and choroidal thickness. Further semi-automated 
segmentation was made of the choroid using Heidelberg eye explorer to separate the Sattler and the 
Haller layer using a recently validated method (Sim et al., 2013).  The thickness of both these 
layers was then measured using the fovea as a landmark. For deposit measurements the fovea was 
again used as a landmark.  A cross section OCT of the fovea was taken.  The image was inverted to 
black on white to enhance contrast in order to visualise the sub-RPE deposit (figure 2.1).  The 
manual measuring tool on the Heidelberg Spectralis software was then used in the 1:1 µm mode in 
order to measure the deposit height at the fovea.  The readings were validated initially by two 
masked graders. A Cronbach’s alpha analysis was used to see the correlation of measures using 






Figure  2.1: Measuring deposit thickness 
The image on the left shows a low magnification OCT cross section of the retina in black on white 
format in order to highlight the sub-RPE deposit.  The image on the right shows the deposit (deep 
black layer) measured using Heidelberg Spectralis software. red arrows signify the thickness of the 
deposit.  The deposits were measured by a scale generated by Heidelberg Spectralis software. The 
images are labelled with photoreceptor inner segment (IS), the photoreceptor inner and outer 
segment junction (IS/OS), photoreceptor outer segment (OS), the retinal pigment epithelium layer 
(RPE), deposit and Bruch’s membrane (BM). 
   
2.2.4 Multifocal electroretinography 
 
The conventional ERG uses different stimuli including flash and flicker to elicit a response in the 
retina.  The response of the whole retina is then recorded. However, the recording of global 
responses may mask more subtle regional changes as found in early macular disease (Palmowski et 
al., 1999, Heinemann-Vernaleken et al., 2001). Multifocal ERG overcomes some of these 
shortcomings by independently recording responses from multiple regions of the retina.  Different 
areas of the retina are stimulated by a pseudo-random binary system. A three dimensional plot is 
then generated from the final amplitudes from the recordings of the different retinal regions.  
 
L-ORMD patients were placed 32 cm from a stimulus monitor, which displayed 61 hexagons 
covering a visual field of 25 degrees. A cross was used to maintain central fixation and a steady 
background illuminance was provided.  Each of the hexagons alternated between black and white. 









outer canthi and monopolar loop scleral electrodes were used to make the recordings. Amplitudes 
and latencies were determined for each region.  A scalar product method using a multiplication and 
summation was used to measure local response.  The median scalar product was compared with the 





Microperimetry was performed using a similar method to those used previously in AMD patients 
(Pilotto et al., 2015). Two factors were altered for L-ORMD cases.  In order to avoid dark 
adaptation abnormalities affecting readings the patient’s readings were dark adapted for 30 minutes 
prior to the test rather than the test being performed under mesopic conditions.  Additionally, as L-
ORMD can cause scotomas beyond the fovea and perifoveal regions the central 40 degrees was 
tested centred on the fovea. A patch was used to cover the untested eye. The MP1 microperimeter 
was used (Nidek, Gamagori, Japan).  This test was only suitable for stage 2 patients as a central 
fixation cross was used.  A 4-2 double staircase threshold strategy was used using a Goldman size 
III target, which was presented for 200ms.  A monochromatic background was set at 2.27 cd/m2 





Human samples were kindly donated from the University of Edinburgh tissue bank by Professor 
James Ironside and from the Professor Ayyagari (University of California, San Diego). Full 
consent for donation was obtained from the institutional review boards of NHS Lothian, University 
of Washington and University of Pennsylvania.  Eyes were donated within 12 hours of death and 
stored in a mixture of 10% formalin saline and fixed for at least 6 hours before dehydrating in a 
series of increasingly concentrated alcohols prior to embedding into paraffin. 
 
The murine C1QTNF5 heterozygous, C1QTNF5 knockout and control sections were from 
C57BL/6J mice and were a kind donation from Professor Radha Ayyagari (University of 
California, San Diego). The maintenance, culling and subsequent use of retinal samples was 
approved by the University of California, San Diego Institutional animal care and use committee.  
After the animals were sacrificed, the eyes were removed, cornea punctured, and lens removed.  
The eyes were immersed for fixation overnight in 2% paraformaldehyde and 2% glutaraldehyde.  
The next day the eyes were washed in phosphate buffered saline (PBS) and then embedded in 30% 




For human paraffin blocks were dewaxed in xylene for 10 minutes, rehydrated in ethanol (absolute, 
90%, 80% and then 70%), and washed in ddH2O. Antigen retrieval was performed using citrate 
based retrieval buffer at pH6  (Leica) in a decloaking chamber, slides were heated to 90oC for 20 
mins then allowed to cool to 80oC before washing in water. Sections were either prepared manually 
or later using the automated Leica Bond immunostaining using the Leica Refine HRP polymer 
detection system using similar timings. Slides were washed three times for 5 minutes in PBS. 
Following this, endogenous peroxidase activity was blocked by incubating the slides for 10 
minutes in Bloxall (Vector laboratories, Burlingame, California, USA) in PBS, 0.05% Tween to 
block endogenous peroxidase activity. Slides were washed twice in PBS for 5 minutes prior to 
incubating the sections for half an hour in 20% normal goat serum (NGS) in PBS.  The slides were 
the incubated for 2 hours at room temperature in primary antibody diluted in 20% NGS in PBS. 
Slides were then washed in PBS three times for 15 minutes before staining for 30 minutes with 
biotinylated secondary antibody.  The slides were then washed twice in PBS and incubated for 30 
minutes with VECTASTAIN® ABC kit   (Vector laboratories) with a final stain of  
3,3'diaminobenzidine  (DAB) or Vector® Red Alkaline Phosphatase Substrate until staining 
became clearly visible before rinsing in tap water. The slides were then counterstained in 
Haematoxylin for approximately five minutes until nuclei were clearly counterstained before a 
final wash with tap water and mounting on slides with pertex mounting medium  (Histolab, 
Gothenburg, Sweden). A negative control, where the primary antibody was omitted was included 
in each run.  
 
To identify Bruch’s membrane collagen and elastin staining was performed. After dewaxing and 
rehydrating slides through a series of alcohols.  For collagen staining a 50 mL of 0.1% Fast Green, 
50mL of 0.1% Direct Red, 900mL of Picric Acid Solution was made.  The solution was incubated 
on slides for two hours before slides were washed with tap water and dehydrated through a graded 
series of alcohols.  For elastin staining slides were incubated with solution composed from 20ml 
5% Alcoholic haematoxylin, 8ml 10% Ferric Chloride solution and 8mL Lugol’s Iodine for 30 
minutes. The slides were then washed in tap water prior to incubation with a further solution made 
from 20mL 10% ferric Chloride Solution and 80ml ddH2O. Van Gieson stain was then used to 
counterstain for 20 seconds prior to the slides being dehydrated in 100% ethanol and mounted. 
Mouse sections were cut on a cryostat at 18 microns (Gonzalez-Cordero et al., 2013).  Slides were 
blocked with 5% NGS and 1% BSA in PBS. The primary antibody was then incubated overnight in 
the same blocking solution.  After three washes with PBS the slides were incubated with the 
secondary antibody for 2 hours at room temperature before a final wash and then counterstaining 
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with DAPI  (sigma-Aldrich). A coverslip was placed onto the slides using mounting medium 
FluoSave (Merck-Millipore). 
In order to see if the changes noted in the L-ORMD samples were different from normal ageing a 
number of aged eye samples were also tested. Some of these samples were also noted to have early 
drusen. These specimens were kindly donated by Dr Luminita Paraoan, (Liverpool University). 
 
 
2.3   Results 
 
2.3.1 Summary of patient cohort 
 
Patients carrying the Ser163Arg mutation in C1QTNF5 are known to progress through a number of 
stages of disease.  All patients were confirmed through sequencing to have L-ORMD in 2010 and 
actively attending the Princess Alexandra eye pavilion, Edinburgh were recruited from the 
Edinburgh arm of the study.  Similarly, in Newcastle, patients with known L-ORMD who were 
actively being monitored by the Royal Victoria Infirmary were recruited in to the study.  
Consequently, 7 patients were recruited from Edinburgh and 10 patients from Newcastle were 
recruited at various stages of disease .  It was understood that this is a relatively small group of 
patients with the condition however the numbers compared favourably with the largest cohort 
studies using older methods of investigation and was far larger than the most recent studies using 
similar methodology including spectral domain OCT.  As a result, the study should provide some 
valuable insights into the clinical phenotype as well as confirming that the patients in this cohort 
have similar characteristics to previously described cohorts with established phenotypic 
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Although imaging was performed on all individuals, I decided to concentrate primarily on stage 2 
disease patients.  These patients present with the most clinical diagnostic difficulty and therefore 
phenotyping will potentially provide the most benefit in the diagnosis and management for these 
patients.  In addition, little is known about the progression of the disease at this stage.  If future 
trials for therapy are envisaged there need to be clear phenotypic markers of progression. The 
differential diagnoses at this stage include geographic atrophy and other inherited deposit diseases 
including Sorsby fundus dystrophy and dominant drusen.  Stage 3 patients develop gross changes.  
The main question was to see whether stage 2 L-ORMD had distinct clinical characteristics or 
whether early L-ORMD shared characteristics with more common diseases such as early macular 
degeneration. 
 
2.3.2 L-ORMD phenotype 
 
In order to start phenotyping the patients I first planned to repeat previous studies on my cohort of 
patients.  Together with Dr Papastavrou (Newcastle University) we designed a longitudinal study 
to encompass older and newer technology for monitoring these patients.  As far as I was aware this 
cohort of patients had never previously been phenotyped.  
 
To start with we planned to repeat basic studies performed in previous studies for our cohort to 
ensure that findings in our cohort were not markedly different from findings in previous reports for 
L-ORMD (table 2.1).  These included visual acuity and colour fundus photography (table 2.3). 
This was important, as later studies would be dependent on cells derived from patients in this 
cohort.  We next wanted to identify new structural features using newer technology including near 
infra-red reflectance, scanning laser ophthalmoscopy. Some of these studies had been already been 
performed on smaller cohorts (Jacobson et al., 2014, Soumplis et al., 2013). Fundus fluorescein 
angiogram (FFA) and indocyanine green angiography (ICG) have previously been used to identify 
focal deposits in AMD (Arnold et al., 1997, Bottoni et al., 1994, Querques et al., 2013, Souied et 
al., 2006).  In order to better understand the early drusenoid picture seen in L-ORMD these studies 
were performed on stage-2 patients. Finally, we looked to compare structure with function by using 
microperimetry and multifocal ERG.  Patients were staged into either group 3 if the fovea was 






List of investigations for the L-ORMD cohort 
Visual acuity 
Colour fundus photography/ wide field colour scanning laser ophthalmoscopy 






Table 2.3 Summary of clinical studies performed on patients 
  
17 patients were recruited into the cohort.  The mean age of patients was 61.3 with 8 female and 9 
male patients.  10 Patients were in stage 2 and 7 patients were in stage 3. The mean age of stage 2 
patients was 57.6 years (SD=1.75) and the mean age of stage three patients was 68.0 (SD=1.61). 
Best corrected visual acuity findings were as expected with stage 2 patients having a mean ETDRS 
letter score of  77.7 letters (SD= 4.08) whilst the stage 3 patients had a mean ETDRS letter score of 
23.7 letters (SD= 6.85) significantly less (P<0.001).  
 
The cohort seemed to be representative of previous descriptions of L-ORMD (Borooah et al., 
2009). All patients showed anterior segment characteristics including long anterior zonules and iris 
atrophy (figure 2.2). Progression appeared to be similar to previous reports with most having 
spared central vision till their seventh decade. Colour fundus photography findings showed an 
expected phenotype of progression with age and stage (figure 2.3). Early stage 2 patients had 
relatively few features on colour fundus photography.  Close inspection identified fine drusenoid 
spots in the para and peri-fovea.  These were most marked temporally. There were no signs of 
atrophy or neovascularisation.  Later stage 2 patients showed more prominent drusenoid lesions 
which were scattered across the macula but concentrated in the temporal macula. This was similar 
to a previous report (Vincent et al., 2012). Pigmentation was noted in the peri-foveal region. There 
were also signs of early atrophy sparing the fovea in the temporal macula.  Stage 3 disease showed 
changes in the fovea with atrophy, pigmentation and occasionally choroidal neovascular scarring. 
The peripheral retina showed marked scalloped areas of atrophy with some associated 





Figure 2.2 Anterior segment photograph.   
The photograph of the left eye shows long anterior zonules extending beyond the pupillary 
margin.  Pupillary atrophy at the pupillary ruff. 
Figure 2.3: Fundus images from different stages of L-ORMD. 
(A) Early stage 2:  Colour fundus photograph. Fine drusenoid deposits visible in the macula 
with a concentration in the temporal macula. Little or no foveal involvement. 
(B) Late stage 2: Colour fundus photograph. Neuro-retinal atrophy in the macula with foveal 
sparing. The fovea also demonstrate drusenoid changes with early pigmentation. 
(C) Stage 3: Widefield scanning laser ophthalmoscope image demonstrating complete atrophy 
of the macula with marked pigmentary changes at the fovea.  In the periphery, there are 
scalloped areas of atrophy extending to the far peripheral fundus. 
 
 
Looking more closely at the colour fundus photographs of stage 2 patients, there appeared to be a 
regional difference in the shape and type of drusenoid deposit (figure 2.4). The peri and para-foveal 
deposits were small discrete and sharply demarcated. This pattern was also seen in the temporal 
deposits however, in some cases the deposits were larger with a softer edges more similar to soft 






Figure 2.4 : Colour fundus photographs from a L-ORMD patient with stage 2 disease. 
(A) The image shows the right fundus.  The white arrows highlight areas of drusenoid change.  
The deposits are more reticular in the peri-foveal region with a more distinct larger 
appearance in the temporal macula. 
(B) The image shows the left fundus.  The arrows highlight small, discrete round drusenoid 
deposits in the peri-fovea.  The white oval encloses a region of the temporal macula with 
large quantities of reticular drusen. 
 
Newer imaging techniques have highlighted different forms of drusen in AMD.  I wanted to use 
similar techniques to see if the drusenoid deposits seen in L-ORMD resembled those previously 
described in AMD. The small punctate drusen seen in the early stage 2 patients were sized <150um 
and resembled cuticular drusen.  The temporal drusen seen in later stage 2 patients resembled 
softer drusen. I sought to further delineate the drusenoid deposits noted on colour fundus 
photography by using infra-red reflectance, SLO autofluorescence and SD-OCT. Infra-red 
reflectance has previously highlighted a mottled appearance in the peri-fovea in L-ORMD patients 
(Jacobson et al., 2014).  Additionally, infra-red imaging has previously highlighted drusen which 
may not be clearly be visible on colour fundus photography. FAF can be used to highlight regions 
in which sub-RPE deposits form (Vincent et al., 2012).  FAF can also help differentiate reticular 
pseudo-drusen. Only three studies have used SD-OCT to study L-ORMD patients.  Of these only 
two have used the Spectralis platform which provides the greatest resolution.  OCT can help 
delineate the type of drusen by size and location. Hard drusen, soft drusen and cuticular drusen are 
all found sub-RPE whilst reticular pseudo-drusen is found above the RPE.  In addition, hard drusen 
are smaller (<83um), whilst soft drusen tend to be larger (>125um).  Cuticular drusen are small and 
occur in groups often giving a sawtooth appearance.   
 




were not visible on colour fundus photography. The distribution mainly spared the fovea and was 
concentrated in the temporal retina and temporal macula (figure 2.5). The lesions are small 
(<100um) (figure 2.6). FAF revealed little or no change in early stage 2 disease.  In later stage 2 
disease, there were marked areas of mottled increased FAF surround the fovea in the rod-rich 
regions which extends into the temporal retina (figure 2.7).  On closer inspection of the peri-fovea, 
pigmentation on colour fundus photography corresponds to areas of increased FAF (figure 2.8). 
 
Figure 2.5: Infra-red reflectance images from the fundus of a stage-2 L-ORMD patient. 
(A) Right fundus image.  The image shows scattered discrete small areas of reflectance 




Figure 2.6: High magnification infra-red reflectance image (820nm) from stage-2 L-ORMD 
patient. Multiple discrete punctate high reflectance spots in the sub-retina.  Their small size 
(<100um) and central bright infra-red reflectance suggest they are similar to cuticular drusen seen 









Figure 2.7: Fundus autofluorescence images (488nm) from a stage 2 L-ORMD. 
Images show mottled increased autofluorescence in the para and peri-foveal regions with some 




Figure 2.8: Foveal autofluorescence images from  a stage 2 L-ORMD. 
(A) Colour fundus photograph.  Photograph shows para-foveal pigmentation (white arrows) 
and yellow drusenoid deposits (black arrow).   
(B) Fundus autofluorescence image.  Both areas of pigmentation and drusenoid change are 
associated with increased autofluorescence (white and black arrows). 
 
Left fundus image.  The image shows multiple discrete sub-retinal areas of high reflectance. 
SD-OCT imaging revealed a variety of different forms of drusen in the same patient.  The sub-RPE 
deposit was found throughout the retina in all patients (figure 2.1).   It was thickest under the 





cuticular drusen in the temporal region. In the same retina in the peri-foveal region there were also 
changes above the RPE which disrupted the IS-OS junction but left the RPE layer intact.  Looking 
at other retina it was clear that these lesions were associated with changes on FAF and were akin to 






Figure 2.9: OCT Images from a stage-2 L-ORMD patient. The upper image shows an en-face 
SLO image of the right fundus.  The green line identifies the cross-section for the OCT images.  
There are focal areas of increased autofluorescence (white arrow).The lower images show the OCT 
cross section of the retina.  The white arrow corresponds to the location of the white arrow on the 
en-face image.  There is increased variable thickening of the sub-RPE (white bracket). The 
magnified image highlights a region of disruption of the RPE and IS/OS junction.  There are areas 
of increased intensity above the RPE.  This is similar to reticular pseudo-drusen.  The white 






Figure 2.10: OCT images form the right fundus of a stage 2 L-ORMD patient. 
The upper image shows the en-face OCT (left) from the right fundus. The image shows multiple 
discrete lesions with increased central autofluorescence surrounded by areas of decreased 
autofluorescence.  The green line signifies the cross section for the OCT.  The white arrows 
highlight two areas of increased autofluorescence surrounded by decreased autofluorescence.   The 
OCT cross section (right) shows two lesions disrupting the IS/OS junction.   The magnified images 
(bottom images) show that the lesions appear above the RPE similar to reticular pseudodrusen in 
AMD.  The image is labelled with external limiting membrane (ELM), photoreceptor inner 
segment (IS), the photoreceptor inner and outer segment junction (IS/OS), photoreceptor outer 
segment (OS), the retinal pigment epithelium layer (RPE) and Bruch’s membrane (BM). 
 
 
We had identified that even in early stage 2 the sub-retinal deposits were found throughout the 
retina.  However, this did not match the focal lesions seen on fundus photography.  As a result, in 
these early stage 2 patients we decided to perform FFA and ICG to see if there was any specific 
staining or leakage pattern associated with these lesions (table 2.4). Although neovascularisation 
has been reported in L-ORMD cases previously (Vincent et al., 2012), we did not note any leakage 
from neovascularisation in our cohort at the time of investigation.  The red free images highlighted 
the areas of drusen (fig 2.15).  Early FFAs revealed little except for mottled choroidal filling in all 
cases.  Late FFA however showed increasing hyperfluorescence of deposits, which were almost 
confluent in nature in the temporal retina and macula. These regions coincided with the increased 
thickness of deposit and the cuticular region of deposit (figure 2.12).  The ICG showed more 
marked changes.  As the ICG progressed, there were clear areas of discrete decreased fluorescence 
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which were found in the temporal macula and temporal retina. There was also a clear demarcation 
from the start of the hypofluorescent region and the area showing normal background fluorescence 
(figure 2.13).  This suggests that there was likely to be focal masking of the choroidal fluorescence 
in the temporal fundus and that although there was a diffuse sub-retinal deposit there were also 
focal changes.  In addition, although the large choroidal vessels were clearly seen in the periphery 
in early ICG images, foveal region developed what appeared to be an opaque plaque really in the 
ICG runs with no clear vasculature visible.  
 
 
Case FFA features ICG features 
1  Marked staining of the 
temporal region in late 
sequences 
 Marked hypofluorescent 
discrete areas in late 
images 
2  Marked window defect 
centrally and temporally 
 Late staining of deposits 
around areas of atrophy 
 
 Marked confluent area 
of increased 
fluorescence at macula 
with some areas of 
hypofluorescence 
4  Marked staining 
temporally 
 Marked hypofluorescent 
areas temporally 
 Central areas of 
increased fluorescence 
5  Window defect 
temporally 
 Marked late staining 
especially temporally 
 Marked hypofluorescent 
areas temporally 
 Central plaque-like 
increased staining 
7  Marked late staining 
across macula but 
especially temporally 
 Marked discrete hypo 
and hyperfluorescent 
areas 
Table 2.4 Summary of FFA and ICG characteristics of stage 2 patients who 






Figure 2.11: Images form the right fundus of an early stage 2 L-ORMD patient. 
(A) Colour fundus photograph.  The photograph shows scattered drusenoid change in the peri-
fovea and temporal retina. 
(B) Red free image. The red-free image shows scattered pale areas in the peri-fovea, peripheral 
macular and in the temporal fundus particularly in the temporal region.  
(C) Venous phase FFA (29 seconds). Image shows patchy background choroidal fluorescence. 
Early increased fluorescence in the area temporal to the fovea. 
(D) Late FFA (1 minute 55 seconds). Marked hyperfluorescence in the temporal macula with 
staining of discrete dots coalescing in many areas.  There is no manifest leakage of 
fluorescein. 
 
Figure 2.12: Indocyanine green images from the fundus of an early stage 2 L-ORMD. 
(A) Early ICG image (1 minute).  The image shows good choroidal filling and no clear 
abnormalities in the intra-retinal vasculature.   
(B) Late ICG image (5 minutes).  The image shows early hypofluorescence masking choroidal 
fluorescence (white arrows) and early generalized staining of the fovea (white oval). 
(C) Late ICG image (11 minutes 30 seconds).  The image shows increased contrast of scattered 
discrete areas of hypofluorescence (white arrows). There is a discrete boundary between 
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OCT provides a measure of structure of the retina.  However, to measure function, perimetry could 
be used.  L-ORMD patients have previously been studied using full field perimetry (Milam et al., 
2000, Vincent et al., 2012). In our experience this did not show any differences until late stage 
disease.  A pilot of this was tested on some of the stage 2 patients. Consequently, we decided to 
test microperimetry.  This offers a more detailed look at macula function and has previously been 
used in macular degeneration looking at the central 45 degrees of the macula and combining 
function with a colour fundus image (Pilotto et al., 2013, Midena et al., 2007).  The microperimetry 
was performed on all our patients.  Patients with very early stage 2 showed no loss of retinal 
function (figure 2.14). However, later stage 2 patients showed an early dense scotoma beginning 
temporally at approximately 15 degrees from the fovea (figure 2.15). The microperimetry findings 
matched the FAF findings. However, interestingly, in later stage 2 patients there was a small deficit 
noted in areas beyond the main areas of atrophy. 
 
Figure 2.13: Microperimetry of an early stage 2 fundus 
The scanning laser ophthalmoscope image (left) shows little aberration in fluorescence.  The 
microperimetry image (right) shows the microperimetry results superimposed on a colour fundus 
image of e the right eye.   The readings show near normal field results using an absolute scale 
where 20 is the most sensitive and 0 the least sensitive region of the retina.  The colour fundus 




Figure 2.14: Scanning laser ophthalmoscope image and microperimetry recording from an 
early stage 3 L-ORMD patient 
The scanning laser ophthalmoscope image (left) shows areas of marked scalloped reduced 
fluorescence temporal to the fovea. These scalloped areas are surrounded by a cuff of increased 
autofluorescence. The microperimetry scoring (left) is superimposed on the colour fundus 
photograph.   There is a clear reduction in sensitivity in the areas of atrophy which also correspond 
to areas of reduced autofluorescence. 
 
 
Multifocal ERG has also been used in AMD (Park et al., 2011, Moschos et al., 2004).  The 
functional findings in the multifocal ERG closely matched those of the microperimetry with few 
changes in early disease but significant deficits once atrophy was apparent temporal to the fovea 
(figure 2.16).  Again there were subtle focal deficits beyond this temporal region. In both the 
















2.3.3 L-ORMD case-control comparison 
 
Having noted the changes at the fovea on the ICG and the generalised patchy choroidal filling on 
the FFA in L-ORMD patients I wanted examine the choroidal vasculature in more detail. During 
the course of my studies two main developments occurred that enabled me to examine choroidal 
structure more deeply.  Firstly, software updates to the Heidelberg Spectralis OCT enabled the 
investigation of deeper structures using an enhanced depth imaging function (EDI).  Secondly, a 
further update to the software allowed autosegmentation of structures including the choroid.  The 
addition of manual segmentation with measurements provided a way to examine the choroid in 
detail.  
 
Using the EDI function, I was able to visualise the choroidal vessels clearly from the BM to the 
sclera.  Early on in these studies I noticed choroidal thinning in early stage 2 patients. Additionally, 






Figure 2.15: Multifocal ERG.   
(A) Normal response density 
amplitude plot. 
(B) Normal trace array. 
(C) Response density plot from the 
right eye of the patient 
described in figure 2.19.  Note 
the central foveal sparing with 
similar amplitudes centrally to 
the normal plot. 
(D) Patient trace array.  Note that 
although the central foveal 
traces have a similar amplitude 
to the normal area there is a 
marked reduction in amplitude 
away from the fovea 
particularly in the temporal 
retinal traces. 
(E) Latency plot.  The latency plot 
shows that the temporal and 
peri-foveal retina in particular 
show increased latency.  These 
areas partly correspond to the 









choroidal thinning in early AMD (Whitmore et al., 2015).  I suspected that choroidal thinning was 
also occurring early in L-ORMD patients.  In order to investigate this I recruited all early stage 2 
patients who had little or no atrophy on FAF.  I compared the choroidal scans of these patients with 
those from randomly selected from a database of control patients held at the Anne Rowling clinic, 
Edinburgh.  The images of the choroid were autosegmented using default Heidelberg software to 
provide a choroidal thickness (figure 2.17).  To ensure that there was a landmark, choroidal 
measurements were taken at the fovea. The measurements were performed by a masked 
ophthalmologist grader.  The measurements had been previously validated by two masked 








In the case group 22 eyes were examined. The average age of the stage 2 patients was 57.6 years, 
with 4 females and 7 males.  In the control group 18 eyes were examined. The average age of the 
controls grouped was 57.9 years with 5 males and 3 females.  The respective refraction of the 
patients is shown in table 2.5. The choroid was significantly thinner in LORMD patients 
(mean=218.8uM, SD=72.5) when compared to controls (mean=278.8um, SD=73.7) (P<0.05) when 
measured at the fovea (figure 2.17). No significant difference was found in the neuro-retinal 
Figure 2.16: Retinal cross section OCTs 
using enhanced depth imaging to measure 
choroidal thickness. 
(A) The image depicts the semi-automated 
quantification of choroidal thickness.  
The Bruch’s membrane (red line) and 
outer choroidal boundary is generated 
automatically by Heidelberg Spectralis 
segmentation software.  The blue line is 
generated manually to separate the 
larger vessels of the Haller layer from 
the smaller vessels of the Sattler’s layer.  
Total choroidal thickness is also 
measured.  The measurements were 
taken at the fovea using Heidelberg 
Spectralis software generated scale (not 
shown). 
(B) A representative image from the fundus 
of a control patient.  The Sattler and 
choriocapillaris is relatively thick 
compared with Haller’s layer. 
(C) A representative image from an early 
stage-2 L-ORMD patient. The Haller 
layer is relatively enlarged compared 
with the Sattler layer and 
choriocapillaris.  The neuro-retina 
shows no obvious atrophy. 
(D) Box plot of the Sattler:Haller ratio.  
When comparing the ratio of Sattler to 
Haller layers in the cases and controls 
the box plots show that there is a 
relative sparing of the Haller layer 
compared to the Sattler layer although 




thickness between cases (mean=237.9um, SD=36.3) and controls (mean=236.4um ,SD=9.5). The 
early treatment of diabetic retinopathy study (ETDRS) divided the macula up into 9 regions with 
the fovea at the centre.  To confirm that the neuro-retinal thickness was not significantly different 
between patients and controls the neuro-retinal volumes in the ETDRS macular regions were also 
investigated separately.  Again no significant difference between cases (mean=8.4mm3, SD=0.9) 
and controls (mean=8.6mm3, SD=0.3) were noted. 
 
Case Spherical equivalent refraction 
(OD,OS) dioptres 
Ctrl 1 0.75, 0.75 
Ctrl 2 2.5, 2.25 
Ctrl 3 2.5, 2 
Ctrl 4 -2,-2 
Ctrl 5 0.5,0.75 
Ctrl 6 1,1 
Ctrl 7 -1,-1 
Ctrl 8 -4.5,-4 
Case 1 -4.5, -4.0 
Case 2 0, 0.5 
Case 3 0, 0 
Case 4 -2,-2 
Case 5 0,0 
Case 6 0,0 
Case 7 0,0 
Table 2.5 Spherical equivalent refraction of the left and right eye of cases and 
controls undergoing imaging for choroidal thickness measurements 
 
This suggests that choroidal changes may occur prior to neuro-retinal changes.  Looking more 
closely at which layer is most affected by the apparent loss in thickness a masked ophthalmologist 
manually segmented the inner choriocapillaris and Sattler layer from the outer Haller layer which 
has larger vessels. A method for defining the thickness of the inner and outer choroid under the 
fovea was first validated by two masked ophthalmologists using 20 test images from cases and 
controls.  This had an extremely high agreement with a Cronbach’s alpha of 0.98. Using this 
approach, an ophthalmologist masked to the diagnosis found a significantly greater proportion of 
the thickness reduced at the fovea due to Sattler layer loss in L-ORMD than in controls (figure 
2.21).  The average thickness of Sattler’s layer in the stage 2 cases was 51um (SD=29.6) and 
138.7um (SD=37.8) in the control group. This was a significant difference (p<0.0001). The 
average thickness for the Haller layers were 89.1um (SD=45.1) for the cases and 136um for the 
controls (SD=39.6).  The Haller layers were also significantly thinner in the case when compared 
to age-matched controls (p<0.01). This suggests that the smaller and medium sized choroidal 
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vessels are initially more vulnerable in L-ORMD than the larger choroidal vessels found in 
Haller’s layer (figure 2.17D). 
   
2.3.4 Assessing the progression of L-ORMD 
 
Having identified that the temporal macula and retina showed the most marked sub-retinal deposit, 
I wanted to investigate whether this was also the site of initial atrophy.  This would help 
differentiate L-ORMD from early geographic atrophy, which would tend to be more central. In 
order to investigate early atrophic disease, I included stage 2 patients (patients affected prior to full 
foveal involvement but with fundus signs of disease). Software on the Heidelberg Spectralis 
superimposed an ETDRS chart on to the FAF image for the patients.  A count was made for the 
number of times an area of reduced FAF was seen in a particular ETDRS region.  The 
methodology used was similar to that described for foveal sparing geographic atrophy in AMD 
(Schmitz-Valckenberg et al., 2009).  
 
The outer temporal macula was found to have the highest percentage of reduced autofluorescence 
(90%) followed by the outer inferior macula (figure 2.18).  This suggested that in L-ORMD 
disease started temporal to the fovea before progressing towards the centre.  This study divided 
patients into stage 2 and stage 3 but did not perform a longitudinal study looking at regional 
progression of disease. 
 
Another recent software update enabled regions of atrophy to be measured on the SD-OCT using 
FAF images (figure 2.19). This technique had recently been used to monitor geographic atrophy 
progression.  This technique had not previously been used in L-ORMD patients.  As a result, the 
measurements were first validated by masking two ophthalmologists who then generated 
measurements of atrophy from 20 sample images from L-ORMD patients.  The pilot study showed 
good agreement (Cronbach’s alpha=0.98). A masked ophthalmologist then used this technique to 





Figure 2.17: Topography of atrophy in stage 2 L-ORMD. 
An automatically generated ETDRS topography grid was generated and overlaid by Heidelberg 
Spectralis software on to stage 2 case FAF images. The images were then analysed to see how 
many times reduced FAF was seen in each ETDRS region. The image depicts the percentage of 
times FAF was seen in each region for stage 2 patients.  This shows a preponderance of the outer 
temporal region.  
 
Figure 2.18: Assessing progression in L-ORMD. 
(A) Fundus autofluorescence images (820nm) of the right macula.  There are clear areas of 
reduced autofluorescence surrounded by areas of increased autofluorescence similar to 
geographic atrophy.   
(B) Heidelberg regionfinder software is used to map areas of reduced autofluorescence.  Each 
number represents a seed point for semi-automated generation of areas.  The red lines 
signify boundaries within which measurements are generated.  The software produces an 
area table of each seeding area for analysis. 
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Measuring the areas of atrophy in LORMD with Heidelberg Region finder software showed good 
agreement Cronbach’s α=0.98 using 2 masked observers. The average size of hypofluorescent 
areas at baselines was 3.6 mm2. There was poor correlation between age and size of areas at 
baseline (R=0.12). The rate of progression was 2.5mm2/year (SD=2.1mm2) in stage 2 patients. 
 
The deposit thickness was also measured in all patients.  This was measured manually using the 
Heidelberg Spectralis software to assign a size.  Again, a validation study was performed using 20 
test images and two ophthalmologists masked to the diagnosis of the images.  A very high 
agreement of 0.99 using Cronbach’s alpha test was achieved. Measurements were performed under 
the fovea to provide a reference landmark for calculations.  The average deposit in all patients was 
16.6 um (SD=1.65).  There was no significant increase in deposit size over two years. In addition, 
there was no significant difference in deposit thickness at the fovea between stage 2 and stage 3 
patient (p=0.82).  This study will however be limited by the resolution of the SD-OCT machine 
which is approximately 4 µm.  
 
 
2.3.5 C1QTNF5 localisation immunohistochemistry 
 
The OCT scans highlighted several types of drusen formation.  I wanted to investigate these further 
using histopathology. In addition, I wanted to investigate the composition of deposits in detail.  
Previous studies have examined sub-RPE deposits in L-ORMD (Malek et al., 2003, Kuntz et al., 
1996). However, these studies were performed prior to identification of the causal gene.  It has 
been proposed that mutant C1QTNF5 forms aggregates (Shu et al., 2006a). However, to date there 
have been no studies examining whether C1QTNF5 protein is found in the deposit. One hypothesis 
is that the deposit is also composed of the mutant protein. 
 
Human post-mortem L-ORMD eyes were rare.  A single human donor sample was located in the 
University of Edinburgh.  Two further samples were later donated by Professor Radha Ayyagari 
(University of California, San Diego) in order to confirm my findings.  Three patient samples were 
provided: 
 
1) An 80 year old male patient with confirmed L-ORMD. The samples had previously been 
described by Duvall et al (Duvall et al., 1986). 
 
2) A 82 years old patient previously described by Milam et al. (Milam et al., 2000)The FFB donor 




3) A 80 years old patient described by Kuntz et al(Kuntz et al., 1996).  The FFB donor number is: 
356. 
 
The initial immunohistochemistry was performed using DAB staining on these paraffin embedded 
samples. After the initial immunohistochemistry it was realised that the brown colour of the DAB 
staining was not clear again the pigmentation of the RPE and choroid.  Consequently, a red refine 
stain (Sigma) was used in later sections.  The samples were reviewed with a histopathologist, Dr 
Colin Smith (University of Edinburgh) who was masked to the diagnosis.  The L-ORMD post 
mortem samples showed marked staining of the sub-retinal deposit for C1QTNF5 (figure 2.20).The 
staining pattern was slightly different between samples. L-ORMD donor 1showed marked sub-
RPE staining with staining extending to the middle of the deposit.  L-ORMD donor II samples 
showed marked staining of the inner deposit.  Staining was most marked in the centre of the 
deposit.  Donor III showed staining throughout the deposit. In all three samples, the immune 
staining was not homogeneous.    
 
 
Figure 2.19 L-ORMD human donor retinal sections immunostained with anti-C1QTNF5 
antibody (1:200).   
The photographs show heavy immunostaining in all samples in the deposit. There is also marked 
loss and disorganization of the RPE (black arrows). In case I and II, the immunostaining is 
greatest in the inner deposit with secondary staining enhancement with DAB and red refine 
respectively (figures 2.24 A and B). In figure 2.24C the whole deposit is immunostained for the 
deposit visualized with red refine. (scale=25 µm).  NR= neuro-retina, RP=retinal pigment 
epithelium, CR=choroid. 
 
In order to confirm that the sub-RPE immunostaining phenotype for C1QTNF5 was specific to L-
ORMD I also performed similar staining on 7 control samples from elderly patients with no known 
eye pathology.  In addition, a further sample from a patient with early AMD was used (table 2.7). 
Both the histopathologist and myself were masked to the diagnosis of the samples.  In these 
samples there was only faint immunostaining directly sub-RPE for C1QTNF5 (figure 2.21).  The 
AMD patient showed no staining of sub-RPE drusen (figure 2.21).  In order to confirm the finding 
that C1QTNF5 I wanted a further positive control.  
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Table 2.6 Details of patients from whom post-mortem donor control retina were 
donated for histopathological studies. 
 
 
Figure 2.20: Images of retinal sections from an aged control patient and a patient with early 
AMD. 
The retinal sections are from a 78 year old male patient with no known eye disease (A) and 71 
year old male patient with early AMD (B). The sections were immunostained with C1QTNF5 
antibody 1:200 and DAB secondary.  There was only minimal staining of the basal RPE. Drusen 
remained unstained for C1QTNF5 (black arrow).  (scale=25 µm)  NR= neuro-retina, RP=retinal 
pigment epithelium, CR=choroid. 
 
Recently a mouse model of L-ORMD had been generated.  The mouse also developed sub-RPE 
deposits. I predicted that the mouse model would also show evidence of C1QTNF5 deposition in a 
similar manner to human L-ORMD retina.  The finding again showed that the mutant mice had 
marked staining of the deposit for C1QTNF5 much like the human L-ORMD post mortem samples 
(figure 2.22) whilst the wild-type control had only faint sub-RPE staining (figures 2.22 and 2.23). 
Consequently, I initially wanted to test this hypothesis by using samples from the recently 
generated murine model for L-ORMD (Chavali et al., 2012).  These samples were kindly donated 
by Professor Radha Ayyaagri (University of California, San Diego) (table 2.7).   
 
Identification Age of donor 
(years) 
sex Eye/medical history 
CTRL1 85 F No eye path noted/hypertension 
CTRL2 71 M Drusen/Parkinson’s, hypertension 
CTRL3 72 F Dementia, cataract surgery 
CTRL4 91 F Cardiac arrest 
CTRL5 78 M Bronchial cancer 
CTRL6 88 M Acute pancreatitis 
CTRL7 35 M Pneumonia, carcinomatosis 
CTRL8 81 F COAD peritonitis 




Table 2.7 Summary of mice genotypes used for murine histopathological studies. 
 
 
Figure 2.21 Immunofluorescence images of mouse retinal sections immunostained with anti 
C1QTNF5 The sections were stained with C1QTNF5 antibody (1:200) with secondary staining 
(555 µm).  The image from a wild-type mouse retina show minimal amounts of staining of the 
basal RPE membrane (A).  The image from the heterozygous C1QTNF5 mutant knock in shows a 
marked sub-RPE deposit.  The deposit shows dense staining for C1QTNF5 (B) (scale=10 µm).  
RP=RPE 
 
Figure 2.22 Wide-field immunofluorescence images of retinal sections from three 
heterozygous mutant C1QTNF5 knock in 19 month mice immunostained for anti C1TQNF5 
antibody 1:200.  The images show staining with DAPI for nuclei (blue) and C1QTNF5 (red).  A 
primary of anti-C1QTNF5 was used with an Alexa-fluor secondary fluorescing at 555nm for the 
secondary. The images show strong staining of the sub-RPE deposit.  There is also 




2.3.6 Complement immunohistochemistry 
 
Complement dysfunction has been implicated in the macular degenerations (Anderson et al., 2002, 
Fernandez-Godino et al., 2015).   However, immunohistochemistry had never been performed on 
L-ORMD retina previously. I predicted that complement dysfunction also played a role in L-
ORMD pathogenesis. L-ORMD human donor retina is rare. Consequently, I initially wanted to test 
this hypothesis by using samples from the recently generated murine model for L-ORMD (Chavali 
et al., 2011).  These samples were kindly donated by Professor Radha Ayyaagri (University of 
California, San Diego).   
 
I prepared sections of similar species of mice (C57BL/6) as controls in order to optimise the 
staining method. The mice were noted to have not only pigmented RPE but also a pigmented 
choroid. Initially I attempted to perform immunohistochemistry on the samples using fluorescence.  
However, the marked autofluorescence at 488nm and 555nm wavelengths precluded a clear image 
of staining in controls for C1QTNF5 As a result I switched to using red refine (Sigma) and 
brightfield microscopy for images. Recently, Professor Eric Pierce’s group (Harvard university) 
have published on a mouse model of another inherited retinal dystrophy, Malattia Leventinese 
(Fernandez-Godino et al., 2015).  They were able to demonstrate complement component 
deposition in the retina of these mice, which was increased when compared to controls.  I proposed 
using a similar approach and contacted Prof Pierce’s group who kindly provided information about 
antibodies. 
 
C3d is a breakdown product of C3b after lysis by CFH.  It is a marker for complement activation.  
After performing immunohistochemistry for C3d, the slides were reviewed by a consultant 
histopathologist who was masked to the genetic status of the mice.    C5b-9 is the TCC of the 
complement pathway.  Positive staining would suggest that complement was not only active but 
also incompletely controlled as c5b-9 can cause cellular damage with membrane pore formation.  
Staining for C5b-9 has previously been reported in both inherited and age-related macular 
degenerations (Fernandez-Godino et al., 2015, Anderson et al., 2002).   
 
Looking firstly at the murine retinal samples, strong C3d immunostaining was noted in the sub-
retinal deposit of the heterozygote knock in mouse with some faint staining of the choroid (figure 
2.24). In the knockout C1QTNF5 mouse not only was there no staining for C1QTNF5 but also for 
C3d with no discernible sub-retinal deposit (figure 2.25). There was a lack of C5b-9 






Figure 2.23 Sections from retina of three 20 month old heterozygous mutant mice 
immunostained with antibody to anti-C3d.  Sections were initially incubated with a primary of 
anti C3d. A secondary of anti-rabbit was used and highlighted using a red-refine stain.(red). All 
three retinal sections show red refine staining of the sub-RPE deposit (black arrows).  There is also 
minimal staining of the pigmented choroid which is most clearly seen in image C. (scale=20 µm) 
 
Figure 2.24  Image of a retinal section from a 19 month old C1QTNF5 knockout mouse 
immunostained with antibody to C3d.   The knockout mouse section was prepared in a a similar 
manner to the sections shown in figure 2.23. The image shows that there is no sub-deposit. In 
addition, there is no staining of the retina or choroid for c3d..  (scale= 20 µm) 
 
 
Figure 2.25: Sections from the retina of three 20 month old heterozygous mutant mice 
immunostained with antibody to anti-C5b-9.  The sections were initially incubated with anti-
C5b-9 antibody.  A secondary of anti-rabbit was used and red refine used to highlight any staining. 
The images show a clear sub-RPE deposit.  However, there is no staining of the neuro-retina, RPE, 




Building on the findings that the deposit in mouse model stained for C3d, I next optimised staining 
for C3d and C5b-9 using control human retinal samples (figure 2.27).  The normal aged control 
and the AMD control both showed immunostaining of the inner choroid for C3d.  In addition, the 
drusen seen in the AMD control showed dense staining for C3d in a similar manner to the sub-RPE 
deposits in L-ORMD mice. After optimisation, I immunostained L-ORMD donor post-mortem 
samples. All three L-ORMD samples showed staining for C3d in the sub-RPE deposit and the 
inner choroid (figure 2.28). The pattern of staining was mainly on the inner and outer part of the 
deposit with relative sparing of the central deposit.  All the aged human retinal samples also 
showed similar choroidal staining with staining most prominent directly below the RPE (figure 
2.31).  This suggested that findings complement dysregulation identified in AMD and on the L-




Figure 2.26 Sections from the retina of a 72 year old control post-mortem donor (A) and 71 
year old post-mortem donor with early AMD (B) immunostained with anti-C3d antibody. 
The sections were initially incubated with anti-C3d antibody primary and DAB secondary. Both 
sections show marked brown immunostaining of the inner choroid (black star).  In image (B) the 




Figure 2.27 Sections from the post mortem retinas of three L-ORMD cases immunostained 
with anti-C3d antibody.  
The sections were all incubated with anti-C3d human primary.  In figure 2.27A DAB was used as a 
secondary.  In figures 2.27B and 2.27C red refine was used to highlight primary immunostaining. 
(A) There is marked immunostaining of the deposit (brown) particularly in the inner deposit and 
outer deposit.  There is also lighter staining of the choroid. Focal areas of protrusion of the deposit 
through the RPE which appear similar to the OCT images in figure 2.14 (B)  Marked red 
immunostaining of the choroid and focal areas of the outer deposit. (C) Strong immunostaining of 
the inner and outer sub-RPE deposit. The image also shows strong staining of the inner choroid. 
The black arrow highlights an area of deposit protrusion. (scale=25 µm) 
 
 
Although the mouse staining showed no obvious staining for C5b-9, I repeated the staining in the 
human post mortem samples to see if there was any difference in TCC deposition. The L-ORMD 
samples stained positively for C5b-9 in the deposit and the choroid (figure 2.29).  The pattern of 
staining was slightly different between the cases. Case I showed staining in the middle of the 
deposit (figure 2.29A). Case II showed staining in the central and outer half of the deposit sparing 
the outer most part of the deposit (figure 2.29B). Case III showed only faint staining of the outer 
half of the deposit (figure 2.29C).  The control lines showed little or no immunostaining for C5b-9 
(figure 2.30). However, the early AMD post mortem sample showed marked staining of the sub-
RPE drusen. Again this suggested that the complement dysregulation seen in the deposit may have 
similarities to AMD drusen. This variation was likely due to the different stage of disease found 






Figure 2.28: Sections from the post mortem retinas of three L-ORMD cases immunostained 
with anti-C5b-9 antibody.  
(A) Brown immunostaining of the deposit particularly in a band in the centre of the deposit. (B) 
Red immunostaining of the deposit and choroid with some focal areas of staining in between RPE. 
(C) Faint staining of outer deposit and choroid. (scale= 20 µm) 
 
 
Figure 2.29: Sections from the retina of a 72 year old control post-mortem donor (A) and 71 
year old post-mortem donor with early AMD (B) immunostained with anti-C5b-9 antibody. 
(A) shows only minimal staining in the sub-RPE. (B) Little staining of the neuro-retina or choroid 





   
In this study, clinical phenotyping of L-ORMD patients revealed that in early patients central 
visual acuity remained normal until late stage 2 disease.  This was mirrored by functional 
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investigations with multifocal ERG and microperimetry also showing normal measurements at the 
fovea.  The earliest changes in this cohort occurred in the temporal macula where deposits were 
also thickest.  Choroidal thickness was reduced in particular in the inner small to medium sized 
vessels in L-ORMD patients prior to neuro-retinal atrophy when compared to normal controls. In 
addition, the rate of growth of geographic atrophy could be monitored using semi-automated 
system, which would provide a method of monitoring disease progression in stage 2 disease.  OCT 
studies highlighted an early reticular pattern of drusen formation, which was highlighted by FFA 
and late ICG studies. However, drusenoid deposits were heterogeneous.  Some reticular and 
cuticular type drusen were see in early stage 2 disease in addition to thickening of the sub-RPE 
deposits. All these forms of drusen are also associated with AMD.  However, unlike AMD, L-
ORMD deposits predominate in the temporal retina and macula in early disease and this can 
distinguish the disease from AMD.  In addition, drusenoid deposits also commonly develop 
beyond the retinal vascular arcades which is rare in AMD. 
 
Novel findings in this set of studies include the use of automated segmentation software on the 
OCT to help delineate the choroid with the addition of manual segmentation to look at specific 
layers within the choroid in L-ORMD.  Additionally, the use of multifocal ERG and 
microperimetry can be used to highlight reduced function.  The reduced amplitude and increased 
latency in the multifocal ERG correspond to early atrophic damage in the temporal region of the 
macula. Finally, histopathology studies of heterozygous C1QTNF5 mutant mouse retina and from 
human L-ORMD retina have demonstrated immunostaining suggesting increased complement 
activation in both the sub-RPE deposit and inner choroid of L-ORMD samples a when compared 
with control retinal samples. 
 
Previously, Jacobsen et al. had shown that in patients suspected to have L-ORMD, dark 
adaptometry abnormalities were observed prior to retinal findings (Jacobson et al., 2001).  The 
dark adaptation delay was most sensitive at 15 degrees from foveal fixation.  In this study we have 
shown that deposit thickness varies but is initially greatest temporal to the fovea. Additionally, the 
initial site of atrophy occurs just temporal to the fovea.  Some forms of GA also have demonstrate 
early foveal sparing (Schmitz-Valckenberg et al., 2009). Published rates of progression for GA 
vary from 0.74-1.68mm2/year (Schmitz-Valckenberg et al., 2009, Steinberg et al., 2013, 
Fleckenstein et al., 2011, Fleckenstein et al., 2010).  However, the rate of progression for early L-
ORMD is greater than that for GA.  It would be interesting to also compare figures for later disease 
as L-ORMD continues to progress beyond the macula whilst GA is usually confined to the macula.  
 
In this study, we identified changes above the RPE in early disease.  These pseudodrusen masked 
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ICG fluorescence and were stained by fluorescein.  These changes were also visible on SLO and 
IR.  The deposits resembled reticular pseudodrusen (RPD) which have recently been described in 
early AMD (Spaide and Curcio, 2010, Finger et al., 2014).  As RPD are found between the RPE 
and photoreceptors, it has been hypothesised that they cause damage to adjacent photoreceptors 
earlier than sub RPE drusen.  This may account for the loss of rod function in the mid-peripheral 
macular seen in L-ORMD patients.  Similarly, in AMD, RPD is associated with early field loss on 
microperimetry (Wu et al., 2015, Ooto et al., 2013, Querques et al., 2014).  
 
RPD in AMD has been associated with choroidal thinning.  There is increasing evidence that 
choroidal changes may precede changes in the RPE or neuro-retina in AMD (Whitmore et al., 
2015). As L-ORMD is a peripherally progressive disease, it allows the study of changes prior to 
RPE or neuro-retinal loss.  In this study, the histopathology specimens showed increased 
deposition of complement pathway components in L-ORMD eyes when compared to age matched 
controls suggesting a role for complement pathway dysfunction in early disease. Staining for these 
components was also seen in the inner choroid, a region of the choroid we have identified as most 
greatly affected in L-ORMD patients.  Similar findings are also beginning to emerge in AMD 
(Whitmore et al., 2015, Whitmore et al., 2014, Mullins et al., 2014a).  
 
The key histopathology findings are the demonstration that the deposits in both the mouse and the 
human stain for C1QTNF5 protein.  Secondly, both the mouse and human L-ORMD retinal 
samples show evidence of complement dysregulation when compared to similarly aged control 
retinal sections. Recently, another deposit Malattia Leventinese or Doyne’s honeycomb retinal 
dystrophy results from a mutation in the EFEMP1 gene.  In the mouse model, deposit formation 
was demonstrated (Fu et al., 2007).  The deposit contained increased quantities of extra-cellular 
matrix material and also immunostained for Efemp1 protein (Fernandez-Godino et al., 2015, 
Garland et al., 2014a). Similarly deposit in the L-ORMD samples stained for C1QTNF5.  Studies 
in AMD have demonstrated a number of components in sub-RPE deposits including basal laminar 
deposits and drusen (Hageman and Mullins, 1999a). These include CFB, CFH, C3, C3d, C3b, C5, 
C6, C7, C8, C9 and C5b-9 (Mullins et al., 2000a, Gold et al., 2006, Crabb et al., 2002, Anderson et 
al., 2002). Immunohistochemistry and expression analyses of the RPE-Bruch’s membrane-choroid 
complex reveal that the choroid together with the RPE are able to generate most of the components 
of the complement pathway in order to activate the TCC (Anderson et al., 2010).  This suggests 
that there is a localised complement dysregulation. The findings from this series of studies fit in 
well with those from the other studies.  However, one difference is found in the pattern of 
immunostaining. Whilst drusen appear to be uniformly immunostained for C3d and C5b-9, the 
deposit in L-ORMD appears to be more heterogeneous with variable staining of the inner middle 
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and outer deposit.  This difference in immunostaining may result from differences in composition 
of the deposit which has been shown to be a bilayer with wide-spaced collagen and ECM 
deposition on the inner deposit and lipid composition in the outer deposit (Kuntz et al., 1996).  
 
In summary, the phenotyping of L-ORMD has revealed several tools to identify and monitor L-
ORMD.  Additionally, the multi-modal approach has highlighted several changes in L-ORMD, 
which are similar to changes in early AMD.  Together with histopathology investigations, this 
suggests that the initial site of injury may also involve the choroid and implicates dysregulation of 
the complement pathway in L-ORMD disease pathogenesis. Similarities between the findings in L-
ORMD and AMD further confirm that L-ORMD is a good model for AMD and demonstrate the 
utility of using L-ORMD to investigate disease mechanisms in early macular degeneration. 

































3.      Generating retinal pigment epithelium (RPE) from human 
induced pluripotent stem cells (hiPSCs) 
 
 
3.1       Introduction and rationale 
 
The earliest changes in AMD occur at the level of the RPE and BM.  It is likely that RPE cellular 
injury initiates AMD although the exact mechanism is still unclear (Hogan, 1972, Dorey et al., 
1989).  Obtaining diseased RPE for investigation of early disease mechanism would be useful. 
However, obtaining intraocular samples of RPE in sufficient quantity is problematic due to the 
potential risks of organ damage. HiPSCs offer a potential solution.  They have been used to model 
a number of diseases by differentiating hiSPCs to cell types implicated in disease (Tucker et al., 
2015, Johnson et al., 2015, Yang et al., 2014a, Jin et al., 2012, Singh et al., 2013b).  By 
reprogramming patients’ cells carrying harbouring mutations and then differentiating these to 
hiPSC-RPE to disease causing cell types it is potentially possible to generate an unlimited supply 
of RPE for investigation of disease mechanisms in vitro.   
 
There has been a rapid evolution of protocols for reprogramming cells to hiPSCs. The original 
reprogramming strategies used two different sets of transcription factors   (Takahashi et al., 2007) 
(Yu et al., 2007). Both initial protocols used OCT4 and SOX2 but Takahashi et al. used KLF4 and 
c-MYC whereas Yu et al. used NANOG and LIN28. Both groups used retroviral vectors with a 
plasmid backbone that integrated in to the host cell genome. For reprogramming to occur a number 
of different criteria are required to be fulfilled.  Firstly, the genes encoding the transcription factors 
have to be integrated and expressed.  The expression is limited to within a relatively narrow 
stochastic window.  Finally, following reprogramming the expression of transcription factors 
should be silenced to enable differentiation.  This results in a relatively low reprogramming 
efficiency (Hanna et al., 2009). Additional limitations include the  generation of partially 
reprogrammed cells which reduce efficiency and the need to use irradiated mouse embryonic 
fibroblasts (MEFs)which increase variability in culture  (Mikkelsen et al., 2008)(Chan et al., 
2009). MEFs were the original platform for maintaining pluripotent cells.  However, this 
technology has now been superseded by defined media used to maintain pluripotency. 
 
During the course of my doctoral studies a number of new protocols were standardised that used 
non integrating expression of transcription factors. Initially the use of non-integrating viral vectors 
was used successfully including adenovirus, adeno-associated virus and Sendai virus. However, the 
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use of these vectors was still limited because the viruses may remain in the cells for several 
passages (Rashid et al., 2010). A further step change resulted from episomal reprogramming which 
combined the benefits of a non-integrative methodology, the use of non-biologically active vectors 
and the use of a feeder free system  (Takahashi et al., 2007 , Yu et al., 2007; Lowry et al., 
2008, Okita et al., 2008,  Fusaki et al., 2009,  Si-Tayeb et al., 2010 and Nakanishi and Otsu, 2012).  
 
RPE differentiation from pluripotent stem cells was optimised firstly using hESCs (Vugler et al., 
2008, Gamm et al., 2008, Klimanskaya et al., 2004, Idelson et al., 2009) and latterly with hiPSCs 
(Meyer et al., 2011, Buchholz et al., 2009, Osakada et al., 2009a). A well-characterised 
differentiation protocol replicating embryology was published by Meyer et al.(Meyer et al., 2009).  
Following a period of training in the laboratory of Professor David Gamm. this protocol was 
adopted, with adaptations, as the primary protocol for hiPSC-RPE differentiation in these doctoral 




3.2       Methods  
 
Patient and sibling recruitment was performed by Dr Shyamanga Borooah.  All fibroblast biopsies 
and cultures were performed by Dr Shyamanga Borooah. HiPSC reprogramming for case lines 1 
and control lines 1 and 2 was performed by Dr Shyamanga Borooah in the laboratory of Dr 
Ludovic Vallier (University of Cambridge), with the guidance of Ms Imbisaat Geti (University of 
Cambridge).  Generation of episomal case lines 2 and 3 was performed at the MRC centre for 
regenerative medicine under the supervision of Dr Karen Burr (University of Edinburgh).  
Validation of hiPSCs was performed by Dr Shyamanga Borooah with the assistance of Dr Karen 
Burr (University of Edinburgh).  HiPSC maintenance was performed initially by Dr Shyamanga 
Borooah and later by the core stem cell team in Professor Chandran’s laboratory.  Dr Nina 
Rzercheck and Dr Bhuvaneish Thangar (University of Edinburgh) provided advice for western blot 
optimisation. 
HiPSC differentiation to RPE was performed by Dr Shyamanga Borooah.  In addition, Dr 
Shyamanga Borooah performed all characterisation including microscopy, electron microscopy, 
PCR, western blot, immunohistochemistry, phagocytosis assay, electron microscopy.  Time was 
spent in the laboratory of Dr David Gamm (University of Wisconsin, Madison) who provided 





3.2.1 Generation and maintenance of case and control hiPSCs 
 
In order to obtain patient cells for cellular reprogramming to hiPSCs a fibroblast sample was taken 
from cases and controls.  Procedures were performed following informed consent and covered by 
NHS Lothian ethics committee approval (REC 08/S1101/1). Subcutaneous 2% xylocaine with 
adrenaline 1:100,000 (Astra-Zeneca) was allowed to take effect on the forearm of donors for 10 
minutes.  A 3.5 mm punch biopsy was then taken.  The area was cauterised to provide haemostasis 
before 5/0 prolene purse string suture (Ethicon) was used to close the wound.  The punch biopsy 
sample was placed in DMEM + 10% FBS and placed in ice for transport prior to further 
processing.  
 
Figure 3.1 L-ORMD family pedigree *=affected 
The biopsy sample was carefully dissected under a microscope to remove the epidermis and sub-
cutaneous fat.  The fibroblast layer was then placed in a 100mm plate with a coverslip placed on 
top before 10% FBS DMEM was carefully added to cover the biopsy.  Outgrowth of fibroblasts 
from the biopsy sample occurred between 3 to 7 days. 
 
After a further two weeks when fibroblasts were near confluent, the cells were removed using 
0.05% trypsin/EDTA (Gibco) and decanted into a 15 ml conical tube.  10% FCS+ DMEM (Gibco) 
was added to neutralise the trypsin and then the cells were spun at 1500g to remove excess trypsin.  
The cells were then resuspended in 10% FCS+ DMEM before being plated in a T25 flask.  After a 
week, the same process was performed to plate cells into three T75 flasks. Once confluent, the cell 
were stored in cryovials in 10% DMSO+DMEM freezing solution and stored in liquid nitrogen for 
long-term storage. 
 
Three main methods were used for fibroblast reprogramming.  Different methods were used because 
of the rapid development in reprogramming technologies during the course of the doctoral work. 
Each of the methods are outlined below: 1) Lentiviral reprogramming using a lentiviral backbone, 
2) Sendai virus reprogramming and 3) Episomal reprogramming.   
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Lentiviral reprogramming was performed as previously described (Banito et al., 2009).  Briefly, 
Fibroblasts were thawed into a 6 well plate in 10% FBS+ DMEM. When cells reached 80% 
confluence the medium the cells were lifted to single cells by incubating in 0.05% trypsin for 5 
minutes at 37°C. Cells were resuspended in 5 mls MEF medium and the counted using a 
haemocytometer.  105 cells were plated into 1well of a 6well plate. Cells were incubated at 37oC 
5% CO2 for 24 hours. Yamanaka factors OCT4, SOX2, KLF4 and c-MYC (Vectalys,Toulouse, 
France) at MOI 10 were used to transduce the cells for 24 hours and the cells were incubated. On 
the fifth day, cells were split into single cells using trypsin 0.05% incubation for five minutes 
before being transferred to a 100MM plate with irradiated MEFs and grown for a further 2 days.  
After day 9, cells were grown in standard hESC culture medium. The first hiPSC colonies 
appeared approximately fifteen days later and were picked approximately five days after appearing. 
Individual colonies were picked and transferred to a 12 well plates containing MEFs feeders in 
KSR + FGF. Colonies were expanded by enzymatic dissociation 
 
Sendai virus reprogramming was performed as previously described (Rashid et al., 2010). 
Fibroblasts were plated in wells of a 6 well plate at 1 X 105 two days prior to transduction in 
fibroblast medium. When cells reached 80% confluency, the Sendai reprogramming kit was used 
(Cytotune, invtirogen) by transducing using Sendai virus expressing Yamanaka factors at 
recommended concentrations to reach the target MOI within the kit. Virus was added to the 
medium at the calculated concentration to 1 ml of fibroblast medium.  The fibroblasts were 
transduced under incubation at 37oC for 24 hours before medium was replaced with fresh fibroblast 
medium. Cells were cultured for a further 6 days before enzymatic dissociation on to radiated MEF 
100mm culture dishes at a concentration of 2 x105 cells per plate. Cells were maintained in hESC 
medium for approximately three further weeks before hiPSC colonies appeared.  Colonies were 
picked manually using a microscope and placed individually into MEF 24 well culture plates prior 
to further culture and expansion. 
 
The episomal protocol used was a variation on that already published (Okita et al., 2011).  0.2% 
gelatin (Sigma) coated 5 x 105 fibroblasts were harvested using enzymatic dissociation and counted 
using a haemocytometer.  18ul Amaxa supplement1 and 82ul nucleofection solution were mixed to 
create a transfection solution. Fibroblasts were spun down in a centrifuge at 300g for 3 minutes 
before the dried cell pellet was resuspended in the transfection solution.  1.7 µg of three episomal 
DNA suspensions OCT3/4/shP53, Sox2/Klf4 and L-Myc/Lin28 episomal vectors (Addgene) were 
added.  The electroporation was performed using an Amaxa 4D-nucleofector (Lonza).  Following 
transfection the fibroblasts were plated into one well of a 1 in 60 matrigel coated six well plate 
containing fibroblast media before the plate was placed in an incubator under standard incubation 
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conditions.   Media was replaced every 2 days.  After one week when fibroblasts were nearly 
confluent cells were harvested using 0.05% trypsin/EDTA (Gibco) before being replated onto 
100mm Geltrex (Thermo Fisher scientific) coated plates in fibroblast media. After a further two days 
media was switched to pluripotent cell medium (E6+bFGF) (Stem cell technologies).  Media was 
changed every two days.  Colonies emerged from the third week and were mechanically picked and 
placed into 24 well plates coated with matrigel and covered in E8 media (Stem cell technologies).   
For maintenance all cells were transitioned to feeder free E8 media on to 1:60 matrigel (BD 
bioscience) coated plates. Every 7 days as cells became confluent cells were passaged to single cells 
using dispase and collagenase (1:1).  Cells were left under standard incubation conditions for 
approximately 15 minutes till cells dissociated from the plates. The cell colonies from all wells of a 
six well plate were then aspirated into a 15 ml tube and allowed to settle.  The colonies were allowed 
to settle and the media aspirated.  The cells were then washed in 10 mls of PBS.  After 5 minutes, 
the media was aspirated and replaced with 1 ml E8 media. The cells were then aspirated repeatedly 
with a 1000ul pipette to break colonies in to single cells.  A further 5 mls of E8 was added before 
500ul of media form the tube was placed in each well of a fresh matrigel coated six well plate.  A 
further 1.5 ml of E8 was added to each well.  The plates were transferred to an incubator and shaken 
in a figure of eight to evenly spread cells across the well. The plate was incubated under standard 
conditions and media was completely replaced with 2mls fresh E8 on a daily basis. For the 
experiments, only cells from passage number 15 to 65 were used. 
HiPSC validation included immunostaining, PCR, DNA sequencing, karyotyping and confirmation 
of 3 germ layer differentiation. In order to confirm mutant and wild type genes in case and control 
lines DNA was extracted from the lines using the Wizard SV genomic DNA kit (Promega) 
according to kit instructions using spin columns.  To briefly summarise the protocol.  Cell pellets 
from a well of a six well plate were sheared by passing them through a 20 gauge needle ten times 
attached to a 1ml syringe.  The entire sample was transferred to spin-column containing sample 
lysate and the column spun for 1minute at 12000g.  The flow through was discarded. The kit wash 
solution was added to the spin column and the membrane washed by centrifuging at 12000g for 1 
minute and the flow through once again discarded. These steps were repeated a total of three times. 
A final spin of 12000g for 2 minutes was perfomed in order to dry the membrane.  The spin 
column was placed into a 1.5 ml microfuge tube.  RNAase solution was added and nuclease free 
water was added to elute the membrane. The column was spun for a final time at 12,000g for 1 
minute. Confirmation of DNA content was made using a NanoDrop (Thermo fisher scientific). The 
microfuge tube containing the eluent was then used directly for amplification.  A mastermix was 
made up using the high fidelity Q5 TAQ polymerase kit (New England Bioscience).  Amplification 




To check amplicon size the product was run on 2% agarose gel for half an hour at 100V.  After 
confirmation, the DNA was cleaned up using ChargeSwitch® gDNA Mini Tissue Kit (Thermo 
Fisher scientific).  A final check on a NanoDrop for a concentration of at least 1ng/ul per 100 base 
pairs was performed on a NanoDrop (Thermo Fisher scientific).  Sanger sequencing was performed 
by source bioscience (Nottingham, United Kingdom). Information about primers is available in the 
appendix. 
For karyotyping 0.2 ml colcemid (Sigma) at a working solution of 0.1ug/ml was added to the media 
of each well of a six well plate.  The plates were then placed under standard incubation conditions 
for 2 hours. Cells were then enzymatically dissociated with 0.05% trypsin. The cells were transferred 
to a 15 ml conical flask and then spun at 1200 RPM for 5 minutes.  The supernatant was discarded 
and the cells resuspended in 5ml KCl.  A 75%methanol 25% acetic acid fixative was prepared and 
added dropwise to the conical flask to a volume of 3ml.  The fixed cell suspension was then frozen 
at –20oC and sent to the cytogenetics laboratory for formal screening under microscopy 
(Addenbrookes, hospital, Cambridge, United Kingdom)  
For three germ layer differentiation cells were split onto new six well matrigel coated plates as per 
normal passaging of hiPSCs and fed with 2 mls of E8 before incubation overnight. For mesodermal 
differentiation, a three-day protocol was used.  The cells were fed with chemically defined media 
(CDM) with the addition of Activin  (10ug/ml), FGF2 (4 µg/ml) BMP4  (10ug/ml), Ly (10mM) 
and CHIR (3mM). Media was completely replaced every day for three days. For endodermal 
differentiation, a 3-day protocol was used.  On day 1 cells were fed with CDM containing activin 
(10ug/ml), FGF2  (4ug/ml), BMP4 (10ug/ml), Ly (10mM) and CHIR 3mM. ON day 2 the cells 
were fed with day 1 media minus CHIR.  On day 3 cells were fed with CDM with the addition of 
activing (10ug/ml), FGF2 (4ug/ml) and B27 (1:50). For neuroectodermal differentiation cells were 
fed with CDM with SB (1ul/ml), FGF2 (4ug/ml), and LDN (1ul/ml).  The cells were maintained in 
this media for 12 days and fed on alternate days. After differentiation protocols were complete 
cells were wither harvested for PCR studies or fixed for staining.  Methods for these procedures are 
described below. 
 
3.2.2 Generation of case and control retinal pigment epithelium (RPE) from hiPSCs 
 
Differentiation of case and control hiPSC-RPE was performed using a previously published 
method (Meyer et al., 2011).  HiPSCs were enzymatically lifted using dispase (1mg/ml) (Life 
Technologies, 17105-041).  Following washing, the cells were grown as embryoid bodies in E8 
medium for 4 days in a 100mm plate and placed on a shaker under normal incubation conditions.  
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During days 2-4 the cells were incubated with 100 ng/ml Noggin (or Dorsomorphin) and XAV939 
(Tocris) added to basal media. On day 5 media was changed to neural induction medium (NIM).  
After 6 days, the aggregates were plated onto laminin-coated 6 well plates. Media was changed 
every 2 days. On day 16 media was changed to retinal differentiation media (RDM) without 
retinoic acid with B27.  From days 20-40 Activin A (100 ng/ml) (kind donation from Marko 
Hyvonen, University of Cambridge) was added to RDM from day 20–40. Pigmented RPE 
gradually developed from day 21.  At day 50 RPE were manually picked under microscopy.  
Collected cells were enzymatically dissociated into single cells and replated at 50,000 cells per cm2 
onto laminin coated 6 well plates initially in 10% FCS+RDM before being transitioned over one 
week to RDM.  Cells were maintained in RDM for four weeks prior to use in experiments.  RDM 
media was changed thrice weekly for maintenance.  In order to optimise the protocol advice was 
obtained from Prof David Gamm, Dr Wei Shen and Dr Ruchira Singh (University of Wisconsin, 




Figure 3.2: Diagram depicting the differentiation protocol from hiPSC to hiPSC-RPE. 
Differentiation occurs in three main phases.  Firstly neural cell specification of pluripotent cells in 
EB medium minus FGF.  Neural induction in neural induction medium to promote the growth of 
primitive anterior neural cells.  Finally retinal differentiation.  Activin A is added (100ng/ml) from 
day 20 to 40 to enrich the pigmented RPE population. After approximately 50 days colonies of 
pigmented cells are manually selected for expansion. 
3.2.3 Immunohistochemistry 
 
For immunohistochemistry followed standard procedures which have been previously published 
for RPE (Singh et al., 2013a).  Media was aspirated and washed two times with PBS (Gibco). The 
cells were then incubated at room temperature with 4% PFA for half an hour.  After a further wash 
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with PBS the cells were permabialised with 3% TritonX-100 in PBS for 15 minutes.  Cells were 
then blocked in 3% normal goat serum (Dako) in PBS for one hour. Primary antibody was 
prepared to the appropriate concentration in blocking solution.  (For a full list of antibodies please 
see the appendix.) Cells were incubated a 4oC overnight with the primary antibody.  After three 
washes in PBS with 0.01% Triton-X100 the cells were incubated in Alexafluor (Invitrogen) 
secondary antibodies for 30 minutes.  The cells had a final staining with DAPI (1:500).  After a 
final three washes in PBS the cells were mounted in Fluorsave  (Merck-EMD Millipore) mounting 
medium.  
 
The same technique was used for immunohistochemistry hiPSCs with some minor modifications.  
Cells were blocked for 10 minutes in 4% PFA, 0.1% Triton x-100 was used to permabialise the 
cells and DAPI (1:2500) for 5 minutes was used to counterstain the cells. 
 
 
3.2.4 Transmission electron microscopy 
 
For electron microscopy, samples were fixed in 3% glutaraldehyde in 0.1M Sodium Cacodylate 
buffer; pH 7.3, for 2 hours then washed in three 10 minute changes of 0.1M Sodium Cacodylate.  
Specimens were then post-fixed in 1% Osmium Tetroxide in 0.1M Sodium Cacodylate for 45 
minutes, then washed in three 10 minute changes of 0.1M Sodium Cacodylate buffer.  These samples 
were then dehydrated in 50%, 70%, 90% and 100% normal grade acetone for 10 minutes each, then 
for a further two 10-minute changes in acetone. Samples were then embedded in Araldite resin.   
 
 
3.2.5 Trans-epithelial resistance 
 
The transepithelial resistance (TER) was measured using a previously established protocol (Sonoda 
et al., 2009). Measurements were made using an epithelial voltohmeter EVOM2 (World precision 
instruments, Sarasota, Florida).All measurements were performed in the cell culture hood within 3 
minutes of removal from the incubator.  The electrode heads were placed inside the well and 
outside the well in the media of a 24 well transwell (Corning).  Measurements of TER were made.  
To obtain a resistance per well the resistance of a blank laminin coated well was subtracted and the 
result multiplied by the growth area of the well (0.33CM2). 
 
 
3.2.6 Phagocytosis assay 
 
Phagocytosis assays were performed as a modification of existing assays (Mao and Finnemann, 
2013).  Bovine photoreceptor rod outer segments (OS) were commercially prepared under dim 
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light from Bovine retina (InVision Bioresources, Seattle, USA).  In order to fluorescently label the 
OS the OS were washed in a wash solution composed of 10% sucrose, 20 mM phosphate buffer pH 
7.2, 5 mM taurine. After three washes the OS were resuspended in 5ml of the same solution in a 
15ml tube. A FITC working solution was made by dissolving 10 mg FITC isomer I (Invitrogen) in 
5 mL 0.1 M sodium-carbonate buffer at pH 9.5. 1.5 ml of the working solution was added to the 
5ml OS suspension. The suspension was rotated for 1 hour in the dark.  The OS were then washed 
in the wash suspension twice and then twice in 2.5% sucrose DMEM before being resuspended in 
2.5% sucrose DMEM in the appropriate concentration.  Counts of OS were made using a 
haemocytometer. 
For the phagocytosis assays, RPE were plated in 96 well plates at 50,000 cells per cm2.  At least 
three replicates were plated for each experimental condition. 50 POS per cell were calculated 
(Singh et al., 2013b, Singh et al., 2013a). 50ul of suspension at the appropriate concentration were 
added to each well for varying lengths of time.  In order to terminate phagocytosis the wells were 
washed three times with PBS. In order to detect only internalised OS the cells were then incubated 
in 0.4% trypan blue for ten minutes to stain any external OS before a two final washes with PBS. 
The wells were then fixed in 4% PFA for 30 minutes.  3% Triton PBS was added for 30 minutes 
and then DAPI 1 in 500 was placed on the cells for ten minutes.  The wells were then coated in 
mounting medium Fluorsave (Merck-Millipore).  Cells were imaged on a Zeiss fluorescent 
microscope and the number of OS per cell analysed using imageJ. 
 
 
3.3      Results 
In chapter 2, it had been established that the cohort developed L-ORMD in a similar manner to 
previous reports of the disease.  For further studies a smaller family of patients were identified who 
had unaffected siblings. Five cases were initially identified and two controls for donating 
fibroblasts.  Sibling cases and controls were chosen to provide the closest relationship between 
case and control lines. This would mean the genetic background would have as little variation 
between cases and controls.  Therefore any differences between lines could more confidently be 
attributed to mutations in C1QTNF5. These fibroblast lines were labelled 1 to 7 (table 3.1). The 
cases had previously been identified by the regional genetics unit to carry the mutation and were 
part of the cohort described in chapter 2 who were shown to have clinical signs of stage 2 L-
ORMD.  The fibroblasts grew from all punch biopsy samples (figure 3.3) Fibroblasts were stored 
at low passage (<4) as previously senescence had been shown to impair reprogramming (Banito et 
al., 2009).  Initially, fibroblast lines 1, 2, 5 and 7 were reprogrammed.  During the course of the 
studies, reprogramming techniques were constantly evolving from retroviral integration based 
methods to non-integrated viral and finally non-integrated episomal techniques.  Therefore a 
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variety of different techniques were used to reprogram the fibroblasts to hiPSCs.  The first set of 
fibroblasts were reprogrammed using retroviral and Sendai virus (table 3.2).  Reprogramming 
generated several clones from each fibroblast line.  A minimum of two clones were stored for each 
line.  A further two fibroblasts were from lines 3 and 4 were reprogrammed separately at a later 
date using episomal methods and validated similarly. 
 
Fibroblast cell line details Patient details Case/Control 
Line 1 58 year old male Case  
Line 2 56 year old female Control  
Line 3 51 year old male Case  
Line 4 54 year old male Case  
Line 5 54 year old male Case  
Line 6 57 year old male Case 
Line 7 54 year old female Control 




Figure 3.3: Brightfield image of fibroblasts growing in fibroblast culture media from punch 





Fibroblast origin Stem cell Type 
Line 1(case) 
Clone 0.5 Sendai 
Clone 1 Sendai 
Clone 3* Sendai 
Clone 5 Sendai 
Line 2(Control) 
Clone 1 Sendai 
Clone 2* Sendai 
Clone 6* Retroviral 
Line 3(Case) 
Clone 1* Episomal 
Clone 2 Episomal 
Line 4(Case) 
Clone 1* Episomal 
Clone 2 Episomal 
Line 5(Case) Clone 3 Sendai 
Line 6(case) 
Clone 1 Retroviral 
Clone 2 Retroviral 
Line 7(Control) 
Clone 1 Sendai 
Clone 3 Sendai 
Table 3.2 : Summary table of hiPSC clones generated by reprogramming. The 
asterisks highlight the clones used in these studies. 
 
In order to validate the generation of hiPSCs from patients and controls, established validation 
criteria were investigated (Takahashi et al., 2007). Cells were first investigated for morphology. 
All cell types revealed cells with large nuclei forming densely packed colonies with retractile edges 
which is similar to that described form pluripotent cells (figure 3.4) (Takahashi et al., 2007, 
Thomson et al., 1998).  The cells expressed and immunostained for markers of pluripotency (figure 
3.5 and 3.6). To fulfil criteria of pluripotency the cells were all differentiated to the three germ 
layers using protocols optimised previously (Rashid et al., 2010). PCR using primers for neuro-
ectoderm, mesoderm and endoderm showed expression of relevant markers identified by 
immunohistochemistry (figure 3.7). This showed that the cells were pluripotent.  Cells were 
cryopreserved after approximately passage 10 to 20 as a bank for later studies once the hiPSC 







Figure 3.4: Brightfield images of hiPSC lines. The images show features commonly seen in 
pluripotent cells including densely packed colonies of cell with large nuclei.  The colonies have 
refractile edges. (scale=200 µm) 
 
Figure 3.5: Imaging from agarose gels of PCR products for pluripotency gene expression. All 




Figure 3.6: Immunofluorescent images of hiPSC colonies The images show that all cell lines 
express markers of pluripotency including Nanog (green), Sox2 (red), Tra 1-60 (purple) and Oct4 
(red).  Unlike the other markers Tra 1-60 is a surface antigen and therefore less clearly defined. 




Figure 3.7 Immunohistochemistry of three germ layer differentiation hiPSCs.  Markers 
include neuroectoderm (SOX1 and nestin); mesoderm (brachyury and Eomes); and endoderm 
(FOXA2 and GATA-4op row is from CTRL1 and the bottom  (scale  =50µm). The representative 






Prior to differentiating the cells, I also wanted to ensure chromosomal and genetic integrity. I 
initially prepared G-banded karyotyping which was performed by Addenbrooke’s hospital 
cytogenetics unit 83.7).  At this stage two cell lines were rejected from fibroblast line 5 and 7. The 
hiPSCs generated from fibroblast line 5 was noted to have a balanced translocation between the 
short arm of chromosome 12 and the long arm of chromosome 15 whilst those generated from 
fibroblast line 7 were noted to have a 48 XXX karyotype.  However, karyotyping of the fibroblasts 
also revealed the same mutations.   In order to quality control the reprogramming of the cell lines 
an initial fibroblast karyotyping step was performed prior to reprogramming. For the final 
experiments case lines 1, 2, 3 and control lines 1 and 2 had a normal karyotype.  In order to check 
that the mutation had transferred correctly, I performed sequencing analysis of the primer product 
including the mutation.  All cases were confirmed to be heterozygote for the mutation and all the 
controls were found to be homozygote for the wild type (figure 3.9). 
 
Figure 3.8: Digital photographs of G-banded karyotyping performed on case and control 





Fig 3.9: Direct sequencing of case and control lines 
The sequencing analysis shows that at base 686 in the gene (line) there is a homozygous cytosine 
in the control lines.  In the mutant lines at the same point there is a mixed guanosine and cytosine 
suggesting heterozygosity with insertion of the mutant allele  caused by a C>G substitution 
resulting in the p.Ser163Arg 
 
HiPSC differentiation to RPE was performed using a modification of a protocol learnt at the 
University of Wisconsin under Dr David Gamm (Meyer et al., 2011).  The protocol was limited 
because of the inability to increase the yield of RPE with a proliferation stage. In order to increase 
the amount of RPE generated with each differentiation I trialled different plating techniques.  An 
attempt to keep the hiPSCs in suspension throughout the differentiation successfully led to an 
increase yield of RPE with greater proliferation of cells. However, the cells formed 3 dimensional 
organoids which made it difficult to manually dissect the pigmented RPE. This resulted in a lower 
final yield of RPE. Instead the plates were placed on an orbital shaker from day 0 to day 7.   This 
enabled large amounts of hiPSCs to be differentiated in one 100mm dish resulting in larger 
amounts of RPE with each differentiation although the efficiency was likely unchanged.  The 






Figure 3.10: Brightfield images illustrating hiPSC differentiation to hiPSC-RPE. Day 0 shows a 
hiPSC colony with typical close packed cell morphology.  Day 2 shows embryoid bodies (EBs) 
which are maintained on an orbital shaker. These are clumps of differentiating hiPSCs in 
suspension and simulate the blastocyst. Day 7 shows an EB 2 days after plating onto a laminin 
coated plate which simulates implantation.  There is early evidence of neural induction with the 
sprouting of small neurites. This is because cells transition through a primitive anterior neural 
stage prior to eyefield specification. Day 30 shows early pigmentation of a colony of retinal 




In order to validate the RPE a number of phenotypic investigations were performed looking for 
gene expression and markers of mature RPE function (Singh et al., 2013a).  The pigmented 
colonies were firstly examined under light microscopy (figure 3.11).  Examination revealed a 
pigmented, polygonal monolayer of cells.  Electron microscopy showed cells with a characteristic 
apical basal polarisation (figures 3.12 and 3.13).  These included apical microvilli, mitochondria 
and melanosomes within the cells, tight junctions and basal infoldings and an RPE basement 
membrane forming.  A western blot showed protein expression for proteins found in RPE (figure 
3.14).  Immunostaining showed expression of RPE specific markers (figure 3.11).  The basic 






Figure 3.11: Images of case and control lines showing characteristics of RPE cells 
The top row show brightfield images of pigmented RPE grown in a 24 well plate showing a 
classical polygonal, pigmented monolayer. The second row of images show deeply pigmented RPE 
grown on membrane inserts.  The third row of images show fluorescence images showing 
classical RPE morphology highlighted by phalloidin. They also show membrane immunostaining 
for RPE specific marker Bestrophin. The fourth row of images show immunofluorescence images 
highlighting staining for RPE specific marker CRALBP. The fifth row of images show 







Figure 3.12 : Electron micrograph image of Ctrl1 hiPSC-RPE on a membrane insert. The image 
shows classical features attributed to a polarized RPE including apical microvilli (black arrows), 
melanosomes (white arrows), mitochondria and a basal lamina membrane. (scale= 5 µm)  
 
Figure 3.13: Electron micrograph images of case and control hiPSC-RPE. Images show that 
all the case and control hiPSC-RPE demonstrate the features of RPE cells. (scale = 5 µm) 
 
Figure 3.14: Western blot of RPE markers. The western blot of Ctrl1 (left) and Case1 (right) 
identifies similar expression of standard RPE markers Bestrophin, CRALBP  and Ezrin in both the 
case and control lines. 
 
In order to investigate whether the cells were functional and resembled previous report of in vitro 
culture of human primary cultured RPE functional studies were performed. The first functional 
study was to investigate Transepithelial resistance (TER) (figure 3.15).  This was performed using 
a technique previously described on primary human RPE culture. The results revealed no 
significant difference between case and control lines between cases and control lines when samples 
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were pooled. All cell lines produced a TER of >150 Ω/cm2.  RPE also perform phagocytosis of 
photoreceptor OS on a daily basis. The phagocytosis assay was performed and revealed an 
increased phagocytosis in the case line than the control lines (figure 3.16).  
 
 
Figure 3.15 : Graph showing transepithelial resistance measurements for case and control 
hiPSC-RPE from membranes with confluent hiPSC-RPE monolayers. The results show that the 
hiPSC-RPE attain high TER values four weeks after plating.  There was no significant difference in 
basal TER between case and control lines with line to line variation. The values shown are the 
calculations after subtracting the value of resistance obtained from a control well with the same 
media but no cells with standard error bars.  (*= mean TER of 3 inserts, **=mean TER of 6 




Figure 3.16: Phagocytosis assay. Top left image is a tiled brightfield image of RPE in a 96 well. 
The cells were stained for DAPI to aid cell counting. Top right image is an autofluorescent image 
in the 488 channel highlighting FITC-OS.  The number OS were counted using automated software 
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and the count divided by the number of cells in each image. The graph shows the number of OS 
ingested per cell (y axis) at 0.5, 1, 2 and 4 hours (x-axis).  The graph shows standard error bars 
from 3 wells at each condition. 
 
Another important property of RPE is that they do not continue to proliferate for instance in 
tumour lines or some immortalized cell lines.  Ki67 is a marker of cell proliferation. Cells which 
had been plated for only one week continued to express ki67. However, cells which had been 
plated for approximately four weeks not only developed traditional RPE structure but also stopped 




Figure 3.17: Tiled Immunofluorescence imaging of a control hiPSC-RPE to test for proliferation. 
The top set of images show cells 1 week after plating.  There is marked ki67 staining suggesting 
that there is continuing proliferation of cells.  Additionally the disorganized phalloidin staining 
suggests that the monolayer is remodeling.  
The bottom set of images shows cells 4 weeks after plating.  There is no ki67 staining suggesting 
that the monolayer is not proliferating. The phalloidin staining shows a clear RPE like polygonal 
structure associated with mature RPE. Cells used for experiments were plated for at least 4 
weeks. 
 
For the experiments used in the studies eventually hiPSCs from fibroblast lines 1, 3 and 4 were 
used as cases and two clones of fibroblast line 2, reprogrammed separately using different 








HiPSC-RPE have now been well characterised (Mekala et al., 2013, Carr et al., 2009, Singh et al., 
2013a) have been found to resemble native RPE in functional characteristics and protein 
expression profile (Blenkinsop et al., 2015). The hiPSC-RPE generated in this study fulfil the key 
phenotypic characteristics of RPE.  Morphologically they resemble RPE being pigmented and 
polygonal.  Electron microscopy also reveals that they grow apical microvilli, contain 
melanosomes and develop basal infoldings that resemble native RPE (Singh et al., 2013a, Carr et 
al., 2009). They express tight junction marker ZO-1.  In addition, they express RPE specific 
proteins including Bestrophin and CRALBP (Mekala et al., 2013).  The hiPSC-RPE in this study 
show apical basal polarity on electron micrograph (Singh et al., 2013a). 
 
Additionally, hiPSC-RPE appear functionally similar to mature RPE.  Monolayer cultures have 
been used in experiments when they have a TER of at least 200Ω/cm2 based on studies showing 
that TER of human RPE monolayers in vivo is 150Ω/cm2 (Maminishkis et al., 2006, Quinn and 
Miller, 1992). One of the primary roles of RPE is the phagocytosis of POS.  Phagocytosis had been 
studied in vitro using immunohistochemistry, western blot and FACS (Buchholz et al., 2009, Singh 
et al., 2013b, Westenskow et al., 2012). In this study, immunohistochemistry was used to confirm 
ROS phagocytosis by hiPSC-RPE. 
 
An important characteristic of terminally differentiated cells that do not show tumour potential is 
that they do no continue to proliferate and are post mitotic. HiPSC-RPE have previously been 
shown to downregulate proliferation marker KI67 after long term culture (Reichman et al., 2014, 
Kanemura et al., 2014). The cells in this study also appear to downregulate KI67 after 
approximately four weeks of plating. 
 
In summary, the hiPSC-RPE generated from case and controls show standard functional and 
expression profiles for mature RPE. This suggests that the cells are suitable for investigating early  

































4. Investigating in vitro differences between C1QTNF5 mutant and control hiPSC-
RPE 
 
4.1       Introduction and rationale 
 
HiPSC-RPE provide a platform for the in vitro study of human retinal disease. This method has 
already been used to study a number of RPE diseases including Best vitelliform maculopathy 
(Singh et al., 2015, Singh et al., 2013b), retinitis pigmentosa (Li et al., 2014), choroideraemia 
(Cereso et al., 2014) and gyrate atrophy (Meyer et al., 2011). 
C1QTNF5 is predominantly expressed by the RPE and ciliary body within the eye (Mandal et al., 
2006b).  C1QTNF5 is secreted and then is located on cell membranes in the outer retina (Mandal et 
al., 2006b).  Several lines of evidence point to dysfunction in the RPE occurring early in the 
disease process including histological samples showing RPE disorganisation (Duvall et al., 1986).  
Transfected cell studies showed that mutant C1QTNF5 formed high order aggregates which 
accumulated within the ER (Shu et al., 2006b). Therefore the RPE is thought to be a key mediator 
of disease. We have shown that hiPSC-RPE generated from patients and sibling controls show 
mature phenotypes and properties of mature physiological function in chapter 3.  Taken together 
the above suggests investigating L-ORMD using hiPSC-RPE generated from cases and controls. 
The initial aim of this series of studies was to characterise an in vitro phenotype comparing hiPSC-
RPE generated from cases with hiPSC-RPE generated from an unaffected control. The hypothesis 
was that cells harbouring the C1QTNF5 mutation would demonstrate cell autonomous differences 
in standard tests of RPE function. 
4.2       Methods  
 
All the experiments in this section were performed by Dr Shyamanga Borooah at the 
University of Edinburgh.  
 
4.2.1 Cell viability 
 
To assess cell viability a lactate dehydrogenase cytotoxicity kit was used as an adaptation of an 
existing protocol (Yang et al., 2014b). HiPSC-RPE were plated at a density of 50,000 cells per cm2 
on laminin coated 96 well microtitre plates.  Cells were initially fed for two days with 10% FCS in 
RDM, followed by 7 days in 2% FCS in RDM before reverting to plain RDM for a minimum of 
three weeks prior to experiments.   
 
A LDH cytotoxicity assay kit (Thermo Scientific) was used according to kit instructions.  
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For each condition, cells were plated in triplicate.   In further experiments cells were incubated 
with 100ul RDM.  For a set of triplicates 10ul lysis buffer was added to the media to act as a 
positive control 45 minutes prior to harvesting the supernatant and 10ul of sterile water was added 
to other wells.  50 ul of the supernatant was transferred to a fresh flat-bottomed microtitre plate. 
50ul reaction mixture was added to each well.  These were mixed for 3 seconds in a plate reader 
and the incubated in the plate reader for 30 minutes at 25oC. 50ul stop solution was added and the 
plate measured at absorbance 490nm and 680nm.  The 680nm absorbance value was subtracted 
from the 490nm value to minus the background.  To calculate the LDH activity LDH activity from 
the plain media was subtracted from cell supernatant absorbance. Data from the plate readers was 
transferred to Excel 2013 (Microsoft corporation, Redmond, USA). 
 
 
4.2.2 OS processing 
 
To investigate the build-up of autofluorescent material in hiPSC-RPE following long term feeding 
with ROS a previously published protocol by Singh et al was used (Singh et al., 2013b). HiPSC-
RPE were plated at a density of 50,000 cells/cm2 onto laminin coated µ-slide 8 chamber glass 
bottom slide wells.  After two days media was changed to 2%FCS in RDM. After one week media 
was changed to RDM.  Cells were fed every two days with 50 ROS per RPE cell in RDM for a 
total of two months.  After two months, the cells were reverted back to RDM only feeding for one 
week.   The cells were fixed in 4% PFA for 30 minutes and then mounted in fluorsave (Merck-
Millipore). The plates were imaged at 555nm and 488nm wavelengths in order to image lipofuscin 
(Sparrow and Boulton, 2005).  ImageJ was used to analyse the area of fluorescent material per cell. 
 
 
 4.3 Results 
 
4.3.1 Expression of C1QTNF5 protein 
 
Studies using transfected cell lines showed that C1QTNF5 was secreted (Shu et al., 
2006b). The mutant protein was not secreted and accumulated within the ER (Shu et al., 
2006b). The histopathology investigations performed in chapter 2 suggested that 
C1QTNF5 was secreted and deposited particularly in the inner deposit adjacent to the RPE 
cells in the case donor retina. To see if there was a difference in secretion of C1QTNF5 
between case and control, conditioned media was obtained.  Conditioned media was 
generated by maintaining RPE in the same media for 5 days.  The media was tested using 
western blot and showed clear differences in the pattern of staining between the case and 
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control lines (figure 4.1). The conditioned media showed a far greater amount of staining 
for C1QTNF5.  In addition, in the non-reduced sample the C1QTNF5 formed more high 
order multimers.  It appears that the normal arrangement of multimeric bouquets suggested 
by protein studies is inhibited by the mutant protein (Tu and Palczewski, 2014).  The 
western blot also shows that the multimers are not exact multiples in molecular weight of 
the predicted monomeric predicted weight of 26 kDa. Next, I wanted to see if the 
multimers could be reduced to a monomeric species.  The C1QTNF5 generated from the 
control hiPSC-RPE could be reduced to monomers. However, in the protein secreted by 
the control  hiPSC-RPE heterogeneous multimers are still present.  Next I wanted to see if 
there was a difference in localisation of C1QTNF5 within the cell.  A western blot of cell 
lysate showed a difference in C1QTNF5 localisation within the cell.  (figure 4.2).  Again 
the wild type protein alone seemed able to easily form multimers in the non-reduced state 
whilst the addition of the mutant appeared to reduce formation of multimers, leaving 
mainly a monomeric form under non-reducing conditions.  
 
 
Figure 4.1: Western blots of conditioned media from case and control hiPSC-RPE lines 
under non-reduced and reduced conditions. Under non-reducing conditions (left) the media 
from the control line appeared to produce marked multimers.  The media from the two case lines 
formed fewer multimers and instead resulted in monomers and dimers.  Under reduced conditions 
(right) the media from the control line was still not reduced completely to a monomeric form whilst 





Figure 4.2: Western blot with antibody to C1QTNF5. The image shows the results of a western 
blot for non-reduced recombinant wild type full length C1QTNF5 (Lane 1), reduced recombinant 
wild type C1QTNF5 (lane 2), Non-reduced cell lysate from Ctrl1 (lane 3), reduced cell lysate from 
Ctrl1 (lane 4), non-reduced cell lysate from Case1 (lane 6) reduced cell lysate from Case1 (lane 7) 
and a negative control of HEK cell lysate (lane 8). The cell lysates were controlled for GAPDH.  
There is evidence that when wild type C1QTNF5 is in a non-reduced state it forms multimers (lane 
1). This is still maintained even after strong reduction with dimers and trimers visible (lane 2).  
Non-reduced cell lysate from Ctrl1 surprisingly shows little staining except some faint staining as a 
multimers.  This could suggest that multimers occur (lane 3). However, when reduced a strong 
monomeric band at approximately 26 kDA is seen (lane 4). Meanwhile both the non-reduced and 
reduced lysates of the case provide a strong band at the predicted monomer (lane 6 and 7) 
suggesting that polymerization of C1QTNF5 is reduced in the case. Finally, the negative control 
fails to show a specific band (lane 8 ) 
  
In order to investigate differences between the case and control lines further an 
immunostaining experiment for C1QTNF5 was performed on case and control lines (figure 
4.3).  The immunohistochemistry study showed that in the control cell line C1QTNF5 was 
localised both apically and basally in the membrane with little intracellular staining.  Both 
the case and control lines showed some staining apically and intracellularly although the 
case lines appeared to have more intracellular staining. In addition, the case lines had 
marked immunostaining basally in the sub-RPE in the membrane.  This is somewhat 




Figure 4.3 : Immunocytochemistry for C1QTNF5. The figure shows cross sections of 
membrane and stained with DAPI and immunostained with anti-C1QTNF5 antibody. There is 
intra-cellular immunostaining of both case and control lines. There is also some staining of the 
membrane inset below the cells in the control and more marked staining of the membrane in the 
case line. (scale= 50 µm) 
 
 
4.3.2 Comparison of TEM basal deposit in mutant and control lines 
 
One of the key phenotypic characteristics in L-ORMD is a thick sub-RPE deposit.  I next 
sought to replicate conditions seen in the outer retina by growing the cells on membrane 
inserts. Previously, Amin et al had shown that sub-RPE deposits could be modified (Amin 
et al., 2004).  Cells were grown for two months on membrane inserts in RDM and then fixed 
using glutaraldehyde and prepared for electron microscopy.  The size of the sub-RPE deposit 
between the RPE and the membrane was measured.  Three membrane inserts were measured 
for a case line and a control line (figure 4.4). No significant difference between the deposit 
thickness measured in three different places was found between the case and control line 





Figure 4.4 : Transmission electron microscopy images of sub-RPE deposit. Representative 
images of sub-RPE deposit in control line 2 (left) and case line 1(right).  There was no significant 
difference in deposit thickness between cases and controls. 
 
 
4.3.3 Comparison of TER in mutant and control lines 
 
TER has been routinely used to test the function of the RPE monolayer in in vitro 
experiments (Maminishkis et al., 2006, Singh et al., 2013a).  Recently, it was found that 
TER could provide phenotypic differences between different cell types in studies 
performed by one of our collaborators.  The initial experiments looked to see if there was a 
difference in TER between the case and control hiPSC-RPE in RDM.  There was a 
variability in TER in all lines.  There was no significant difference between case and 
control lines when the results were pooled.  
 
A further set of studies was performed to test the cells before and after the addition of 40% 
serum to more closely simulate findings in the outer retina.  Georgianikkis et al. found that 
an increase in TER after serum and with increased C5b-9 staining. No significant 
differences were found in the TER pre and post serum in the case or control hiPSC-RPE 
cell lines (figure 3.14).  
 
4.3.4 Comparison of ROS phagocytosis in mutant and control lines 
 
A previous unpublished study (Dr Fern Slingsby, University of Edinburgh) using 
transfected ARPE-19 cells transfected to overexpress either wild type protein or mutant 
protein showed a phagocytosis deficit with the mutant transfected cell lines compared with 
the wild–type cell lines. This pointed towards a role for C1QTNF5 in phagocytosis.  The 
strong apical staining in the control hiPSC-RPE lines suggested that C1QTNF5 was 
located in the correct part of the RPE to potentially modify phagocytic interactions. 
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Consequently, we compared mutant and wild type RPE lines initially with one case and 
control line to see if these findings were replicate in hiPSC-RPE with more physiological 
levels of RPE protein expression.  The studies used a case and control hiPSC-RPE line 
differentiated at the same time and plated under the same conditions into a 96 well plate.   
The tests were performed at the same time under the same conditions with 3 repeats and 
the wells fixed at set time points. Hoescht stain was added to label nuclei.  The FITC-ROS 
were then imaged using fluorescent microscopy counted using imageJ and normalised for 
cell numbers labelled with Hoescht stain.  The assay found a significantly increased 
number of phagocytosed FITC-ROS (p<0.05) at the half an hour, one hour, two hours and 
four hours after the addition of FITC-ROS respectively (figure 3.15).  
 
 
4.3.5 Comparison of OS processing in case and control lines 
 
Having found differences in the phagocytosis rate between case and control lines.  I 
wanted to see if this also led to downstream differences in OS processing. Singh et al. had 
shown that in the hiPSC-RPE derived from patients with mutations coding for Best 
vitelliform dystrophy there was an increased build up of lipofuscin in the case lines when 
compared with control lines (Singh et al., 2013b).  Similarly, both case and control L-
ORMD lines were fed OS for two months and then investigated for autofluorescence using 
confocal microscopy at 488nm and 555nm wavelengths (figure 4.5).  Nine confluent wells 
of each cell line were tested.  A 500 um by 500 um image was chosen of each well under 
brightfield conditions.  Autofluorescence z-stack images were then taken at 488 and 
555nm wavelengths and a DAPI image taken to count cell numbers.  The area of 
lipofuscin was then measured on maximal intensity images of combined z-stacks. Both 
case and control lines had increased autofluorescence compared with a control line that 
was maintained for the same length of time but not fed with OS. When statistical analysis 
was performed although the mean fluorescence of the case lines was greater than the 
control hiPSC-RPE there was no significant difference (p=0.59) between the amount of 




Figure 4.5 : Confocal images looking for autofluorescence in hiPSC-RPE lines.  Representative 
images showing a buildup of intra-cellular autofluorescent material measured at 488 and 555nm 
wavelength after 2 months feeding with OS laden media.  Although there appeared increased 
autofluorescence in the case line when statistical analysis was performed there was no significant 
difference between the lines when analyzed by automated pixel density measurements.  This 
suggested that there was no significant difference in lipofuscin formation between the case and 





In this set of studies C1QTNF5 protein was found to be expressed in greater quantity in the control 
lines when compared with the case lines.  Secretion of C1QTNF5 was also found to be greater in 
the control lines when compared to the case lines.  Examination of sub-RPE deposit using TEM 
showed that the deposit was significantly greater in case lines compared with control lines.  
However, there was no difference in TER in case lines when compared with control lines.  There 
was also a significantly increased generation of lipofuscin in case lines when compared with 
control lines following long term feeding with ROS. 
 
Hayward et al. (2003) demonstrated that C1QTNF5 is expressed by RPE and is predicted to be 
secreted (Hayward et al., 2003). In order to investigate C1QTNF5 secretion HEK293-EBNA cells 
were stably transfected with wild-type or mutant His-tagged C1QTNF5  (Shu et al., 2006b). His 
tagged protein was found in the cell lysates of both cells transfected with mutant and wild type 
plasmids however, protein was only found to be secreted in control cell lines.  Mandal et al, 
similarly transfected COS-7 cells with V5-tagged wild type and mutant C1QTNF5 with similar 
outcomes. Immunostaining found co-localisation of the mutant protein with ER markers (Mandal 
et al., 2006b). Polyacrylamide gel electrophoresis (PAGE) showed that only the wild type protein 
migrated whilst the mutant did not under non-reducing conditions however the proteins formed 
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monomers under reducing conditions.  Taken to together this suggested that mutant C1QTNF5 
formed high order aggregates that were retained within the cell and not secreted. The findings are 
similar to those in this study. The findings were slightly different from this study which showed 
that C1QTNF5 was found in the media of control and case lines.  However, the media from the 
control lines, containing wild-type C1QTNF5 readily formed high order multimers. Whilst the 
media from the mutant lines showed that C1QTNF5 formed mainly monomers and dimers.   
 
L-ORMD retina are known to have a thick sub-RPE deposit (Duvall et al., 1986, Kuntz et al., 
1996, Malek et al., 2003).  We found that both case and control RPE produced a sub-RPE deposit.  
The case lines appeared to produce a deposit of greater thickness.  Staining of L-ORMD deposits 
have shown that the sub-RPE deposit is a bilayer. The inner layer is composed of components 
similar to those found in other degenerative diseases. We also found that the inner layer stained 
well for C1QTNF5 on immunohistochemistry. 
   
The formation of deposits in vitro has been reported in another inherited macular degeneration.  
Murine RPE harbouring a mutation in the gene EFEMP1 responsible for the retinal degeneration 
Malattia Leventinese grown on transwells also resulted in sub-RPE deposits (Fernandez-Godino et 
al., 2015). The deposits were found to contain the extracellular membrane components collagen I, 
elastin, TIMP-3, fibrillin-1 and fibronectin in abnormal amounts.  In addition, the deposits from the 
case lines contained increased amounts of EFEMP1.  To see if substances secreted by the mutant 
RPE cells were responsible for deposit formation wild type cells were incubated in conditioned 
media from mutant cells. The wild type cells also proceeded to develop a deposit. Analysis of the 
condition media revealed C3a as a potential stimulator of deposit formation. This was confirmed 
by a dose dependent reduction of deposit formation when the cells were incubated in media 
containing C3a-neutralising antibodies. The studies suggested that in a model Malattia Leventinese 
complement activation is required for deposit formation. Antibodies neutralising C5 however did 
not appear to reduce deposits.  We also showed that the use of C3 depleted serum abolished c5b-9 
staining.  However, in contrast to Fernandez-Godino et al.  we noted that the use of C5 depleted 
sera also abolished TCC deposition whilst C5 neutralising antibody reduced TCC deposition in a 
dose-dependent manner (see section 2.3.6). We suspect that the EFEMP1 model may not be 
mediated by dysfunction of later regulators of the complement pathway as in our model.  Levels of 
C3d a marker of C3b degradation by CFH were found to be the same between case and control 
lines.  Additionally although TCC deposition was detected, there was no significant difference 




In phagocytosis experiments case hiPSC-RPE were found to have a higher rate of phagocytosis 
when compared with control hiPSC-RPE.  In addition, we noted increased autofluorescence in case 
hiPSC-RPE when compared to control hiPSC-RPE following long term feeding with ROS 
although this was not significantly different. The increased phagocytosis rate in case lines is 
difficult to explain.  In unpublished data Dr Xinhua Shu and Dr Fern Slingsby performed ROS 
phagocytosis experiments using transfected HRPE-1 cells.  Cells transfected with mutant 
C1QTNF5 were found to have a reduced rate of phagocytosis when compared with cells 
transfected with wild type C1QTNF5.  Singh et al, investigated phagocytosis in both short term 
and long term culture of hiPSC-RPE from patients with a mutation in BEST1 (Singh et al., 2013b).  
After long term feeding with ROS the RPE were found to have increased autofluorescence.  In this 
series of studies, however long term feeding with OS did result in increased autofluorescence 
although there was no significant difference in the amount of autofluorescent material generated 
between the case and control line.  This may reflect different disease pathogenesis.  Lipofuscin 
builds early within and below the cell in Best vitelliform dystrophy disease whereas in L-ORMD 
FAF is noted to increase late in the disease and is especially noted to occur in areas adjacent to 
existing neuro-retinal atrophy.  Interestingly, Singh et al. also noted an increased phagocytosis rate 
for FITC-labelled POS at the 4 hour time point in case hiPSC-RPE when compared to control 
hiPSC-RPE.  However, the differences were lost at 24 hours (Singh et al., 2013b). In our 



























5. Investigating interactions between control and mutant C1QTNF5 hiPSC-RPE and 
the complement pathway 
 
5.1 Introduction and rationale 
 
Oxidative stress has been implicated in AMD disease mechanism (Hollyfield et al., 2008).  
Different stressors have previously been used to investigate oxidative stress in RPE cell lines 
(Rabin et al., 2013, Garcia et al., 2015, Cano et al., 2014, Joseph et al., 2013, Klettner, 2012, Lu et 
al., 2006).  Incubating cells in hydrogen peroxide provides a simple method of assessing the effects 
of oxidative stress in vitro (Hsiung et al., 2015). We hypothesise that the addition of hydrogen 
peroxide to media will expose an increased vulnerability of hiPSC-RPE cell lines to cell death. 
 
Complement pathway dysfunction has been implicated in AMD.  Amongst the earliest 
histopathological signs of AMD are sub-RPE deposits (Curcio et al., 2013). These deposits have 
been shown to contain components of the complement pathway and in addition, many activated 
components of the pathway suggesting that inflammation plays a part in early macular 
degeneration (Anderson et al., 2002, Crabb et al., 2002, Mullins et al., 2001).  Allelic variants in 
complement pathway components have been found to increase the risk of AMD (Hageman et al., 
2005, Seddon et al., 2011). Taken together this implicates complement pathway dysfunction in 
early macular degeneration. 
 
We have already shown that localised complement pathway deposition may also be involved in L-
ORMD pathogenesis using both a mouse model of L-ORMD and donor retina from L-ORMD 
patients.  Recently, several groups had reported systems to study complement activation on 
different types of RPE cells in vitro using complement containing media (Johnson et al., 2011, 
Lueck et al., 2015, Georgiannakis et al., 2015). RPE cells were grown on permeable membrane 
supports recapitulating RPE Bruch’s membrane interactions.  L-ORMD hiPSC-RPE display 
phenotypic and physiologic characteristics resembling mature RPE.  Combining the use of L-
ORMD hiPSC-RPE in a system that mimics the outer retinal microenvironment would allow the 
interrogation of early in vitro disease phenotypes in L-ORMD. Although RPE have already been 
shown to generate the majority of components of the complement pathway human serum 
containing active complement components was added to enable formation of the terminal 
complement complex (TCC). The hypothesis is that mutant C1QTNF5 hiPSC-RPE would show 






5.2 Methods  
 
All the studies presented within this chapter were performed by Dr Shyamanga Borooah except 
FACS studies which were performed by Dr Anai Gonzalez-Cordeiro (University College, 
London).  Advice for live cell microscopy was sought from Dr Dario Magnani (University of 
Edinburgh). Advice of setting up the complement serum studies on membrane inserts was sought 
from Professor Stephen Moss and his PhD student Apostolos Georgianikkis (University College 
London).   
 
5.2.1 Oxidative stress studies 
 
After initial cell viability studies showed no significant difference in cell death between case and 
control lines we investigated whether factors implicate in AMD pathology may differentially 
increase the vulnerability of hiPSC-RPE carrying mutations when compared to controls. Oxidative 
stress has been previously shown to induce differences between cell lines in a model of AMD 
(Radu et al., 2014).  For oxidative stress experiments, protocols previously used on RPE were 
optimised for hiPSC-RPE having previously been optimised for other cell lines (Rzechorzek et al., 
2016, Yang et al., 2014b). HiPSC-RPE cells were plated onto laminin coated 96 well plates at a 
density of 50,000 cells per cm2 .  Cells were initially fed with 10% FCS RDM for two days, and 
then 2% FCS in RDM for one week before reverting to RDM for a further two weeks.  One week 
prior to studies the hiPSC-RPE were fed with standard RDM with B27 supplement minus 
antioxidants (Gibco). At the start of the experiment,  media was switched to RDM minus 
antioxidants containing different concentrations of hydrogen peroxide  (Sigma) and 1 :5000 
SYTOX® green membrane dead cell stain  (molecular probes, life technologies) as per kit 
instructions. Triplicates were prepared for each condition. Cells were placed in a live cell imaging 
platform and maintained for 12 hours under standard incubation conditions.  They were imaged at 
set timepoints using an automated setup on a Zeiss fluorescent microscope.  ImageJ was used to 
analyse the tiled image from each well.  Three non-overlapping fields from each well were used for 
analyses. The average of three wells were used to produce a mean and standard error for each 
condition. For ROS identification 500um hydrogen peroxide was added to cells for 6 hours in order 
to gain maximal chance of ROS production.  The cellROX® ROS identification kit was used as per 
instructions in order to identify ROS generated intracellularly.  The cells were imaged at 488 






5.2.2 Human complement serum studies 
Human complement serum assays were performed on transwell plates and generated as per 
previously published protocols (Singh et al., 2013a). The investigation of complement activation of 
RPE cells on membranes was performed using modifications of previously published protocols 
(Johnson et al., 2011). RPE cells from confluent monolayers were dissociated into single cells 
using 0.5% trypsin/EDTA. 24 well transwell membranes were coated with 1% laminin in DMEM 5 
hours prior to plating and then incubated under standard conditions.  Half an hour prior to plating 
the membranes were incubated with 10% FBS in RDM.  HiPSC-RPE were then plated at a density 
of 50,000 cells per cm2.  The cells were maintained in 10% FBS RDM for two days before being 
switched to 2% FBS RDM for 7 days. After this, the cells were maintained for a minimum of three 
weeks in serum free RDM prior to any experiments.  
For initial complement serum studies human complement serum (HCS)  (Complement 
technologies incorporated, Tyler, USA) was incubated at various concentrations of HCS in RDM 
for 12 hours.  For timecourse studies hiPSC-RPE were incubated under standard conditions in 40% 
HCS in RDM over varying lengths of time.  For HCS quantification and depletion studies hiPSC-
RPE cells were incubated for 12 hours in 40% HCS in RDM or 40% depleted serum in RDM. For 
treatment studies case hiPSC-RPE were incubated in 40% HCS in RDM with varying 
concentrations of anti-complement C5. 
 
For all studies, the experiments were terminated by washing membranes three times in PBS and 
then fixing the membranes for 30 minutes in 4% PFA in PBS.  The membranes were then 
incubated in 3% Triton X100 in PBS for 30 minutes prior to blocking in 2% NGS and 1% BSA in 
PBS for one hour.  Membranes were then removed and placed in 50ul of primary antibody was 
added in blocking solution for overnight incubation at 4oC. The antibody primarily used for the 
assays was anti-C5b-9 1:100 (DAKO, Ely, United Kingdom) however a full list of antibodies used 
can be found in the appendix.  The following day after three washes in PBS an Alexafluor 
secondary antibody (Invitrogen) was added for 30 minutes.  After a further three washes in PBS 
DAPI 1:500 and Rhodamine phalloidin (Invitrogen) 1:2500 we were added for 10 minutes. After a 
final wash in PBS the membranes were dried and mounted on slides cell side up and mounted with 
coverslips using fluorsave (Merck-Millipore).  The membranes were imaged using Zeiss confocal 
microscopy.  A minimum of three fields of 100uM x 100uM  were selected from each membrane 
and three repeats of each condition were imaged for analyses.  The mean intensity density of the 
fields was calculated in the channel of the C5b-9 staining using imageJ. Advice from Professor 
Stephen Moss and Dr Apostolos Georgiannakis  (University College London) was obtained to 






5.3   Results 
5.3.1 Comparing cell viability following oxidative stress insult in case and control 
lines 
In the human donor pathology samples there was RPE disorganisation and loss in the L-ORMD 
cases.  I hypothesised that L-ORMD hiPSC-RPE would also show a differential vulnerability in 
vitro when compared to control hiPSC-RPE.   To test this hypothesis a live dead cell assay was 
used initially under basal conditions (Prajapati et al., 2015, Berner et al., 2014, Yang et al., 
2014c)(Figure 5.1). Neither case lines nor control lines showed marked signs of cell death and 
there was no significant difference in cell death between the lines at baseline (figure 5.2). 
 
 
Figure 5.1:  Oxidative stress studies. The left image is merged image of brightfield and channel 
488nm wavelength from a 96 well plate.  The middle image shows the SYTOX green 
immunofluorescence staining in a case line after 3 hours of 500 µm hydrogen peroxide. The image 
on the right shows SYTOX green immunofluorescence staining in a control line after 3 hours of 






Figure 5.2: Live cell viability studies.  Ctrl2 and Case1 were studied under basal condition to see 





In order to investigate what potential stressors the cells may be vulnerable to I chose to perform a 
targeted RNA screen of cellular stress and toxicity comparing case and control lines.  The screen 
showed that there were several genes with variable expression of greater than two fold between 
cases and control lines after normalisation to GAPDH expression (figure 5.3). From the genes 
identified the highest differences in expression were found in genes involved with oxidative stress 
catalase (14.1 fold higher in the case).  Catalase is an enzyme found in the peroxisome of human 
cells and is a key regulator of oxidative stress. It converts hydrogen peroxide to water and oxygen. 
It has been found to be upregulated in a number of cell lines to protect against hydrogen peroxide 




Figure 5.3 : Cellular stress array.  Quantitative real-time PCR array with three repeats performed 
for each gene using cDNA from Case1 and Ctrl1 hiPSC-RPE. The graph shows how many genes 
showed a greater than two fold difference between case and control lines. The table on the left 
shows genes expressed greater in the case compared with the control. The table on the right shows 
genes that were expressed at less than two fold less than the control line.  The most marked fold 
change is noted in catalase expression in the case. In addition, there is also an increase in haem 
oxygenase expression 
 
To investigate a potential role for oxidative stress and hydrogen peroxide in particular on cell 
viability, I developed a live-cell imaging platform for testing the effect of different concentrations 
of hydrogen peroxide on my the hiPSC-RPE cells.  Using methods previously described in studies 
using ARPE-19 cells in oxidative stress cells were plated into a 96 well plate (Yang et al., 2014c).   
The cells were imaged at 15 minutes after baseline and at 3 hours (figures 5.4 and 5.5).  There was 
no significant difference between case and control lines with basal media at 15 minutes (p=0.51).  
However, there was a significant increase in SYTOX® staining with hydrogen peroxide at each 
concentration and at each time point in the case line when compared to the control lines (p<0.05) 
(figure ).  The SYTOX® staining appeared to increase in a dose dependent manner with hydrogen 
peroxide concentration. This suggested that the case hiPSC-RPE had an increased vulnerability to 





Figure 5.4: SYTOX  green staining at 15 minutes in case and control hiPSC-RPE.  The results 
show the number of cells with positive staining corrected for baseline.  Each condition had three 
repeats with standard error bars shown.  The case lines show a dose dependent increase in 
vulnerability when compared to control cell lines.  The control cell lines do not show any increase 
in cell viability at this timepoint. 
 
Figure 5.5 : SYTOX  green staining at 3 hours in case and control hiPSC-RPE.  The results 
show the number of cells with positive staining corrected for baseline.  Each condition had three 
repeats with standard error bars shown.  The case lines show a dose dependent increase in 
vulnerability when compared to control cell lines.  The only control cell line to show an increased 





To understand the mechanism of cell death a further set of studies were performed.  Firstly, to see 
if cell death resulted from an apoptotic pathway activation a caspase-3 staining was performed 
(figure 5.6).  This showed that caspase-3 staining was not increased in the case line when 
compared with the control lines after 3 hours of oxidative stress. This suggested that there was 
little change in intracellular redox state.  Hydrogen peroxide has previously been shown to induce 
necrosis in cells in higher concentrations (Saito et al., 2006).  This is thought to be an effect 
extracellularly at the cell membrane. To see whether hydrogen peroxide induced any ROS 
formation intracellularly cells were imaged using the IMAGE-IT™ assay (Thermofisher scientific) 
which stains for 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-
H2DCFDA).  Little intracellular staining was noted (figure 5.7). This together with the membrane 
permeability stain SYTOX® suggest that necrosis with disruption of the cell membrane may be the 
key mechanistic difference between the lines. 
 
Figure 5 6: Apoptosis immunostaining.  The images show fluorescent images at 647 for 
immunostaining for caspase-3 using a kit (BD bioscience).  The top row shows images for a 
positive control treated with 1 x 10-6 M staurosporine for four hours showing small amounts of 
positive immunostaining.  Neither the case nor the control hiPSC-RPE show any staining for 
caspase-3. (scale =200 µm) 
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Free radical and positive control
 
Figure 5 7: Intracellular ROS generation assay.  This study was performed to investigate 
intracellular oxidative stress after hydrogen peroxide administration.  The study was performed 
using the which stains for 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-
H2DCFDA).  A positive control was prepared with tert-butyl hydroperoxide (TBHP). The positive 
control shows intracellular staining. The hiPSC-RPE case line shows no intracellular staining 
despite 6 hours of 500 µm hydrogen peroxide. (scale = 100 µm) 
 
5.3.2 Investigating terminal complement complex (TCC) deposition 
During the histopathology studies increased complement pathway activation was noted in the case 
lines.  This appeared to be far greater than in controls of similar age. I wanted to see if this could 
be replicated in vitro using hiPSC-RPE.  The hypothesis was that case hiPSC-RPE would also 
activate complement at a greater level than control hiPSC-RPE.  In order to test this hypothesis I 
optimised a cell model using inserts.  Following discussion with Professor Stephen Moss’ team 
(University College London) a membrane insert system was established with human complement 
serum in the basal compartment and normal RDM in the apical compartment (figure 5.8). A system 
was used which was similar to one published using foetal RPE cells which found some C5b-9 
activation (Johnson et al., 2011). Since TCC deposition had been seen in the histopathology studies 






Figure 5.8. : Schematic of a membrane insert.  The diagram shows a microporous polyester 
hanging insert used for the complement activation assay. RDM is placed in the upper compartment 
and the serum-RDM placed in the lower compartment. The hiPSC-RPE are grown on the 





Cells were plated on the membranes and maintained in 40% serum in the basal compartment to see 
if this would induce TCC deposition (figure 5.9). To see whether any of the apparent 
immunostaining was due to non-specific adherence of the antibody to elements in the system a set 
of case cells was treated with serum that had been heated thereby inactivating the complement 
proteins. The heat inactivation abolished TCC deposition (figure 5.9).  There was a significantly 
greater deposition of TCC in the case hiPSC-RPE when compared to the control hiPSC-RPE lines 
(<0.01 comparing any case line to either control line)(figure 5.9).  To see what was being stained I 
performed confocal Z-stack image capture.  The Z-stacks were started at the bottom of the 
membrane insert and ended at the top of the cells.  The predominant immunostaining in the case 
lines occurred below and in between hiPSC-RPE.  In addition, there was a smaller but definite 
immunostaining of the deep membrane below the case hiPSC-RPE in all cell lines (figure 5.9). 






Figure 5.9: Confocal microscopy of complement activation assay. The upper left image shows 
little C5b-9 deposition in in a representative image from the Case1 hiPSC-RPE incubated in 40% 
serum–RDM for 12 hours.  The middle image on the top row shows marked C5b-9 deposition 
across cells.  The right image on the top row shows marked reduction in C5b-9 deposition with the 
use of heat inactivated 40% serum-RDM on Case1 hiPSC-RPE. The lower image shows a cross 
section generated from Z-stacks of a membrane insert. There is clear immunostaining of C5b-9 





Figure 5.10: Comparison of C5b-9 staining in cases and controls.  Using the model a minimum 
of three repeat experiments were performed on three membrane inserts.  A minimum of three 
images were taken from each well. Standard error bars are shown.  The images were analysed in 
each channel for mean pixel intensity density per cell.  There was a significant difference between 
case and control lines (P<0.01) 
 
After verifying that there was differential deposition of C5b-9 in the case lines when compared to 
the control lines, I performed timepoint and concentration experiments to optimise the model. 
Various concentrations of serum were used in the basal compartment.  Maximal TCC deposition 
was found with 40% serum diluted in RDM (figure 5.11). In timepoint experiments it was found 
that TCC deposition was greatest at 12 hours before slowly decreasing at higher concentrations in 







Figure 5.11 : Timepoint analysis of the c5b-9 deposition assay. Using the model a minimum of 
three repeats were performed and three images taken from each with standard error bars shown.  
The figure shows that the 12 hour timepoint appears to result in the greatest deposition of c5b-9. 
 
Figure 5.12 : Serum concentration analysis for C5b-9: Using the model a minimum of three 
repeat experiments were performed.  A minimum of three images were taken from each well. 
Standard error bars are shown.  The results show a gradual increase in C5b-9 deposition to 40% 
serum-RDM at the 12 hour timepoint. 
 
Next I wanted to see if the 40% serum concentration was affecting viability.  Previously (section 
5.3.2) I had optimised a live dead cell permeability assay.  I decided to stain the case and control 
lines similarly.  There was a marked increased in green uptake in the case lines when compared 
with the control lines when the cell lines were placed in 40% serum-RDM for 12 hours (figure 
5.13).  This was abolished when heat inactivated serum was used suggesting that this could be a 
complement mediated process. A caspase-3 staining again revealed no staining suggestive of 
apoptosis. The C5b-9 appeared to form clusters.  However, it was not clear whether there was co-
staining with the SYTOX® green. To gain a better understanding of what the C5b-9 was binding to 
in the assay I planned a FACS experiment with Dr Anai Gonzalez-Cordeiro (University College 
London). She performed the FACS studies using a set of cells which had been grown in RDM 
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alone and a further set which had been placed in 40% RDM-serum for 12 hours as per the model.  
The cells were stained with annexin V, a marker for apoptosis and DRAQ7, a nuclear marker of 
cell death.  In the untreated lines, there was a small but significant difference between Cb5b-9 
staining in the cases and the control (figure 5.14). After treatment, there was a significant increase 
in C5b-9 immunostained cells in the case lines when compared to control lines  The control line 
was noted to have a small increase in the percentage of C5b-9 immunostained cells after treatment 
with serum. When gating for necrosis the number of cells with necrotic characteristics i.e. negative 
for apoptosis but positive for cell death was significantly increased in the case lines when 
compared to control lines (figure 5.15). Taken together the studies showed that the case lines 
which immunostained for C5b-9 had an increased susceptibility to cell death by necrosis after the 
addition of serum.  This suggested that necrosis was predominant in the case lines compared to the 
control lines.  
 
Figure 5.13: Cell viability in the model.  The model was combined with cell viability/membrane 
permeability dye SYTOX green.  In addition, C5b-9 deposition was immunostained (white).  The 
cells were stained with DAPI (blue) and phalloidin (red). The control line showed no signs of loss 
of viability and membrane integrity and also no C5b-9 deposition.  The case line under the same 
conditions showed marked loss of membrane integrity and also marked clusters of C5b-9 
deposition. To test whether this resulted from serum and complement components heat inactivated 




Figure 5.14 : Fluorescence activated cell sorting (FACS) analysis of C5b-9 (MAC)  coated 
cells. HiPSCs are immunostained with anti-C5b-9 antibody and annexin V and stained with cell 
viability marker DRAQ7.  The cells are then gated appropriately through FACS and counted.  
Gating for DRAQ7 +ve and annexin V –ve cell suggest necrotic cells.  There is a greater 
percentage of C5b-9 coated cells in the case lines when serum is added than when the cells are 
maintained in RDM. This suggest that necrosis increases when serum is added and that C5b-9 






Figure 5.15 : Results of the FACS analysis of C5b-9 (MAC)  coated cells. HiPSCs are 
immunostained with anti-C5b-9 antibody and annexin V and stained with cell viability marker 
DRAQ7.  The cells are then gated appropriately through FACS and counted.  Gating for DRAQ7 
+ve and annexin V –ve cell suggest necrotic cells.  There is a greater percentage of C5b-9 coated 
cells in the case lines when serum is added than when the cells are maintained in RDM. This 
suggest that necrosis increases when serum is added and that C5b-9 coats necrotic cells. Standard 




5.3.3 Investigating the differential triggers for complement activation 
 
To see which arm of the complement pathway was mediating the TCC activation in the model the 
serum was depleted of components from different arms of the complement pathways (figure 5.16).   
At least 5 membrane studies were performed per condition.  The studies were all performed at the 
same time and immunohistochemistry was also performed at the same time with images taken 
under the same conditions on the confocal microscope. The results are from the pooled results of 





Figure 5.16: C5b-9 deposition in the model using depleted sera. Using the model a minimum of 
three repeat experiments were performed.  A minimum of three images were taken from each well. 
Standard error bars are shown.  The images above are representative 100 µm x 100um images from 
different conditions.  When compared to normal serum there was a small non-significant decrease 
in C5b-9 deposition when classical pathway component C1Q was depleted (p=0.076). Depletion of 
C4, a component of both the classical and Lectin mediated pathways resulted in no difference in 
TCC deposition when compared to the normal serum (p=0.35). Their depletion of factors B and D, 
alternative pathway components, resulted in a small but significant reduction of TCC activation 
(p<0.01). Depletion of common complement pathway components C3 and C5 resulted in a 
significant decrease in deposition (P<0.01). 
 
 
The depletion of C1Q a component of the classical pathway led to a small non-significant decrease 
in TCC deposition when compared with a two-tailed Mann-Whitney U-test (p=0.076). Depletion of 
C4, a component of both the classical and Lectin mediated pathways resulted in no difference in 
TCC deposition when compared to the normal serum (p=0.35). Factors B and D are part of the 
alternative complement pathway.  Their depletion resulted in a small but significant reduction of 
TCC activation. Statistically, using non-parametric comparative analyses Factor D depleted serum 
resulted in significantly reduced TCC (p<0.01) whilst factor B depleted serum also resulted in a 
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significantly reduced TCC deposition (P<0.01). 
 
However, depletion of complement components C3 and C5 which are necessary for C5b-9 
formation in all pathways resulted in a near complete loss of TCC deposition (figures 5.16).  
Statistically, C3 depletion resulted in a significant decrease in deposition (P<0.01) whilst C5 
depletion resulted in a significant reduction in TCC deposition (p<0.01). Taken together the results 
of the serum depletion studies suggest that in this model C5b-9 activation may be secondary to a 
number of pathways with the alternative complement pathway activation providing the greatest 
activation. 
 
From the previous FACS on case and control hiPSC-RPE lines it appears that there is some TCC 
formation and deposition even without the addition of serum.  I wanted to investigate whether 
endogenous expression of complement pathway components results in the failure to abolish TCC 
activation despite depletion of the different pathway components from serum.  To see if the cells 
expressed complement pathway components I performed a quantitative real time PCR array on 
cDNA generated from RNA pooled from case lines using a qPCR array (figure 5.17).  The analysis 
revealed that most complement components were expressed by the hiPSC-RPE. 
 
Figure 5.17 : Complement pathway expression analysis in hiPSC-RPE.  The array shows the 
pooled results from the complement array performed on case and control hiPSC-RPE cDNA. Three 
repeats for each gene were performed on each cell line.  Standard error bars are shown.  The CT 
was normalized to GAPDH.  The results show that there is endogenous expression in hiPSC RPE 
of most complement pathway components.  
 
 
To see if the genotypic differences between cells in key complement regulatory genes could 
account for the differences in TCC activation, I sequenced the hiPSC lines for four main risk 
alleles for AMD as identified by a comprehensive meta-analysis of recent studies (table 5.1). The 
132 
 
findings were mixed with cell lines harbouring different risk alleles for AMD risk (table 5.2).  This 
suggested that in cases and controls the risk alleles  AMD did not play a significant role in altering 
the phenotype. 
 
Gene Locus Risk 
allele 










A 1 1 × 10−434 2.43 
(2.39–
2.47) 
C2-CFB rs429608 G 6 4 × 10−89 1.74 
(1.68–
1.79) 
C3 rs2230199 C 19 1 × 10−41 1.42 
(1.37–
1.47) 







Case1 + - - - 
Case2 - + - + 
Case3 + + - + 
Ctrl1 + - - + 
Ctrl2 + - - + 




5.3.4 Examining complement activation in the in vitro L-ORMD model 
The TCC for complement is composed of complements C5b, C5, C7, C8 and C9.  Depletion of C5 
from serum had been shown to almost completely abolished TCC immunostaining in the model.  
This suggested a potential treatment approach to correct the C5b-9 activation phenotype on the 
cells.  There was already a humanised monoclonal anti C5 antibody that had been used clinically to 
treat a number of other conditions (Hillmen et al., 2006, Radhakrishnan et al., 2012, Vivarelli et al., 
2012). I wanted to see whether a monoclonal C5 antibody could be used to correct the phenotype 
in this model of macular degeneration.   
 
Firstly, to confirm that C5 would be a suitable target for treating the model I repeated the C5 
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depletion study to ensure that only the loss of C5 resulted in a loss of C5b-9 activation.  I replaced 
C5 to the concentration found in serum to some of the inserts containing C5 depleted serum. These 
studies showed that replacement of C5 returned complement activation and C5b-9 deposition on 
the inserts (figure 5.18).  The addition of C5 to C5 depleted serum resulted in a significant increase 
in TCC deposition (p<0.01). 
 
A suitable mouse monoclonal antibody to C5 which had previously been shown to have some 
efficacy in preventing complement mediated lysis of sheep red blood cells (Sandoval et al., 2000).   
Reports from the manufacturer had shown that this antibody had a functional effect being able to 
reduce lysis of sheep red blood cells by human serum.  I treated the inserts containing 10% serum-
RDM, with a high concentration of anti-C5 antibody (figure 5.18).  There was a marked reduction 
in TCC deposition (figure 5.18).  To investigate whether the drug was responsible for this I tested 
various concentrations of the monoclonal antibody in 10% serum-RDM (figure 5.19).  This 
showed a dose-dependent reduction in TCC deposition. A concentration of 500ng/ul lead to a non-
significant decrease in TCC deposition (p=0.08). However, a dose of 2000ng/ul led to a significant 
drop in TCC deposition (p=0.03) when compared to the 10% serum.  A further significant 
reduction in TCC deposition resulted from 4000 ng/ul resulted in an almost complete loss of TCC 
deposition when compared to the 10% serum-RDM (p<0.01) suggesting that an anti-C5 
monoclonal antibody could be used to reduce TCC deposition in the model. Ideally, I would have 
liked to have performed a similar experiment using an isotype control to verify that the reduction 





Figure 5.18 : C5b-9 deposition in the model focusing on C5. Using the model a minimum of 
three repeat experiments were performed.  A minimum of three images were taken from each well. 
Standard error bars are shown.  The images above are representative 100 µm x 100um images from 
different conditions.  This depletion replacement assay confirmed the findings above.  There was a 
significant decrease in C5b-9 deposition with C5 depletion form serum.  This was reduced when 
C5 was replaced suggesting that the depleted serum contained all other active components except 
for the C5.  In order to test a treatment, A  4000ng/ul dose of monoclonal anti C5 antibody was 




Figure 5.19 : Anti-C5 antibody dose-response. Using the model a minimum of three repeat 
experiments were performed.  A minimum of three images were taken from each well. Standard 
error bars are shown.  The images above are representative 100 µm x 100um images from different 
conditions.  A decrease in C5 deposition was noted with increasing monoclonal antibody 
concentration. A concentration of 500ng/ul lead to a non-significant decrease in TCC deposition 
(p=0.08). However, a dose of 2000ng/ul led to a significant drop in TCC deposition (p=0.03) and 
4000 ng/ul concentration of monoclonal antibody resulted in an almost complete loss of TCC 




In these set of studies we have shown that when mutant C1QTNF5 hiPSC-RPE were cultured in 
the presence of human serum, significantly greater TCC deposition was seen on mutant C1QTNF5 
hiPSC-RPE when compared to control hiPSC-RPE. TCC deposition was time dependent an 
increased peaking at 12 hours.  By depleting factors essential for different complement pathways 
TCC formation was found to be mainly alternative complement pathway dependent. These studies 
replicate the human in vivo findings described in earlier chapters. 
 
Johnson et al. grew human foetal RPE on similar membrane supports (Johnson et al., 2011). When 
these cells were exposed to human serum they were found to develop two types of sub-RPE 
deposit in a similar way to the deposits in this study. The first deposit was found directly sub-RPE 
whilst the second deposit was found deeper within the pores of the membrane. TCC activation was 
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also noted however when similar complement pathway depletion studies were performed TCC 
formation was found to be classical pathway dependent. 
 
Radhu et al. used a similar setup to examine foetal human RPE cells carrying protective and risk 
alleles for AMD (Radu et al., 2014).  In order to stimulate complement activation the RPE were fed 
with ROS from ATP-dependent transporter for phosphatidylethanolamine (ABCA4) knockout 
mice.  The ABCA4 gene encodes for a protein that binds to retinoids on photoreceptor outer 
segments and assists in the processing of ROS in RPE.  Mutations in the gene can lead to Stargardt 
disease which results in lipofuscin and bisretinoids in RPE. The RPE carrying AMD predisposing 
risk alleles were shown to have C5b-9 deposition.  The TCC formation was identified as alternative 
pathway dependent.  The difference when compared to the system described by Johnson et al. 
suggests that different arms of the complement pathway may be activated under different 
conditions.  Lipofuscin formation may result in activation of the alternative complement pathway. 
 
In our study, we showed that TCC formation increased with time till approximately 12 hours.  
After 12 hours, there was a slow reduction in TCC deposition.  TCC deposition in this model may 
peak at this time because of depletion of complement components in the serum inhibiting the 
formation of new complexes.  Clearance of TCC may result from endocytosis mediated clearance 
by RPE cells as suggested by recent studies by Georgiannikis et al. (Georgiannakis et al., 2015).  
The long-term culture of cells in human serum was not investigated in this series of studies but 
may potentially propagate the complement response.  This would certainly be interesting to 
investigate particularly as the complement response has been implicated in deposit formation 
(Fernandez-Godino et al., 2015). 
 
TER was not found to be significantly different between case and control lines in the previous 
chapter. TER is a marker of RPE function and monolayer integrity and is maintained by tight 
junction formation and active ion transport . The hypothesis was that C5-9 formation would disrupt 
monolayer integrity and result in a lower TER.  Giorgianikkis et al.  showed c5b-9 formation on 
porcine RPE grown in human serum using a similar model system (Georgiannakis et al., 2015). 
They noted that TER increased with C5b-9 deposition suggesting that although TCC were 
deposited they were not resulting in cell lysis. The SYTOX® experiments revealed an increase in 
nuclear staining with SYTOX® in case lines compared with controls. The increased staining was 
exacerbated with oxidative stress and with time. However, a baseline LDH assay showed no 
significant difference in LDH levels between case and control lines.  The findings suggest that case 
hiPSC-RPE have a deficit in membrane integrity making cells susceptible to oxidative damage 
(Kim et al., 2003).  Study of apoptosis using caspase-3 also showed that apoptotic cell death was 
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not the primary mechanism of cell death.  Kim et al. also showed that necrosis resulted from 
hydrogen peroxide exposure in a model using ARPE-19 cells (Yang et al., 2014b). Interestingly, 
Yang et al. noted SYTOX® staining when activating the alternative complement pathway on 
ARPE-19 cells. 
 
Taken together the studies in this section show that the model appears to replicate in vivo findings 
of complement activation from L-ORMD human donor samples.  In addition, the model also offers 
a method to study alternative complement pathway activation, the main complement pathway 




























6. Investigating an interaction between C1QTNF5 and the complement pathway 
 
6.1       Introduction and rationale 
 
The C1QTNF5 gene encodes a 25 kDa protein (Hayward et al., 2003; Mandal et al., 2006; Wong 
et al., 2008). C1QTNF5 contains three domains: a signal peptide domain (amino acids 1–15), a 
collagen domain (amino acids 30–98), and a gC1q domain (amino acids 103–243) 
 (Fig. 1A) C1QTNF5 shares features with other members of the C1q family including 
mulitmerisation. C1QTNF5 readily forms trimers, which leads to the formation of a globular head 
composed of three gC1q domains (Shapiro and Scherer, 1998). C1QTNF5 can also forms 
octadecameric bouquets (Tu and Palczewski, 2014). The Ser163Arg mutation is found in the gC1q 
domain.  
 
CFH is an important regulator of the alternative complement pathway.  Mutations in CFH have 
already been implicated in macular degeneration.  CFH is composed of 1213 amino acids.  The 
amino acids are arranged into 20 complement control protein modules (CCPs) each of which 
contains approximately 60 amino acids. Each CCP is connected to its adjacent CCP by a linking 
region which allows marked flexibility and enables CFH to have a highly variable three 
dimensional structure.  In unpublished data from Shu et al. C1QTNF5 has already been shown to 
bind to CFH. The hypothesis is that mutant and wild-type C1QTNF5 will have differential affinity 
for CFH. 
 
In order to see if C1QTNF5 has an affinity for CFH we will first generate mutant and wild type 
proteins.  C1QTNF5 has previously been generated from both cell and bacterial expression 
systems.  Recently studies using a bacterial expression system were able to reliably express the 
gC1Q domain of both wild type and mutant C1QTNF5 (Tu and Palczewski, 2012). As the 
mutation was found in the globular domain the aim was to use a similar protocol to generate wild 
type and mutant gC1q domains.   
 
Surface plasmon resonance (SPR) is a highly sensitive, label-free method of investigating 
interactions between complexes (Daghestani and Day, 2010)(figure 6.1). The method was first 
described in 1968 (Otto, 1968). The technique uses the understanding that electromagnetic 
oscillations occur when light encounters charged conducting surfaces. Plasmons represent quantum 
oscillations of electron clouds within a conducting material. The transverse oscillations are called 
surface plasmon polaritons (SPP).  When vector of light waves travelling parallel to the conducting 
surface matches the SPP then resonance occurs.  SPR only occurs at certain angles of incidence of 
light.  SPR will cause a change in the angle of reflectivity at a reflective surface. The sensors note 
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the reduced incidence of light with SPR. The detectors identify change in angle of light reflection 
when there is new binding on the surface of the sensor. The method is useful because it only 
requires small concentrations of ligands to provide reliable repeatable results.  SPR has been used 
to probe protein to ligand, protein to protein and nucleotide hybridisation (Karlsson and Falt, 1997, 
Moon et al., 2010). SPR has already used to understand the binding of CFH to a number of ligands 
(Yu et al., 2005, Weismann et al., 2011).  We aim to use SPR to investigate protein-protein 
interactions between C1QTNF5 and CFH. The hypothesis is that CFH also interacts with 
C1QTNF5 and that it interacts differently to mutant C1QTNF5 protein when compared to wild 
type C1QTNF5. 
 
Figure 6.1 : A diagram showing surface plasmon resonance. Polarised light is incident on a gold 
membrane.  When a substrate (red) binds to ligands (yellow circles) a resonance signal is released 
and this is sensed as a change in reflected light. (http://www.rci.rutgers.edu/~longhu/Biacore/) 
 
 
6.2       Methods 
 
The studies creating E.Coli lines, generating, purifying and analysing proteins were performed by 
Dr Shyamanga Borooah and Dr Chloe Stanton (University of Edinburgh) and suggested by 
Professor Alan Wright (University of Edinburgh).  These studies were performed at the core 
protein facility (University of Edinburgh).   
 
Preparation for the surface plasmon resonance experiments was performed by Dr Shyamanga 
Boroah and Dr Chloe Stanton (University of Edinburgh).  The SPR experiments were performed 
by Dr Andrew Herbert (University of Edinburgh). Preparation of materials for the CFH functional 
strudies was performed by Drs Shyamanga Borooah and Chloe Stanton. The Coomassie was 






6.2.1 Creating E.Coli lines stably expressing wild-type gC1QTNF5 and mutant 
gC1QTNF5  
 
Recombinant His-gC1q was purified from individual E. coli colonies grown in Luria Broth  (LB) 
containing 0.1mg/ml ampicillin and incubated overnight at 37 °C with shaking and expression was 
induced overnight with 1 mM IPTG at 20 °C. Cell pellets were collected by centrifugation at 
10,000g for 10 minutes, then resuspended and incubated for 30 minutes in 50 mM sodium 
phosphate, 300 mM sodium chloride, 10 mM imidazole pH 8.0 plus 1 mg/ml lysozyme.  
A codon-optimized gC1QTNF5 coding sequence was synthesised and amplified. The C-terminal 
also coded for His. These were made using a codon-optimised C1QTNF5 sequence for bacterial 
expression (GeneART), and cloned using the following primers and sequential Gateway cloning 
steps into pDONR221 and pDEST-14. 
Step1: 
C1QTNF5_gC1Q_nc C-His_F 
Fwd 5’- GCT TCG AAG GAG ATA TAC ATA TG CGTAGCGCATTTAGCGCAAAACG -3’ 
C1QTNF5_ nc C-His _R 
5’-TGA TGG TGA TGG TGA TGG CCA TC TGCAAAAACCGGACTGCTATGCC -3’ 
 
Step2: 
Fwd 5’-com-GGG GAC AAG TTT GTA CAA AAA AGC AGG CTT CGA AGG AGA TAT 
ACA TAT G-3’ (49) 
Rev 5’-com-GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC CTA GTG ATG GTG ATG 
GTG ATG GCC ATC-3’ (57) 
 
The mutants were designed similarly with the G>C substitution. Again, the mutants were made by 
site directed mutagenesis.  This work was performed by Dr Chloe Stanton.  The recombinant 
plasmid construction was verified by DNA sequencing (the plasmid was constructed and supplied 
by Dr Chloe Stanton, University of Edinburgh). The methodology used for the expression of the 
gC1Q protein was based on a previously published successful methodology for expressing gC1q 
(Tu and Palczewski, 2012). The recombinant plasmids were transformed into Rosetta™ 
(DE3)pLysS Competent cells  (Novagen) E.Coli. These strains supply tRNAs for AGG, AGA, 
AUA, CUA, CCC, GGA codons which is otherwise limited by the codon usage of normal E. coli.  
The bacteria were initially grown out on agar plates with recombinant plasmid added to plates.  
Colonies were individually picked using a P200 tip and added to a cultivation tube containing 2ml 
Luria broth. The cells were grown for twelve hours at 37oC and placed on a shaker at 250rpm.  
After 6 hours the broth was testedg for starting cell density using OD600 on a NanoDrop (Thermo-
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Scientific). Wells with an optical density of 0.1-0.2 were used prior to shaking flask culture.  The 
Enpresso B (BioSilta, Oulu, Finland) culture system was used for protein expression A 500ml 
shake flask was prepared with 2 tablets from the Enpresso B kit of supporting chemicals in 50 ml 
ddH20.  The flask was shaken for 30 minutes at 37oC until tablets were fully dissolved. 
Chloramphenicol was added and 2ml of the culture medium from the transformed bacteria were 
added before a glucose-releasing reagent was added to the flask. The flask was sealed and 
incubated at 30oC and shaken at 250rpm.  After 15 hours a further supplement of glucose reagent 
and a booster supplement tablet were added from the kit.  At 24 hours the cells were cooled to 
16oC.  0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to induce expression.  
The cells were then lysed using a Soni-Prep 150 sonicator  (MES UK, London, United Kingdom) 
and Constant systems 1.1 kW TS cell disruptor  (Constant systems limited, Daventry, United 
Kingdom) an automated high-pressure  (40 kpsi) lysis system with temperature control. The lysed 
mixture was centrifuged at 10,000g for 30 minutes (Beckman Avanti) to remove cellular debris 
and the supernatant was retained.  
 
The supernatant was filtered through 0.22uM Amicon® filters to remove further debris.  ÅKTA 
Xpress - Low pressure, automated, unattended parallel lab-scale production unit (GE Healthcare)  
(4˚C) was used to sequester and elute protein fractions from the supernatant.  The supernatant was 
run through a Superdex 200 10/300 GL column (GE Healthcare) bead columns using 30 mM 
sodium phosphate 20 mM imidazole pH 8.0, followed by the same buffer containing 50 mM 
imidazole pH 8.0 and His-gC1q was finally eluted using 1M imidazole pH 10. Every 10ul of eluent 
was collected separately. Eluents with matched spectrophotometric profiles were pooled and 
analysed by Coomasie gel and SDS-PAGE targeting the FLAG tag and by mass spectrometry. The 
molecular weight of 16KDa was predicted for the gC1Q.  
 
In order to perform size exclusion chromatography using multi-angle light scattering (SEC-MALS) 
a 100ul of 1mg/ml protein in 1M imidazole pH 10 buffer was run through a Viscotek MALS-20 
detector which was attached to an AKTA 10 purifier (Mogridge, 2004).  The detector used an 
incident light beam (660 nm) to detect not only concentration of solute but also the molar mass and 
the system was connected to a collector to collect different fractions. 
 
   
6.2.2 Thermal denaturing assay 
 
In order to compare the stability of the generated mutant and wild type gC1Q a thermal 
denaturation assay was used.  Protein concentrations were all standardised using quantitative 
spectrophotometry at 280nm using a NanoDrop (Thermo fisher scientific) to get a concentration of 
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0.1mg/ml.  50ul of protein diluent was placed in each well with at least three replicates in order to 
calculate the protein unfolding temperature (Tm) in a 96 well plate. Fluorescent dye Sypro orange 
(life technologies) in a 5X concentration was added.  The plates were briefly spun for 1 minute at 
1000g in a centrifuge to ensure mixing of protein and Sypro orange and then sealed with optical 
sealing film prior to a thermal denaturation run on a Biorad iQ5 iCycler set up to detect 
fluorescence from the Sypro orange. As proteins unfolded due to increasing temperatures, the dye 
exposed large hydrophobic regions, resulting in a large increase in fluorescence (ex/em 485/575) 
measured by the iCycler. The iCycler was set to run from 20 to 80oC with a hold of 30 seconds at 
each temperature and ramping at 1oC increments. Data was exported onto excel (2013 Microsoft, 
Redmond, USA) for analysis. The melting temperature (Tm) was taken as the peak inflexion of the 
denaturation curve.   
 
6.2.3 Surface plasmon resonance (SPR) 
 
All SPR experiments were carried out using a Biacore T100 machine by Dr Andrew Herbert 
(University of Edinburgh).  Preparation of substrates and media for each run was performed by Drs 
Shyamanga Borooah and Chloe Stanton (University of Edinburgh). T100 software was used for pH 
scouting, coating the chips and kinetic assays. All buffers, protein samples and the Biacore sample 
compartment and operating temperatures were maintained at 25°C. The running buffer was 10 mM 
HEPES pH 7.4, 150 mM sodium chloride, 0.005% P20  (Biacore, Little Chalfont, UK).  The 
optimal conditions were 25 oC 0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% v/v Surfactant P20 + 
50uM EDTA. Immobilisation of His-C1QTNF5 to the NTA chips was carried out through the His 
tag via nickel on a nitrilotriacetic acid (NTA) biacore chip. This was performed by flowing 100um 
NiCl2 over the cells initially prior to flowing the proteins. The stability of the nickel-protein 
complexes were initially verified by measuring resonance after multiple cycles of buffer flow.   For 
the experiments, the injection times were for 180 seconds with different concentrations of CFH 
flowing over the chip with dissociation times allowed for 600 seconds with only running buffer 
flowing over the chip.  These parameters were set after initial test runs with both proteins.   An 
internal repeat was carried out for each run, taking a mid-range dilution. There was also a reference 
cell coated just with nickel to see if there was any binding of CFH to the substrate. One experiment 
was run on at least one chip loaded with wild-type and mutant His-C1QTNF5. Six injections of 
increasing concentrations of CFH in buffer were performed for 180 second with a flow rate of 
30ul/second.  Each injection had a concentration of CFH which was double the concentration of 





6.2.4 CFH functional studies 
These studies were performed in two parts to see if C1QTNF5 resulted in a difference in CFH 
function in the fluid phase and the solid phase. The solid phase studies were performed using sheep 
red blood cells (RBCs) using a method that had previously been published (Morgan, 2000).  One of 
CFH’s functions is to breakdown C3b with the help of CFI. C3b has a molecular weight of 176 
kDa and is composed of an alpha chain (101 kDa) and a beta chain (75 kDa) linked by a disulphide 
bridge. CFH acts as a co-factor so that factor I can cleave the alpha chain into fragments.  Various 
combinations of C1QTNF5, CFI, CFH and C3b were tested.  C3b (4ug) was added to CFH (1ug) 
and CFI (1ug) in a total volume of 15ul and incubated for 10 minutes at 37oC.  SDS sample buffer 
with reducing agent was added to the tubes at 10 minutes and heated at 95oC for 5 minutes. SDS 
PAGE gels run under reducing conditions should reveal cleavage of the alpha chain of C3b. The 
gels were stained for 20 minutes using Coomassie brilliant blue and then imaged on a Licor 
geldock imaging device. 
For the solid phase assays a RBC lysis assay was used (Pangburn, 2002).  Sensitised sheep RBCs 
(Comptech), Briefly, a complement-containing serum sample is diluted so that the final dilutions in 
the assay are in the range from 1/100 to 1/500.   Assay tubes were kept on ice. For the addition of 
CFH to depleted sera 50ug/ml was added as soon as the depleted serum thawed.  The volume is 
brought to 1.3 mL with GVB++, (0.1 % gelatin, 5 mM Veronal, 145 mM NaCl, 
.025  NaN3 ,  pH 7.3.  Containing 0.15 mM calcium chloride and  0.5 mM magnesium chloride). 
0.2 mL of RBCs  at 5 x 108 EA/mL (Comptech) were added.  The mixtures were incubated at 37oC 
for 60 minutes. The mixtures were then spun down to isolate remaining cells at 500g for 3 minutes. 
The absorbance of the supernatant determined at 541 nm in a 1 cm cuvette to calculate the 
percentage of RBC lysis. 
6.3 Results 
 
6.3.1 Comparison of wild type and mutant gC1QTNF5 
 
The supernatant, following centrifugation, was passed through a gel filtration column and the 
eluents analysed by spectrophotometry. The characteristics of the proteins were markedly different 
(figures 6.2 and 6.3). Wild-type tagged gC1QTNF5 produced a single main peak whilst the mutant 
produced multiple peaks generating a number of different constituents. A Coomassie stain of the 
eluents revealed that the protein eluted had two molecular weights.  Firstly, at approximately 
16kDa and a second weight at approximately double this at 28kDA. To confirm that the protein 
was expressed correctly as per the plasmid design a western blot was prepared using anti-His 
antibody (figure 6.4).  This showed that the proteins also contained His sequences as intended and 
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that the molecular weights corresponded to a monomer and dimer.  There was also a higher order 
stain for potentially a trimer.  Once again as in the cell studies the mutant appeared to preferentially 
form the monomer without higher order multimers. Eluents with similar western blot 
characteristics were pooled to provide an increased volume of protein. Protein was then maintained 
at 4oC or frozen at -20oC.  The stability was checked after a week at these temperatures by 
performing a further Coomassie gel which was unchanged.  This showed that the proteins were 
stable to be stored prior to further experiments. 
 
Figure 6.2 : Readout for wild-type gC1QTNF5 using spectrophotometry after gel filtration.  The 
readout shows a clear uniform peak suggesting a pure species.  When the flow through from the 
peak is analyzed with Coomassie staining there is a clear band at 16 kDa and a potential dimer 
with little else stained suggested a relatively pure extraction. The y axis of the graph is the 
absorbance in milli absorbance units the x-axis shows the volume of fluid in millilitres.  The 




Figure 6.3 : Readout for mutant gC1QTNF5 using spectroscopy after gel filtration.  The readout 
shows multiple peaks.  When the flow through from the different peaks are analyzed on 
Coomassie staining gel the third and fourth follow through provide a relatively pure protein at the 
expected molecular weight for mutant gC1QTNF5. The y axis of the graph is the absorbance in 
milli absorbance units (mAU) and the x-axis shows the volume of fluid in millilitres.  The proteins 
were measured at 260 and 280 nm wavelength. 
 
Figure 6.4: Reducing SDS-PAGE for HiS-C1QTNF5 fractions. The gel on the left shows the 
reducing gel for the His-gC1QTNF5 wild type.  The gel shows that despite reducing conditions 
there is still formation of the dimer and trimer. The gel on the right shows that after reduction the 






 The profile of mutant elution from the column revealed multiple different weighted moieties. As a 
result, the first eluent was discarded and groups 2, 3 and 4 were pooled pending a thermal 
denaturation assay (see below).   
 
When measuring the amount of protein after pooling there was a far lower concentration of the 
mutant protein (mean=0.18mg/ml) than the wild type (3.3 mg/ml) prompting questions of stability 
in the mutant compared to the wild type.  A thermal denaturation assay was also performed to 
check the thermal stability of the generated proteins and to test the different eluents prior to 
pooling (figures 6.5 and 6.6).  The wild type protein was highly stable. The different eluents 
appeared to all denature at approximately 80oC with an inflexion temperature of approximately 
90oC.  This suggested that the wild type eluents are highly stable and relatively pure.  A similar 
denaturation assay of the mutant protein eluents revealed a mixed picture with a variety of thermal 
denaturation curves  (figure 6.6).  In addition, the denaturation began at approximately 45oC with 
inflexion points varying from 50 to 65oC. This suggested that there was some variability in the 
eluents and that the mutant globular domain was more unstable.  The four most unstable eluent 
batches were discarded at this stage. 
 
 
Figure 6.5. : Thermal denaturation assay for the wild-type g-C1QTNF5. The denaturation of 
gC1QTNF5 shows similar characteristics from different fractions suggesting that the eluted 




Figure 6.6 : Thermal denaturation assay for mutant g-C1QTNF5. The mutant eluted fractions 
show different denaturation characteristics. This suggests that there are different proteins in the 
different elution fractions. The bottom four fractions were discarded.  The top four fractions show 




6.3.2 Interaction of wild type C1QTNF5 with complement factor H (CFH) 
 
Both the wild-type and mutant protein were found to be stably bound to the chip with less than 
10% loss during the course of the initial substrate quality control stage (figure 6.7).  This suggested 
that loss of resonance would not be secondary to loss of protein from the chip throughout the 
course of the experiments. 
 
Figure 6.7 Stability of ligand binding to the chip.  The wild-type and mutant gC1QTNF5 were 
bound to the gold plated chip. During the course of the experiment there was less than 10 percent 




The values for the kinetics were obtained after three repeats of the experiments on the same chip. 
The complex formation constant (Ka) and dissociation constant (Kd) were calculated using 
supplier provided software.  Initially a 1:1 model of affinity was tested unsuccessfully. The data 
were eventually fitted to a heterogeneous ligand model on the basis that the ligands would contain 
a mixture of mainly monomers and trimers as seen in the Coomassie stains.  There are several 
different features of binding of CFH to the wild-type (figure 6.8).  There is a strong on rate Ka1 
(monomer) and Ka2 (trimer) with both forms of the protein with values of 2.7x 10-5 M and 5.5 x10-
6 M respectively. The formation of the complex with the proposed trimeric form is greater. The 
dissociation constants are 6.32x10-7 and 6.68x10-10 respectively for the two forms suggesting that 
the trimeric form is almost 1000 fold greater average affinity than the monomeric form. 
 
Figure 6.8:  SPR sensorgrams demonstrating CFH interaction with mutant and wild type 
His-gC1QTNF5 Three separate experiments were performed. A heterogeneous ligand model was 
used to fit the affinities (Kd) and association rates (Ka). CFH is flowed over the gC1QTNF5 which 
is bound to the SPR chip.  The lines represent different concentrations of CFH.  Each line 
represents a twofold greater concentration of CFH than the line below.  The CFH is flowed for 180 
seconds.  The dissociation was then measured for 600 seconds. The affinities for the monomeric 
and multimeric wild type are 6.32x10-7 M and 6.68x10-10 M respectively suggesting that the 
multimeric form has almost 1000 fold greater average affinity. The strong affinity of the 
multimeric form is shown by the prolonged resonance even after 600 seconds.  
The affinity values for the mutant were 5.49 x 10-8 M and 8.61 x 10-7 M.  The mutant has a similar 
affinity to the monomeric form of the wild type.    
 
The mutant protein affinity fitted better to a 1:1 model (figure 6.8).  However, for comparison a 
heterogeneous ligand model was used as the previous analysis had shown that the samples 
contained multiple different elements.  Perhaps unsurprisingly, as the protein appeared to be 
mainly monomeric the Ka and Kd were similar for the different predicted ligands. With Ka values 
of 1.7x10-5 and 2.2 x 10-5. The Kd values were 5.49 x 10-8 M and 8.61 x 10-7 M.  The affinities 
were similar to the monomeric forms of wild-type protein. This suggested that the main difference 
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between the proteins in CFH affinity resulted from the inability of the mutant to form trimers and 
potentially multimers. 
After establishing that CFH binds to C1TQNF5, I wanted to see if a functional role for C1QTNF5 
in mediating localised complement pathway activation could be found.  C1QTNF5 is secreted by 
the cell and we showed in chapter 4 that C1QTNF5 could be found in the media.  As a result the 
first functional studies test the effects of C1QTNF5 on CFH function in the fluid phase.  
In the biacore studies, monomeric form of the mutant was found to have a similar affinity for CFH 
as the monomeric form of the wild-type.  Ideally, it would have been good to see if the mutant 
protein altered CFH function. Unfortunately, the mutant was found to degenerate over days. When 
the mutant was retested for protein concentration using spectrophotometry there was not sufficient 
concentration of the protein to perform the solid phase functional analyses.  The fluid phase 
functional studies looked to see how the addition of wild-type and mutant C1QTNF5 altered the 
breakdown of C3b alpha chain into fragments (67kDa and 43 kDa).  To ensure that the system was 
valid the system was tested without CFI or CFH (figure 6.9).  There was no breakdown of C3b 
without all C3b, CFH and CFI being present. The addition of the wild type appeared to make little 
difference to breakdown. The addition of the mutant C1QTNF5 led to a minimal decrease in 
fragment density. Large amounts of C3b and C3b alpha chain were still present in the solution 
even after addition of C1QTNF5. This suggests that in the fluid phase C1QTNF5 appears to make 




Figure 6.9 : Fluid phase CFH functional studies.  CFH breaks C3b with the help of CFI. C3b has a 
molecular weight of 176 kDa and is composed of an alpha chain (101 kDa) and a beta chain (75 
kDa) linked by a disulphide bridge.  Breakdown of C3b results in a fragment at 67kDa and 43 kDa. 
Various combinations of C1QTNF5, CFI, CFH and C3b were tested. The gels were stained for 20 
minutes using Coomassie brilliant blue and then imaged on a Licor geldock imaging device. The 
negative controls in the first three columns show that there is no breakdown of C3b.  The addition 
of the wild type appears to make little difference in breakdown.  The mutant appears to reduce 
breakdown. 
 
The solid phase assay used sensitised sheep red blood cells to see if CFH could prevent 
complement mediated lysis in different quantities of serum. CFH depleted serum quickly loses 
complement activation as C3 is converted to C3-H2O and/or C3b.  This is shown by the lack of 
lysis in the CFH depleted sera (figure 6.10).  However, when CFH is added back into the depleted 
sera it can retain near normal activity levels to normal serum (figure 6.10). The addition of 
C1QTNF5 to this serum appears to minimally protect RBCs from lysis.  Only one concentration of 
C1QTNF5 was tested and a limited amount of test points in serum could be attempted due to the 
lack of necessary wild-type C1QTNF5 required for this experiment. It would be useful to repeat 
this at various concentrations of C1QTNF5 to confirm that C1QTNF5 modifies CFH function in 




The data in these set of results showed that CFH bound to C1QTNF5.  Secondly, the Biacore data 
also shows that there is difference in binding characteristic between the wild-type and mutant 
globular domains. In addition, the data suggests that there is also role for C1QTNF5 in protecting 




Figure 6.10 : Solid phase CFH functional study using RBC haemolysis.  Sensitised sheep RBCs 
were placed in varying concentrations of serum with normal serum, CFH depleted serum, CFH 
depleted serum with gC1QTNF5, CFH depleted serum with CFH added and CFH depleted serum 
with C1QTNF5 and CFH added. Haemolysis did not occur in either of the CFH depleted sera 
conditions without addition of CFH which suggests that the media burnt out of C3 and was no 
longer complement active.  This provided a good negative control of the system.  The addition of 
CFH was able to maintain C3 levels within the media and maintain complement activity and is 
shown by an increase in haemolysis with serum concentration.  The normal serum is a good 
positive control.  The addition of gC1QTNF5 to the CFH depleted media with CFH added reduced 
the amount of haemolysis at the 10% and 20% serum concentrations suggesting that the addition 






6.4      Discussion 
 
In this series of studies C1QTNF5 generated by E.Coli was found to bind to CFH.  The wild-type 
protein was found to at a significantly higher affinity to CFH than mutant C1QTNF5. Previously, 
different regions of CFH have been shown to bind to different substances. CCPs 1-4 bind C3b and 
act as a cofactor for CFI to catalyse the breakdown of C3b to form iC3b.  CCPs 1-4 also help decay 
the C3 convertase C3bBb which also negatively regulates the alternative complement pathway. 
C3d is essentially the buried thioester domain of C3b.  Crystallography of C3d and CCP19-20 
fragments of CFH show close association of the two fragments (Jokiranta et al., 2006).  Affinity 
studies have also confirmed that 19-20 fragments bind strongly to C3d in a similar manner as to 
C3b (Morgan et al., 2011). This suggests that there are two binding sites on CFH for different parts 
of C3b. There is also evidence that CFH has some evidence of binding to CRP, annexin II, 
malondialdehyde acetaldehyde (MAA) and oxidised lipids (Jarva et al., 1999, Leffler et al., 2010, 
Weismann et al., 2011, Shaw et al., 2012).  CRP is found on cells with an acute phase response and 
is often also found when cells become infected. MAA is known to be produced in oxidative stress. 
CCP 7 and 20 were found to bind to MAA. Annexin II is often a marker of apoptotic cells 
(Weismann et al., 2011).  If binding data are true CFH may play a role in coating dead or dying 
cells and forming iC3b from C3b thus coating the cells in opsonising agents to assist in clearance.   
 
The Y402H variant of CFH is associated with AMD.   The variant substitutes a histidine for a 
tyrosine amino acid at position 402 found on CCP7 of CHF. This region has binding sites for 
heparin, CRP and streptococcal M protein (Giannakis et al., 2003).  In the common variant the 
tyrosine side chain is thought to bind closely to GAG-like structures.  Binding to BM was found to 
be reduced in the variant.  Interestingly glycosylation patterns were also altered in BM with ageing.  
Reduced binding was shown on aged BM. In addition, the AMD associated variant has been shown 
to have reduced binding to RPE (Skerka et al., 2007).  This suggests that CFH binds to RPE and 
BM.  In solid phase CFH can inhibit localised complement pathway activation by inactivating C3b.  
We hypothesise that C1QTNF5 may also act in a similar way to GAGs.  C1QTNF5 is secreted and 
has been found on cell membranes. C1QTNF5 on extra cellular surfaces facilitates CFH binding on 
cell surfaces to prevent cell surface complement activation.   
 
In chapter 4, the studies showed that C1QTNF5 was secreted by the cells.  In conditioned media 
there was a lack of high order polymers in the non-reduced western blot of conditioned media.  
This suggested that the mutant heterozygote disrupted normal C1QTNF5 multimerisation.  This 
was similar to the findings in this chapter with the wild-type protein appearing to form dimers and 
trimers whilst the mutant protein remained mainly monomeric from the western blots. Tu et al  had 
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generated full length C1QTNF5 and found that not only did C1QTNF5 form trimers but that the 
trimers formed bouquets of C1QTNF5. This structure was clearly seen using negative staining 
electron microscopy (Tu and Palczewski, 2014). In this set of studies, we were unable to study 
heterozygote trimer formation in detail or the effects that this might have on binding to CFH.  In 
addition, we were unable to study the formation of high order multimers with wild-type protein as 
only the globular domain was generated.    
 
In these studies, gC1QTNF5 was shown to bind to CFH.  The wild type globular domain had a far 
greater affinity with CFH than the mutant.  One could suggest that the lack of multimerisation 
would reduce the available binding sites for CFH on the cell surface. Reduced CFH binding may 
result in insufficiency and therefore reduce available binding sites for CFH on cell surfaces, which 
in turn leads to increased complement activation and TCC deposition on RPE and in the sub-RPE 
as seen in the L-ORMD donor retinal sections.         
 

























7.      Discussion 
 
Macular degenerations are amongst the commonest causes of sight threatening ophthalmic disease 
(Roy, 1974, Resnikoff et al., 2004). AMD is the commonest form of macular degeneration. 
Although studies have highlighted key factors associated with AMD (Smith et al., 2001), they have 
not been able to clearly demonstrate the stepwise mechanism of pathogenesis.  In particular, the 
initial injury and subsequent development of early disease is poorly understood. Although anti-
VEGF treatments have improved the visual outcome of patients with late-stage neovascular AMD 
these patients continue to reduce vision after diagnosis. Additionally, treatment for geographic 
atrophy is currently inadequate.  A lack of suitable models has hampered the development of new 
treatments for AMD.  AMD is a complex disease resulting from genetic and environmental 
interactions. Inherited macular degenerations offer a potential route to understanding molecular 
pathways involved in disease.  L-ORMD is an autosomal dominant inherited macular degeneration 
which shares many clinical and pathological characteristics with AMD (Kuntz et al., 1996, Milam 
et al., 2000, Ayyagari et al., 2005).   
 
This study aimed to develop a model of macular degeneration using L-ORMD. In the first instance, 
the aim was to see if clinical characteristics of our cohort of patients conformed to previous reports 
of L-ORMD patients.  A secondary aim was to use newer retinal investigation techniques and 
histopathology to see if L-ORMD patients exhibited features described for AMD patients.   
 
HiPSCs had previously been used to model inherited retinal disease (Li et al., 2014, Lukovic et al., 
2015, Meyer et al., 2011, Singh et al., 2013b). Using a similar approach the aim was to model L-
ORMD using hiPSCs. The first aim was to reprogram patient somatic cells to hiPSCs. 
Subsequently the study aimed to differentiate hiPSCs to disease-causing RPE. The study sought to 
investigate cell autonomous vulnerabilities in the generated hiPSC-RPE. Subsequently, the study 
aimed to investigate differences identified during histopathological studies in particular those with 
reference to the complement pathway. In the final chapter, the dissertation looked to see if the 
differences in the complement pathway activation found were due to an interaction of C1QTNF5 
with complement factor H. 
 
The next part of the dissertation aimed to develop an in vitro model for L-ORMD using hiPSCs. 
The aim was to see whether the cells showed any cell autonomous differences from those of 
control cell lines.  Secondly, the aim was to see if the model could be used to study localised 




Finally investigations targeted CFH to see if C1QTNF5 showed altered activation of the alternative 




7.1      Summary of the principal findings and suggestions for future studies 
 
The clinical studies in chapter 2 of this dissertation demonstrated that the L-ORMD patients in this 
cohort shared characteristics with previously described cohorts of L-ORMD.  (Vincent et al., 2012, 
Soumplis et al., 2013, Jacobson et al., 2014).  In particular, the patients were shown to develop a 
thick sub-retinal deposit which extended from the far-periphery to the fovea.  These findings are 
similar to the histopathological reports for L-ORMD (Kuntz et al., 1996, Duvall et al., 1986). The 
SLO studies identified that the region temporal to the fovea appears to the first to develop neuro-
retinal changes and that this region was the most sensitive region for deterioration in functional 
studies including microperimetry and multifocal ERG. Again these findings correspond with 
previous reports of delayed dark adaptation which are most sensitive at 15 degrees temporal to the 
fovea (Jacobson et al., 2001).  
 
Previously, patients with L-ORMD had been described to have features similar to AMD.  These 
included drusenoid white spots, sub-retinal deposit, retinal pigment epithelial loss and neuro-retinal 
atrophy and choroidal neovascularisation (Kuntz et al., 1996, Milam et al., 2000, Ayyagari et al., 
2005). This study revealed that patients with L-ORMD also demonstrated other features of AMD 
including cuticular drusen, reticular pseudodrusen and choroidal thinning.  Recent studies of 
macular degeneration have demonstrated that choroidal thinning appears to be associated with 
cuticular drusen (Garg et al., 2013). In this study we show that choroidal thinning occurs prior to 
neuro-retinal loss, suggesting that initial disease may involve the RPE-Bruchs’ and choroid 
complex prior to the neuro-retina in L-ORMD.  Recently, the choroid has also been attracting 
attention as a site for initial injury in macular degeneration (Mullins et al., 2014b). Additionally, 
methods used to monitor AMD including measurement of atrophy using SLO could also be used to 
monitor L-ORMD progression in stage 2 disease. In chapter 2, this study also identified 
complement staining in the deposit and choriocapillaris in L-ORMD histopathology samples.  
Therefore choroidal complement activation could also be involved early in L-ORMD pathogenesis.  
Mullins et al. also showed TCC deposition in the choroid in their histopathology study suggesting 
a similar mechanism in AMD (Mullins et al., 2014b). A similar process could be confirmed in L-
ORMD if younger donor material was available.  In addition, it would be interesting to investigate 
the serum of patients with L-ORMD to see if they have raised complement components as has been 




Dark adaptation delay is reported as one of the earliest clinical features of L-ORMD (Jacobson et 
al., 2001).  Although dark adaptation delay is also a feature of AMD, it is less commonly reported 
(Haimovici et al., 2002).  It was unclear why this feature was so prominent in L-ORMD patients. 
However, these studies have shown that in the peri-fovea and the temporal macula there are 
marked changes suggestive of reticular pseudodrusen in L-ORMD patients.  This is the region of 
retina with the highest concentration of rods (Jonas et al., 1992). Reticular pseudodrusen are 
located above the RPE layer and are in contact with the photoreceptor layer (figure 2.2). Therefore 
unlike traditional drusen, pseudodrusen can induce direct damage to photoreceptors.  Since the 
pseudodrusen are especially concentrated in the rod-rich areas it is likely that the rod function 
deteriorates prior to cone function.  This may result in early marked dark adaptation delay.  When 
looking at AMD cases, those with pseudodrusen were found to have a significantly greater dark 
adaptation delay (Flamendorf et al., 2015). It is still unclear why these changes occur more 
prominently in rod-rich areas initially sparing cone-rich regions such as the fovea. It would be 
interesting to investigate these differences further by co-culturing either rods or cones with case 
hiPSC-RPE.  The hypothesis being that co00culturing with rods would lead to increased RPE 
damage when compared to co-culturing in cone-rich media. 
 
In chapter 3, hiPSCs were successfully reprogrammed from patient and control fibroblasts.  The 
hiPSCs could be differentiated into functional RPE.  Thus far there have been no published reports 
of hiPSC-RPE derived from L-ORMD patients.  There have however, been other reports of hiPSC-
RPE generation in a small number of inherited diseases (Sun et al., 2015, Li et al., 2014, Yang et 
al., 2014a, Singh et al., 2013a, Singh et al., 2013b, Li et al., 2012, Carr et al., 2009, Buchholz et al., 
2009).  The baseline characteristics of the hiPSC-RPE were similar to those previously described 
in terms of gene expression, TER and phagocytosis. However, the RPE were also stained with 
phalloidin which binds to F-actin (Vandekerckhove et al., 1985). The findings in the case lines 
differs to the suggestions in previous reports which suggest a role for C1QTNF5 and MFRP in 
binding to actin and an imbalance resulting in actin disorganisation (Li et al., 2014). The phalloidin 
staining for the hiPSC-RPE case and control lines in chapter 5 showed no observable differences. 
 
In chapter 4, the study described findings from cell–autonomous studies between case and control 
hiPSC-RPE.  Findings differed from those previously reports using transfected cell lines. Shu et al. 
had found that in cells transfected with mutant C1QTNF5, that mutant C1QTNF5 was not secreted.  
Instead it accumulated intracellularly within the ER forming aggregates (Shu et al., 2006b).  In this 
study, there was heavy immunostaining particularly of the inner deposit for C1QTNF5 in both 
human and mouse histopathology specimens with little staining intracellularly. C1QTNF5 
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expression was noted in hiPSC-RPE and immunostaining noted staining within the RPE. 
Conditioned media from case and control hiPSC did reveal a reduction in secretion of C1QTNF5 
in case lines when compared to control lines. IN addition, there was a marked reduction in 
multimer formation. Markers of ER stress from protein folding were only variably altered in 
expression in the hiPSC case lines when compared with control hiPSC lines. HSPA2 and HSPA6 
showed a greater than 2 fold increased expression in the case line when compared to a control line.  
However, HSPA4 showed a greater than two fold reduced expression in the case compared to the 
control lines. GRP78 expression showed no significant change between case and control lines.  
Other markers of ER stress including BiP, ATF3 and CHOP were not examined during these 
transcript analyses.  Taken together the evidence for these studies suggests that mutant C1QTNF5 
is secreted and forms part of the deposit leading to a gain of function.  This is also supported by 
studies in mice which showed only a 20 percent decrease in C1QTNF5 expression in C1QTNF5 
+/- compared to the wild type making a dominant negative effect unlikely (Chavali et al., 2011). In 
addition, study of the knockout mouse in the studies presented here showed no deposit formation 
or complement activation pointing against a dominant negative effect from C1QTNF5 
insufficiency. The studies presented in this dissertation are limited because the antibodies used 
were not specific for mutant C1QTNF5. Additionally, previous studies have shown evidence for an 
interaction between mutant and wild type C1QTNF5.  This was not investigated further in these 
studies.  With new gene editing techniques (Cong et al., 2013b), it would be possible to knock in a 
double mutant C1QTNF5 gene into human cell lines. The prediction would be that phenotypes 
would be worse with a gain of function mutation.  Alternatively, a knockout of both alleles of the 
C1QTNF5 would be predicted to result in a worse phenotype if the disease was due to 
heterozygote insufficiency. 
 
In chapter 5, when investigating differences between case and control hiPSC-RPE the case lines 
were also found to be vulnerable to oxidative stress.  In addition, case lines expressed increased 
catalase and haem oxygenase1 suggesting that even at baseline, cells were under oxidative stress.  
Haem oxygenase and caeruloplasmin were also found to be significantly raised in the serum of 
C1QTNF5 mutant heterozygote knock in mice at 12 months of age (Chavali et al., 2011).  This 
suggests that oxidative stress may play a part in L-ORMD. The exact role of C1QTNF5 is still 
unclear from this or previous studies.  As yet no role for mediating cellular redox state has been 
shown for C1QTNF5. The case cells did not appear do to undergo apoptotic cell death with no 
Caspase-3 staining after being subjected to oxidative stress.  However, they were sensitive to 
membrane permeability markers suggesting necrotic cell death.  Chavali et al. noted similar 
changes in vivo in the knockout mouse model with signs of RPE damage through necrosis 
(Chavali, 2012).  This points to a potential role for C1QTNF5 protecting against oxidative stress on 
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the cell membrane. Only a targeted screen of cellular stress related gene expression was performed 
here.  Additionally, the findings regarding gene expression are limited as only one case line and 
one control line was used for the expression analyses.  A clearer role may be apparent with whole 
transcriptome screening comparing several case and control lines using RNA sequencing for 
oxidative stress across more than one case line. This may reveal changes in pathway gene 
expression involving oxidative stress.  
 
In non-cell autonomous experiments in chapter 5, the model demonstrated increased complement 
activation in case lines when compared to control cell lines with increased TCC deposition on case 
cells and membrane inserts. The increased immunostaining with antibodies to TCC is similar to 
that seen in the histopathology samples.  In this model, TCC deposition mainly occurred on the 
cells.  However, there was also deeper staining within the membrane which would be similar to 
staining within Bruch’s membrane or the choriocapillaris.   In a similar manner to complement 
component staining seen in AMD, this study shows that complement dysregulation is seen in L-
ORMD.  However, what causes differential complement activation is not clear.  The mutant 
protein may cause complement activation.  
 
In chapter 6, I showed that mutant gC1QTNF5 was relatively unstable compared to the wild type 
gC1QTNF5. Thus, the degradation or breakdown of the mutant protein could be a potential trigger 
for pathogenesis.  A simple experiment of adding mutant protein to the media of wild type cells or 
adding conditioned media to wild type cells could show that the mutant protein may be involved in 
early pathogenesis. This is supported by the lack of deposit formation in the C1QTNF5 knockout 
mouse. 
I would predict that conditioned media would induce increased C5b-9 deposition in wild type cells 
lines. An antibody specific to the mutant was not developed during the course of this thesis. 
However, if a validated antibody could be generated a co-immunostaining or precipitation could be 
performed with C5b-9 to see if complement activation occurred directly on the mutant protein.  
 
A recent study of another inherited deposit degeneration, Malattia Leventinese, revealed the mutant 
protein in this condition Efemp1 was also found in the deposit (Fernandez-Godino et al., 2015).  
Mutant Efemp1 was found to induce abnormal ECM turnover and cause complement activation 
which was C3 mediated.  Complement activation also resulted in increased IL-6 and IL-1β both of 
which were found to be important in deposit formation.  A similar role in altered ECM is suggested 
for mutant C1QTNF5.  C1QTNF5 is composed of a globular C1Q head with a collagen like 
domain and a nitrile end (Tu and Palczewski, 2014).  Electron microscopy of L-ORMD donor 
retina has revealed that the deposit is composed of wide-spaced collagen.  The deposit resembles 
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BLamD (Sarks et al., 2007) BlamD are known to contain ECM components and wide-spaced 
collagen (Sarks, 1976). BlamD has also been shown to harbour complement components in a 
similar manner to drusen (Hageman and Mullins, 1999a, Anderson et al., 2002).  Development of 
BLamD changes in a mouse model ceased with the absence of an active complement system 
suggesting that propagation of the deposit results from complement activation (Garland et al., 
2014a). This study showed marked C3d staining of the deposit suggesting that there is C3 
activation and C3b breakdown in the deposit (figure 7.1).  In AMD basal laminar deposits form 
early in the disease process.  It has been suggested that these are produced secondary to RPE stress 
(van der Schaft et al., 1994). In addition, there is some evidence that oxidative stress may also 
plays a part in AMD.  Hollyfield et al. used a carboxyethylpyrrole (CEP), a downstream product of 
oxidised docosahexaenoic acid (DHA) on cell membranes. These mice developed BLamD 
(Hollyfield et al., 2008).  A similar process may initiate AMD with released protein components 
causing the localised activation of the complement pathway.  It is not clear from AMD studies 
what component of the deposits could initiate a complement response. Drusen and basal laminar 
deposits have been studied in molecular and proteomic studies (Hageman and Mullins, 1999b).  
Serum amyloid P, vitronectin, APOE, immunoglobulin light chains, Factor X, and C5 and C5b-9 
have been identified as the only common components of all types of drusen and basal laminar 
deposit (Mullins et al., 2000b).  In this dissertation, I have shown that the case lines express 
markers of oxidative stress even under basal conditions and are vulnerable to oxidative damage 
when compared to the control cell lines. Both the complement model study and the oxidative stress 
study showed increased staining in case cell lines with cell death and membrane permeability 
markers in the relative absence of apoptosis.  This points to a vulnerability cell membrane 
mediated necrosis in the case lines and suggests that C1QTNF5 plays a key role in stabilising the 




Figure 7.1: A schematic of C1QTNF5 function in health and disease.  The upper diagram 
represents potential C1QTNF5 function in health. It acts as an anchor for multiple species on the 
cell membrane and the extra-cellular matrix. The figure shows that wild type C1QTNF5 is secreted 
and forms multimers binding multiple CFH molecules onto the cell surface and in the extracellular 
matrix (ECM).  This assists local regulation of C3 tickover. 
The bottom diagram shows the possible role of C1QTNF5 in L-ORMD. C1QTNF5 is secreted but 
mainly forms monomers which do not bind CFH well.  This leaves the RPE cell membrane and 
choroid prone to attack from the complement pathway with no regulation of C3 activity.  It also 
makes the RPE vulnerable to other stress such as oxidative stress. The monomeric species 
accumulate in the ECM.   This causes further complement pathway activation preventing clearance 
and resulting in a thick basal laminar like deposit forming. CR=choroid 
 
C1QTNF5 has already been shown to bind to MITF and to form high order polymers (Tu and 
Palczewski, 2014). In chapter 6, this study showed that C1QTNF5 also bound to CFH, a key 
regulator of the alternative complement pathway.  Polymorphisms of CFH have been associated 
with AMD.  An attempt was made to see if there were functional changes with CFH. These 
showed a trend towards functional changes in the solid state but not in fluid phase.  However, the 
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experiments were limited by the lack of available C1QTNF5 protein. CFH is also known to bind to 
ECM products including heparin sulphate and GAGS. The Y402H polymorphism of CFH results 
in an increased risk of AMD.  This polymorphism results in a change to CCP 7 which alters GAG 
binding.  All of the deposit forming macular degenerations show some form of disruption to ECM 
turnover (Weber et al., 1994, Garland et al., 2014b, Kortvely et al., 2010).  CFH may also have a 
role in helping ECM turnover. CFH has been found to coat drusen in AMD and has been shown to 
bind with reduced affinity in Y402H variant and reduced binding to aged Bruch’s (Clark et al., 
2010).  CFH has also been shown to clear iC3b (Paixão-Cavalcante et al., 2009). CFH is also 
known to bind to apoptotic and necrotic cells and is thought to prevent complement activation with 
differential affinity of the Y402H variant (Sjöberg et al., 2007).  Why complement downregulation 
is important when apoptosis and necrosis occurs in the sub-retina is still not clear.  
 
In these experiments, we noted activation of complement on necrotic cells in the case hiPSC-RPE 
cell lines.  Failure of downregulation of the complement pathway may lead to deposit formation 
(Garland et al., 2014a).  Recently, another component of necrotic cell membranes was found to 
bind to CFH (Weismann et al., 2011).   Malondialdehyde (MDA), a lipid peroxidation product is 
exposed on necrotic cells, is a ligand of CFH. This could provide a role for CFH in preventing 
complement activation on damaged cells and regulating oxidative damage at the cell membrane 
and preventing cell death.  MDA has been shown to increase in AMD eyes (Weismann et al., 
2011). CFH has been shown to decrease oxidative stress resulting from MDA. MDA has 
previously been shown to increase at the cell surface with hydrogen peroxide administration 
(Sheridan et al., 1996). The role of MDA was not investigated during these experiments but could 
simply be examined by immunostaining with progressive levels of oxidative stress and combining 
these experiments with complement activation studies.  
 
The exact binding site of C1QTNF5 on CFH was not determined during this set of experiments.  
This could quite easily be tested by assessing individual CCP regions for C1QTNF5.  Another 
potential method by which mutant C1QTNF5 could result in pathology is the modulation of 
localised complement activity. In these studies, I provided evidence that the mutant appears to 
reduce the formation of multimeric C1QTNF5.  I showed that C1QTNF5 binds to CFH. Reduced 
multimerisation of C1QTNF5 on the cell membrane may lead to reduced CFH binding and 
therefore reduced downregulation of complement activity making the cell membranes vulnerable 
to complement mediated attack as shown by the cell model. This could be tested by increasing 
CFH concentration in the cell model and comparing this with increasing functional C1QTNF5 and 




The normal physiological role for C1QTNF5 is still unclear from this study however, it may play a 
role in binding mediators of the ECM on the cell membrane including CFH and MITF.  C1QTNF5 
has previously been shown to interact with other molecules of C1QTNF5 forming high order 
polymers.  Recently, Tu et al. generated full length C1QTNF5 using a bacterial expression system 
(Tu and Palczewski, 2014).  Using negative staining electron microscopy they noted multimeric 
bouquets of C1QTNF5. They suggested that the nitrile and collagen domains lay in the cell 
membrane exposing the globular domains.  Together this suggests that C1QTNF5 plays a complex 
role in the ECM helping bind a number of modifiers of the ECM to cell membranes.  
 
There are several limitations when making conclusions about macular degeneration from the 
model.  The first is that the model is developed from L-ORMD cell lines and not AMD. 
Differences between L-ORMD and AMD have already been highlighted and these include an 
earlier age of onset and increased severity of disease which eventually affects the whole retina. In 
addition, there may be other differences in the diseases. For instance, L-ORMD patients 
demonstrate long anterior zonules (Ayyagari et al., 2005).  Long anterior zonules have also been 
reported in a number of other conditions (Moroi et al., 2003). C1QTNF5 is also expressed by the 
ciliary body.  It is thought that expression of the mutant here may bring about these changes 
however the exact mechanism is unclear.  However, this does highlight that changes are not limited 
to the macula in L-ORMD.  I have also shown that L-ORMD appears to start in the temporal 
macula unlike AMD which usually begins at or near the fovea. So whilst the model appears to 
provide a reliable replication of certain aspects of AMD the inferences are limited and any findings 
would have to be confirmed in AMD itself.   
Chapter 1 also highlights a number of limitations with using hiPSCs to model human disease.  
Amongst the biggest obstacles to using hiPSCs is the variability.  Firstly, hiPSCs retain some 
epigenetic memory from the cell of origin which may skew some of the in vitro findings (Bar-Nur 
et al., 2011). In addition, reprogramming can alter gene expression with the insertion or deletion of 
the host genome. This means that the phenotype does not only result from the mutation but could 
results from a number of other differences in gene expression.  Gene expression beyond the mutant 
gene of interest may also be important when case and control lines are from different sources. In 
this study, I used cells from siblings or close relatives to reduce the variation in gene expression.  
However, newer methods have recently become available. Using gene editing it is possible to 
create isogenic lines from diseased cell lines (Soldner et al., 2011). These corrected control cell 
lines have an identical genome to the case lines except for the gene of interest.  Therefore any 
differences in the cell lines could be more confidently attributed to the gene of interest. In addition, 
the majority of the lines have been derived using integration free methods therefore reducing the 
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risk of unintentional insertions or deletions. In order to validate my findings, I also used in vivo 
findings which appeared to replicate the complement activation found in the model in the disease 
itself.  
There remain a number of unanswered questions which I plan to answer with upcoming studies.  
Firstly, it is still unclear whether L-ORMD results form a gain of function resulting from the 
damaging effect of a mutant protein or whether L-ORMD results from a loss of function from the 
lack of two alleles resulting in haploinsufficiency. I plan to address this question with gene editing 
studies firstly by knocking out C1QTNF5 from control hiPSCs to test loss of function. To test 
whether the phenotype results from a gain of function I will use CRISPR-CAS gene editing on the 
mutant lines to see if there is an increase in severity of the phenotype which suggests a gain of 
function. 
In addition, it is not clear what pathway is involved in increasing complement activation in the 
model. I plan to use RNAseq to provide an unbiased screen of pathways comparing case cell lines 
prior to and after the serum stress tests. This work will provide the foundation of further validation 
studies. 




A human C1QTNF5 knockout line will 
be generated by using CRISPR-CAS 
targeting removal of the whole 
C1QTNF5 gene. 
To see if the disease results from 
loss of function the same serum 
stress tests will be performed with 
this edited line when compared 
with mutant lines. 
CRISPR-CAS 
mutant allele 
knock in line 
generation 
The aim is to create a homozygous 
mutant line with CRISPR CAS-guide 
to target the wild-type allele and a 
DNA template used to insert the 
mutant base pair change. 
To see if the disease results from 
gain of function from the mutant 
allele the double knock in lines will 
be tested using the serum stress 
tests to see if there is any 




3 case lines will be sequenced as 
treatment naïve. A further 3 case lines 
will also be analysed after being 
incubated 12 hours in serum. 
To identify key pathways causing 
differences in c5b-9 deposition in 
the mutant cell lines. 





7.2      Implications for the treatment of L-ORMD 
 
The ultimate aim of this dissertation is to develop treatments for patients with macular 
degeneration.  Degenerative eye diseases progress through a range of stages (figure 7.2).  Prior to 
clinical disease the patients are asymptomatic and there may be no signs of disease.  Developments 
in genetic testing now enable the identification of patients at this stage.  The genetic elements of 
disease can potentially be treated at this stage with gene editing or gene therapy. This study 
highlights a potential gain of function from the mutant protein. Recently, gene editing technology 
has provided a platform for the silencing of gene expression in vivo including retinal disease 
(Ousterout et al., 2015, Bakondi et al., 2015). Using a similar approach with guide RNA encoded 
alongside CRISPR-Cas with a plasmid encased within an AAV capsid it would potentially be 
possible to truncate the mutant C1QTNF5 whilst leaving the wild type allele unaffected.  This 
would leave only wild type C1QTNF5 expressed and potentially resolve any effect from the 
mutant protein. The potential efficiency of this technique are relatively high (Bakondi et al., 2015). 
Ultimately complete gene correction of the mutant allele would yield normal expression of wild 
type protein without the potential effect from a truncated mutant protein.  This would also 
potentially be possible however, the efficiency of this technique would be relatively low (Cong et 
al., 2013a).  In addition, the efficiency would be lowered further in non-dividing cells.  If a loss of 
function is due to a dominant negative effect then AAV gene replacement therapy may be an 
option as has previously been used to treat other inherited eye conditions (Bainbridge et al., 2008).  
 
Figure 7.2: Diagram of treatments for stages of degenerative disease 
In early stages when structure and function is maintained, preventative treatments including 
pharmacological and gene therapeutic treatments could provide useful in preventing disease or 
slowing progression.  As degeneration occurs the structure, function and number of cells is 




In early clinical disease, the structure and integrity of the retina may be largely maintained. 
Therefore disease modifiers may be important.  Pharmacotherapy may play a part.  In this study we 
showed that the depletion of both C3 and C5 resulted in abolishing the phenotype. C3 or C5 
inhibitors could be used to modify the disease.  There is already a clinical grade monoclonal 
antibody against C5 known as eculizumab. Eculizumab has already been used to treat paroxysmal 
nocturnal haematuria (Hillmen et al., 2006).  A trial of eculizumab was attempted with systemic 
dosing (Yehoshua et al., 2014).  However, we show in this study that the RPE also expresses C5 
and therefore systemic administration alone may not be adequate in reducing C5 activity within the 
eye. The trial looking at the treatment of GA showed no difference in progression between cases 
and controls.  Symptomatic but non disease-modifying features of disease could also be treated at 
this stage. There is evidence from dark adaptation studies that there is a deficiency of retinoid 
regeneration in L-ORMD patients in stage 2 (Papastavrou et al., 2015). This may result from the 
development of the thick sub-retinal deposit which results in a barrier between the RPE and the 
choroid. The addition of high dose vitamin A has shown an improvement in dark adaptation 
kinetics in some patients (Jacobson et al., 2001). 
In late stage disease there is marked cell loss. Cell replacement strategies may potentially benefit 
patients at this stage.  Recently, RPE derived from hESCs was transplanted sub-retinally in 
macular degeneration patients. The RPE became pigmented and formed in the correct layer.  The 
transplants had relatively few side effects. At present there is little evidence of RPE function or an 
improvement in clinical function however if timed correctly this could potentially form part of a 
cell replacement strategy to rescue photoreceptors. Recently, photoreceptors with outer segments 
have also been generated from hiPSCs (Zhong et al., 2014).  The replacement of multiple cell lines 
of the outer retina offers the hope of recovery of outer retinal function however many of the 
techniques are as yet untested in vivo.  Importantly, C1QTNF5 is conserved between mammalian 
species. The development of a mouse model for L-ORMD offers the possibility to test a number of 
strategies at various stages of disease before embarking on clinical translation trials in our cohort 
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Appendix I Media  
 
 
MEF medium (510ml) 
DMEM                 (Gibco 10829)               450ml 
2mM Glutamine   (Invitrogen25030024)    5ml 
FBS                       (Biosera S1818)             50ml  (10%) 
P/S                          (Gibco 15140)               5ml 
 
HiPSC media and EB media 
E8 media         Thermofisher (A1517001)  minus FGF for EB 
 
Neural induction media (500mls) 
DMEM/F12 485mls (Gibco 12500-062) 
N2 supplement  5mls (Invitrogen 17504044)  
MEM                5mls (Invitrogen 12634-010) 
2 g/mL heparin 
1% penicillin/streptomycin  5mls (Gibco 152140) 
Retinal differentiation media  (500mls) 
DMEM  (340ml)  (Gibco 11965-118) 
F12  (145ml)  (Gibco 11765-062) 
10ml B27 minus retinoic acid (Gibco 12587010) 







sera Quidel A113 
C1Q depleted Comptech A300 
C4 depleted Comptech A308 
Factor B depleted Comptech A335 
Factor D depleted Comptech A336 
C3 depleted Comptech A314 
C5 depleted Comptech A320 





Appendix II Materials 
 
Equipment 
Equipment Make Catalogue number 
15ml centrifuge tubes Corning 430790 
50ml centrifuge tubes Corning 430828 
100mm dishes Corning 430167 
6 well plates Corning 3516 
24 well plate Corning 3524 
96 well plates TPP 92696 
Filters Nalgene 566-0020 
2ml pipette Corning 4486 
5ml pipette Corning 4051 
10 ml pipette Corning 4101 
Roller mixer Stuart SRT6 
Orbital shaker Stuart SSL4 
Block heater Stuart SBH130DC 
Microscope 
immunofluorescence Zeiss Axiocam 
Confocal microscope Zeiss  
Western blot Bio-Rad  
PCR Bio-Rad C1000 thermal cycler 
Western imaging LiCOR Odyssey 
Protein quantification Nanodrop ND-1000 spectrophotometer 
Centrifuge Eppendorf 5702 





Appendix III Primers 
Standard PCR conditions 
Material Company Volume 
Optimized DyNAzyme 
EXT buffer 10x  
ThermoFisher 
Scientific, F-511L  
1.6 µl 
Betaine, 5M  Sigma, B0300  7.2 µl 
HPE dNTP mix  Scientific Lab 
Supplies, 28406551  
0.3 µl 
F2 primer, 5μM   2.0 µl 
Repeat R primer, 5μM   1.0 µl 
Tail R   3.0 µl 
DyNAzyme DNA 




H2O   1.5 µl 
DNA, 200ng/ μl   1.0 µl 
 
Step Temperature (oC) Duration 
1 95  45 seconds  
2 98  10 seconds  
3 61  30 seconds  
4 78  5 seconds  
(slow ramp, 
0.6°C/second)  
5 78  2 seconds  
6 86  2 seconds  
7 78  2 seconds  
8 90  2 seconds  
9 78  10 minutes  
 




qRT-PCR cycling conditions 
 
Temperature (°C)  Duration  Cycles  
95 7 minutes  
95 15 seconds 40 
59 30 seconds  
65 0.5C/5seconds (melt curve)  





β-Actin TGAAGTGTGACGTGGACATC     GGAGGAGCAATGATCTTGAT 
Endo-Oct4 CCTCACTTCACTGCATGTA CAGGTTTTCTTTCCCTAGCT 
Endo-Sox2 CCCGCAGACTTCACATGT CCTCCCATTTCCCTCGTTTT 
Endo-Myc GCGTCCTGGGAAGGGAGATCCGGAGC 
TTGAGGGGCATCGTCGCGGGAGGCTG 
Endo-Klf4 GATGAACTGACCAGGCACTA GTGGGTCATATCCACTGTCT 
Complement sequencing 
Seq CFH original F TGAGGGTTTCTTCTTGAAAATCA 
Seq CFH original R TTGGTGTGAGATAACGAACCTC 
 
Seq HTRA1 snp2 F AGCCGCTTCCTAGGCTCTCT 
Seq HTRA1 snp2 R GGGGAAAGTTCCTGCAAATC 
 
Seq ARMS2HTRA1 F TACCCAGGACCGATGGTAAC 
Seq ARMS2HTRA1 R AGGCTGGTTAAAATGCAAGC 
 
Seq C3 F CTCGCACCTCCTTCACATGC 
Seq C3 R GACAAAGAGGCCTCGTGAGA 
 
Seq C2CFB F GGACTTCCGAAACACATTCG 
Seq C2CFB R CAACTGGTCCCAAAGGAGAG 
 
L-ORMD sequencing  
LORD seqF: ACG AGC AGG GAC ATT ACG AC 







Appendix IV Antibodies 
Pluripotency 




SOX2  Mouse  Millipore, 
AB5603  
1:250  
TRA-1-60  Mouse  Santa Cruz, 
SC-21705  
1:250  




Three germ layer differentiation 
 
Antibody  Host  Company  Concentratio
n  
SOX1  Goat 
polyclonal  
R&D systems  1:100  
Nestin  Mouse 
monoclonal  
Milipore  1:100  
Brachyury  Goat 
polyclonal  
R&D systems  1:100  
Eomes  Rabbit 
polyclonal  
Abcam  1:600  
Fox A2  Goat 
polyclonal  
R&D systems  1:100  
GATA-4  Mouse 
monoclonal  
Santa Cruz  1:100  
 
HiPSC-RPE staining 













MAB5466  1:100 





























Appendix V Published papers  
 
The information presented in the introduction and methods was published in part in two papers: 
 
Using human induced pluripotent stem cells to treat retinal disease. Borooah S, Phillips MJ, 
Bilican B, Wright AF, Wilmut I, Chandran S, Gamm D, Dhillon B. Progress in Retinal and Eye 
Research. 2013 Nov;37:163-81. 
 
Late-onset retinal macular degeneration: clinical insights into an inherited retinal degeneration. 






The studies presented in chapter 3 were published in part in two articles: 
 
Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are 
dysfunctional despite maintaining viability. Devlin AC, Burr K, Borooah S, Foster JD, Cleary EM, 
Geti I, Vallier L, Shaw CE, Chandran S, Miles GB. Nat Communications 2015 Jan 12;6:5999.  
 
 
Real-time quantitative monitoring of hiPSC-based model of macular degeneration on Electric Cell-
substrate Impedance Sensing microelectrodes. Gamal W, Borooah S,* Smith S, Underwood I, 
Srsen V, Chandran S, Bagnaninchi PO, Dhillon B. Biosensors and Bioelectronics 2015 Sep 
15;71:445-55. 
 
*Joint first author 
 
